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      Chapter 1 
 
 
INTRODUCTION 
 
 
 
1.1 Chronic Obstructive Pulmonary Disease (COPD) 
 
 
³&23'´UHIHUVWRFKURQLFREVWUXFWLYHSXOPRQDU\GLVHDVHDFKURQLFGLVRUGHURIWKHDLUZD\VGXH
to inflammation that leads to hypersecretion of mucus and/or destruction of the airways and 
alveoli in the lungs.  These changes result in narrowing of the airways with the consequent 
airflow limitation causing breathlessness and ultimately disability (Department of Health and 
Human Services, 2010). Spirometry is the accepted method for measuring this obstruction to 
airflow (Gaensler, 1950 and 1951). 
 
COPD is a complex disease with different phenotypes (Marsh et al., 2008).  Around the age of 
forty years, people exposed to environmental air pollution especially cigarette smoke may 
experience a mild cough that produces clear sputum.  During their middle to late 60s, shortness 
of breath with exertion becomes more evident and troublesome, especially if they continue 
smoking. Lower respiratory tract infections occur more often.  As the severity of the disease 
progresses patients may become very breathless during infective exacerbations and sometimes 
require hospital admission (URL 1).  Thus with continuing exposure to pollutants and/or 
recurrent exacerbations, the natural history is of disease progression (Viegi et al., 2007). 
 
 
1.1.1 Diagnosis of COPD 
 
COPD should be suspected in patients with a complaint of breathlessness or chronic cough 
with or without sputum production, especially if there is a history of exposure to tobacco 
smoke or other air pollutants (Raad et al., 2011, Rabe et al., 2007; Badgett et al., 1997).  No 
single sign or symptom can adequately confirm or exclude the diagnosis of COPD (Holleman 
et al., 1995) although COPD rarely occurs under the age of 40 years.  The presence of airflow 
obstruction should be confirmed by performing spirometry which currently represents the gold 
standard in COPD diagnosis.  The severity is then classified using the degree of impairment of 
the forced expiratory volume in one second (FEV1) (NICE, 2010).   
  
 
2 
1.1.2 Assessing the Natural History of COPD 
 
Impairment of FEV1 is seen as central to the progression of the disease. The Fletcher-Peto 
model (1976) is based on FEV1 and was considered as the most comprehensive description of 
the natural history of COPD.  However, only males were studied and this is a major drawback 
of the Fletcher-Peto model because today (30-40 years later) women represent about 50% of 
the COPD population (British Lung Foundation, 2005; Kohansal et al., 2009).   
 
The airway damage in COPD is generally progressive and is linked to an increased 
inflammatory response of the lungs to harmful inhaled gases and particles, primarily from 
cigarette smoke however, various kinds of air pollutants are also commonly known to be risk 
factors for COPD (American Thoracic Society (ATS), 1995).  In addition occupational 
exposure and indirect smoking (passive smoking) may play an important role in COPD 
occurrence, progression and exacerbation.   
 
In COPD, the inflammatory response produces significant systemic consequences (Tkac et al., 
2007; Huertas et al., 2011).  These manifestations commonly include weight loss or obesity, 
reduced lean body mass with muscular weakness, osteoporosis and ischemic heart disease as 
direct effects and loss of appetite, anxiety and depression as indirect effects.  These all lead to 
impairment in overall quality of life and health status (Cecere et al., 2011; Hynninen et al., 
2007; Dourado et al., 2006; Agusti et al., 2003; Vandenbergh et al., 1967).  In more severe 
cases there may be circulatory and respiratory failure.  These complications emphasize the 
necessity for the multidimensional approach to the assessment of the clinical impact of COPD. 
 
 
1.2 Multidimensional Assessment of COPD Progression 
 
A major advancement in understanding the natural history of COPD came in 2004 when Celli 
and colleagues (2004) presented data showing that their multidimensional grading system had 
a significant advantage over the Fletcher-Peto model. They established the BODE index 
(BODE ± BMI, airflow Obstruction, subjective Dyspnoea and Exercise test; a 10 point scale) 
(Celli, 2004) that proved to be a better predictor of the health outcomes than FEV1 alone. More 
recently, Puhan and co-workers (2009) developed another multidimensional index (ADO) 
composed of Age (A), Airway Obstruction (O) and MRC Dyspnoea index (D).  The index 
proved as useful as BODE for prognostic assessment in COPD patients.   
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Similarly Jones and colleagues (2009) developed the DOSE index that contains four COPD 
related measurements i.e. dyspnoea (D), airway obstruction (O), smoking status (S), and 
frequency of exacerbation (E).  The index proved to be a simple tool to assess disease severity 
and future hospital admission events in patients with COPD.   
 
 
1.2.1 Potential Drawbacks 
 
Mobility is a very serious issue for an elderly population with COPD and Celli and colleagues 
(2004) only included patients who could carry out an exercise test.  Soon after publication of 
&HOOL¶VSDSHURQO\RQHRIVL[SDWLHQts seen in a COPD clinic by Dr Niall Keaney (pers. comm., 
March 19, 2007) was capable of carrying out a meaningful exercise test.   
 
Additionally, the exercise test is a time-consuming test which not only needs trained staff but 
also needs equipment and space which makes this test expensive in terms of resources 
required.   
 
The ADO index used to evaluate Swiss and Spanish cohorts looked at 3 year mortality risk in 
these patients.  By introducing age, the ADO index is compromised because age is the most 
important determinant of survival, independent of disease status and diagnosis.  Therefore age 
has limited value in the stratification of a specific disease process (Celli et al., 2009). 
 
Similarly, the DOSE index mainly focuses on markers related to health status, future events 
such as hospitalisation and respiratory failure and also disease management.  However, this 
study did not take account of mortality which is one of the main COPD outcomes of interest 
both for patients as well as their health care providers.   
 
A generally acceptable multidimensional index should be economical, easily measured in most 
clinical settings and applicable to all COPD patients. Furthermore, considering the chronic 
nature of COPD, there is a need to verify the efficacy of the index for assessing progression.   
 
 
 
 
  
 
4 
1.3 Modified Multidimensional Index to Assess COPD Progress 
 
 
BODE is a validated but complex tool.  In this study, the simpler BOD (which removes the 
exercise component from BODE) is presented and the pragmatic efficacy of BOD is explored.   
 
 
1.3.1 Potential Drawbacks 
 
The BOD index and other indices only cover physiological aspects of COPD. However, 
breathlessness (a marker of COPD progression and a component of BOD) is also associated 
with feelings of anxiety and/or depression, a recognised indirect comorbidity in these patients 
(Mikkelson et al., 2004; Norwood et al., 2006; Janssen et al., 2010). Studies suggest that 
anxiety and depression may have an impact on COPD progression with outcomes such as 
hospitalisation, exacerbations and health status (Hynninen et al., 2010; Ng et al., 2007; Xu et 
al., 2008).  However, anxiety and depression are potentially modifiable by changing and 
LPSURYLQJ SDWLHQWV¶ DWWLWXGH RI PLQG (Hynninen et al., 2010).  Health related quality of life 
+54/ LV D UHOHYDQW DVSHFW RI SDWLHQWV¶ SHUFHSWLRQV DQG IRU COPD WKH 6W *HRUJH¶V
Respiratory Questionnaire (SGRQ) (Jones et al., 1992) is widely used to assess health status. 
This is an illness questionnaire and does not represent the whole person including their 
attitudes to their illness. A need exists therefore, to explore wellness as a concept in COPD 
patients.  
 
 
1.4 Psychological Markers of COPD Progression and COPD Outcome 
 
,WLVDFRPPRQSHUFHSWLRQWKDWDSDWLHQW¶V+54/LVYLWDOWRLPSURYH&OPD outcome (Jones et 
al., 2002). However, there is a need to understand all the factors that are 
responsible for supporting the current health status (Daudey et al., 2010).  This can be achieved 
by assessing the degree of wellness in patients with COPD.  Wellness is a more recondite 
picture of health status. 
 
Beneath the current state of health (HRQL) is lifestyle/behaviour, followed by psychological, 
mental stress and motivational levels. Deepest of all is the spiritual-being (Travis, 1970). A 
combination of all these levels indicates overall wellness status. This research has developed a 
wellness assessment questionnaire and applied this to study participants to investigate the role 
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of wellness in patients with COPD and its relationship to clinical status and health status of the 
disease.  
 
 
1.5 Diagnostic Markers of COPD 
 
Spirometry is a key for COPD diagnosis (GOLD, ERS/ATS, NICE) as is the electrocardiogram 
for myocardial infarction and blood pressure measurements for the diagnosis of hypertension. 
Spirometry can be used to monitor disease progression. 
 
As FEV1 is influenced by age, sex, height and ethnicity, it is best considered as a percentage of 
a predicted normal value.  There are equations and reference normal values available in the 
literature (Crapo et al., 1990; Coultas et al., 1988; Glindmayer, 1995); with appropriate norms 
for local populations being used to assess COPD patients.   
 
 
1.5.1 Potential Drawbacks 
 
Impairment of FEV1 is defined with reference to predicted values. Because predicted values are 
dependent on the size of the lungs, predictive equations must take into account the influence of 
height, gender, age and ethnic origin (Becklake et al., 1986).  Of these variables, assessment of 
height is the one that may be subject to error although no predictive methodology deals with 
multi-ethnicity.   
 
 
1.5.2 Examining an alternative Method of Measuring Height  
 
Studies have also revealed that the prevalence of osteoporosis is increased in smokers (Cornuz 
et al., 1999; American Academy of Orthopaedic Surgeons, 2010) and this condition may 
reduce the actual height of COPD patients. Thus using the current height for predicted values 
of FEV1 may mean that the degree impairment of FEV1 is subject to confounding in an elderly 
population.  
 
In the presence of spinal deformity, pulmonary function laboratories use arm span as a 
surrogate for height (Hepper et al., 1965; Golshan et al., 2007; Temple  et al., 1988) and this 
measurement is not likely to be influenced by the presence of osteoporosis (Banik, 2011).  The 
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present research investigates the relationships of armspan to measure current and historical 
height to further help calculating predicted FEV1 in the diagnosis and classification of COPD. 
2YHUDOO HDFK DQG HYHU\ ELRPHGLFDO UHVHDUFKHU¶V XOWLPDWe aim is to overcome adverse 
consequences, reduce the burden, slow the progression, improve the quality of life, and prolong 
the lifespan of sufferers. These are factors that collectively help to build a more healthy society 
and the present study has made an attempt to explore further markers to improve health 
outcomes in patients with COPD. 
 
 
1.6 Evaluation of Markers of Health Status in COPD 
 
Several studies have proposed determinants that improve health status in patients with COPD. 
These well-established determinants of health status in COPD include age (Torres et al., 2006), 
gender (Ferrari et al., 2010), exacerbation frequency (Anzueto et al., 2009; Ansari et al., 2007), 
body mass index (Tsiligianni et al., 2011., Tsukino et al., 1996; Jampat et al., 2008), 
comorbidity (Yeo et al., 2006; Crisafulli et al., 2008) and multidimensional index BODE (Celli 
et al., 2004; Araujo et al., 2010; Casanova et al., 2011).    
 
 
1.6.1 Potential Drawbacks 
 
The above mentioned determinants play an important role in improving health status. 
However, considering COPD as a systemic condition, there are various other factors that need 
attention in order to provide improved information on the health status of patients with COPD.  
 
 
1.6.2 Examination of new markers of Health Status 
 
There are very few longitudinal studies looking at health status over time and the present study 
does this however it also examines potentially new determinants of health status in patients 
with COPD and compares data over time with already known determinants of health status. 
These include dyspnoea, handgrip strength and lean body mass.  The present study also 
examines the relationship of new multidimensional indices of severity with health status 
(measured by SGRQ - 6W*HRUJH¶V5HVSLUDWRU\4XHVWLRQnaire) in patients with COPD.  
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1.7 Haematological and Other Physical Marker of COPD Outcomes 
 
C reactive protein (CRP) is generally used as a marker of acute inflammation in the body 
(Pasceri et al., 2000) and patients with COPD have an on-going inflammation.  The present 
study examines the relationship of other physiological and psychological markers of COPD 
progression, health status and mortality with the degree of inflammation measured by high 
sensitivity CRP (hsCRP). 
 
Long standing cough, breathlessness, and wheezing are common symptoms of COPD 
depending on how much of the lung has been damaged.  Symptoms may suddenly get worse in 
cases of exacerbation.  In this study,  the duration of symptoms (in years), which has not been 
addressed previously, considered as a potential subjective measurement that may have an 
influence on COPD outcomes and this thesis explores the role of symptom duration in COPD 
outcomes. 
 
 
1.8 Aims and Objectives of the Study 
 
 
The main aim of this thesis is to chart the progression of chronic obstructive pulmonary disease 
(COPD) by a critical evaluation of current and newly developed markers.  A novel 
multidimensional index has been used to describe the clinical impact of COPD and its natural 
history and progression over time.  This research can then be utilized to help, improve, reduce, 
DQG FRQWURO WKH GHYDVWDWLQJ HIIHFW RI WKLV GLVHDVH RQ SDWLHQWV¶ KHDOWK ZLWK KHDOWK FDUH
professionals targeting treatments to individual patients. Furthermore, this study can also be 
used to motivate these patients in order to improve their health status and wellbeing. 
 
These aims have been achieved through the following objectives. 
 
9 A detailed and careful literature review of relevant studies. 
9 Identification and development of new markers that can be used to assess the severity 
of COPD and to monitor its progression. 
9 Data collection from the cohort of COPD patients. 
9 Interpretation of data obtained. 
9 Statistical analysis of data obtained. 
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9 &OLQLFDOHYDOXDWLRQRIDQHZO\GHYHORSHGLQGH[³%2'´LQSUHGLFting COPD outcomes.   
9 Critical review of other measures that can be used to improve BOD.   
9 Investigation of wellness status and its influence in COPD outcomes.   
9 Recommendations on the basis of results as to the best measures that can be used to 
predict COPD health outcomes.   
 
 
1.9 Thesis Organization 
 
 
&KDSWHU ,QWURGXFWLRQSUHVHQWVDEULHIEDFNJURXQGRI WKHSUHVHQW VWXG\¶VDLPV &KDSWHU
(Literature Review) contains a review of studies relevant to the aims of the thesis. In the next 
Chapter 3 (Methodology), detailed information about methodology and a brief account of 
statistical techniques and software used is given. Chapters 4, 5, and 6 discuss the critical 
evaluation of the BOD index, physical and psychological measurements, and haematological 
markers in detail on the basis of findings obtained. Chapter 7 (Discussion) reviews the key 
findings obtained, their interpretation, influence and significance in patients with COPD.  The 
findings are compared with all other relevant studies in the literature.  The closing Chapter 8 
(Conclusion) summarizes the most important findings of the thesis and recommendations for 
future work that result from those findings. 
 
 
                                             ____________________________ 
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Chapter 2 
 
 
LITERATURE REVIEW 
 
 
 
2.1 Definition of COPD 
 
Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease (National Heart Lung 
and Blood Institute, 2010).  It is defined as a preventable and treatable airflow limitation that 
significantly interferes with normal breathing and is not fully reversible (World Health 
Organisation (WHO, 2011); Global initiative of Obstructive Lung Disease (GOLD) 2010; 
Raherison & Girodet, 2009). 
 
&ODVVLFDOO\&23'LVFRPSULVHGRIWZRFRQGLWLRQVFOLQLFDOO\GHILQHG³FKURQLFEURQFKLWLV´DQG
SDWKRORJLFDOO\H[SODLQHGDQGUDGLRORJLFDOO\GLDJQRVHG³HPSK\VHPD´1DWLRQDO+HDUW/XQJDQG
Blood Institute., 2010).  In some cases chronic asthma may be included under the umbrella of 
COPD (Figure 2.1).  All of the above entities of COPD are highly influenced by smoking and 
other air pollutants.  
 
Chronic Bronchitis is a clinical description of a symptom complex and is defined by 
hypersecretion, and a cough with mucoid sputum.  There may be progression to narrowing of 
the medium sized airways (bronchi) as a result of the inflammatory response of the airways to 
smoke or other atmospheric pollutants (NICE, 2010). It is characterised by a loose wet cough 
that produces large amount of mucus.  
 
Emphysema is characterized by abnormal dilatation of the distal airways and air sacs and may 
also be associated with a loss of elasticity in the lung tissue. The dilated air sacs (alveoli) are 
less supportive of the airways which tend to collapse during expiration resulting in air trapping 
(hyperinflation) (Snider et al., 1985; MacNee, 2005a). 
 
 In chronic asthma, airway remodelling and fibrosis occurs in the area surrounding the 
bronchioles due to a repeated process of inflammation (Bousquet et al., 2000).   
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According to WHO (2011) the COPD related terminologies 'chronic bronchitis' and 
'emphysema' are no longer applicable in clinics.  Both are now included within the COPD 
diagnosis.  
 
 
     
    Figure 2.1.  Anatomical view of COPD  (URL 1) 
 
 
 
2.2 History of COPD & Its Diagnosis. 
 
The development of our understanding of COPD has continued for more than 250 years.  A 
physical examination by stethoscope and the physiological measurement of lung capacity by 
spirometer, being the most widely used tools, for its assessment and diagnosis.  Spirometry, 
however, is accepted as the most useful means for identification, screening, classification and 
monitoring the course of COPD before, during and after treatment (Petty, 2006).   
 
Various attempts have been made to describe COPD.  Bonet described emphysema as 
³YROXPLQRXV OXQJ¶¶ %RQHW   /DWHU DQRWKHU VFLHQWLVW 0RUJDJQL VWXGLHG  FDVHV RI
HPSK\VHPDDQGODEHOOHGLWDV³WXUJLGOXQJ´GXHWRWKHLUDLUFRQWHQWs (Morgagni, 1769).   
 
Badham (1814) ZDVWKHILUVWWRXVHWKHFROOHFWLYHWHUPLQRORJ\³&DWDUUK´IRUFKURQLFFRXJKDQG
hypersecretion of mucus,  a cardinal symptom of COPD and this is considered to be the first 
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major step in our clinical understanding of an important component of COPD; chronic 
bronchitis. According to Badham, chronic bronchitis and bronchiolitis are disabling disorders. 
Laennec, a famous clinician and pathologist who also invented the stethoscope, clearly 
GHVFULEHGWKHHPSK\VHPDFRPSRQHQWRI&23'LQKLVERRN³7UHDWLVHRIGLVHDVHVRIWKHFKHVW´
Laennec based his findings on careful dissections of patients he studied.  He suggested that 
emphysematous lungs did not seem to be emptied well and were also hyperinflated (Laennec, 
1834). 
 
Smoking was very rare 200 years ago; however, emphysema may also occur in people who are 
non-smokers, SDUWLFXODUO\LQSHRSOHZLWKDJHQHWLFSUHGLVSRVLWLRQĮ1 antitrypsin deficiency) or 
from factors in the environment (Laennec, 1834).   
 
According to Laennec (1834) 
 
³,QRSHQLQJWKHFKHVWLWLVQRWXQXVXDOWRILQGWKDWWKHOXQJVGRQRWFROODSVHEXWWKH\fill 
up the cavity completely on each side of the heart. When experienced, this will appear full 
of air . . . . The bronchus of the trachea is often at the same time a good deal filled with 
PXFRXVIOXLG´ 
 
Therefore, Laennec was the first to describe a combination of chronic bronchitis and 
emphysema.  
 
Later, in 1846, the spirometer was invented by a scientist named John Hutchinson (Hutchinson, 
1846).  It now plays a key role in the diagnosis, classification, monitoring of progression and 
PDQDJHPHQWRI&23'$WWKDWWLPH+XWFKLQVRQ¶VLQVWUXPHQWZDVRQO\XVHGWRPHDVXUHYLWDO
capacity. In 1947, Tiffeneau added the concept of timed vital capacity to measure airflow, 
which turned spirometry into a complete diagnostic device (Tiffeneau & Pinelli, 1947).   
 
In the text book 2VOHU¶V Principles and Practices of Medicine (Osler, 1916) very little is 
mentioned about emphysema.  The author believed that excessive pressure in the alveoli 
caused emphysema; however, he did not mention anything about spirometry and its role in 
COPD.   
 
  
 
12 
Based RQ7LIIHQHDX¶VZRUN*DHQVOHUZDVWKHILUVWWRLQWURGXFHWKHFRQFHSWRIWKHDLUYHORFLW\
index and, later, the forced vital capacity (FVC), which became the foundation of the FEV1 and 
FEV1/FVC percent (Gaensler, 1950 and 1951) used today. 
 
5RQDOG&KULVWLHZKRLVRQHRIWKHJUHDWFOLQLFLDQVRIHPSK\VHPDVXJJHVWHGWKDW³HPSK\VHPD
should be considered certain when dyspnoea on exertion, of insidious onset, not due to 
bronchospasm, or left ventricular failure, appears in a patient who has some physical signs of 
HPSK\VHPDWRJHWKHUZLWKFKURQLFEURQFKLWLVDQGDVWKPD´Christie 1944; p 145).  Therefore, it 
LVYHU\REYLRXVIURP&KULVWLH¶VVWDWHPHQWWKDW&23'KDVPRUHWKDQRQHFRPSRQHQWDQGWKXV
history and physical examination is important for diagnosis.  Oswald and co-workers (1953) 
studied 1000 cases of chronic bronchitis (Oswald et al., 1953) and explained the clinical 
features of COPD in more depth. 
 
Dayman, who was a contributor to the book ³3XOPRQDU\(PSK\VHPD´ (Barach & Bickerman, 
1956), was the first to recognize the importance of spirometric and flow volume curve patterns 
in emphysema that are indicative of dynamic expiratory airway collapse.  Menelee and 
Callaway were the pioneers who described the role of lung function tests in emphysema 
patients.  Overall, there were 17 leading physicians and scientists who contributed to this 
classic volume of the 1950s.   
 
There are two landmark meetings that were critical in the definition of COPD:  The CIBA 
Guest Symposium (Ciba Guest Symposium, 1959; Donald, 1971) and the American Thoracic 
Society (ATS) Committee on Diagnostic Standards (Committee on Diagnostic Standards for 
Non Tuberculous Respiratory Diseases, 1962) respectively.  $FFRUGLQJ WR $76 ³FKURQLF
bronchitis in clinical terms is a chronic cough lasting for at least three months over a two year 
SHULRG´ On the other hand ATS defined emphysema in anatomic terms as an enlargement of 
alveolar spaces and loss of alveolar walls. Neither of the definitions considers physiological 
measurement as a part of the definition.  Asthma was described as a state of airway 
hyperresponsiveness to a variety of stimuli and asthmatic bronchitis was considered an 
overlapping condition (Committee on Diagnostic Standards for Nontuberculous Respiratory 
Diseases, 1962).  Many other attempts have been made to define COPD.  However, neither of 
them has improved these basic definitions.  The only improvement made is that COPD is now 
defined in functional terms. 
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:LOOLDP%ULVFRHLVEHOLHYHGWREHWKHYHU\ILUVWSHUVRQWRXVHWKHWHUP³&23'´LQWKHPHHWLQJ
discussion at the 9th Aspen Emphysema Conference.  This term became established and today 
we refer to COPD as the designation of this growing health problem (Briscoe & Nash, 1965).   
 
2.3 PATHOGENESIS OF COPD 
 
In 1968, Hogg and colleagues suggested that the major site of increased airway resistance is 
the airways that are situated peripherally, in the lungs of smokers, with airflow limitation, i.e. 
bronchi and bronchioles of < 2 mm in diameter.  Another study suggested that hematopoietic 
cells including macrophages, lymphocytes, and neutrophils play vital roles in the pathogenesis 
of COPD (Spurzem et al., 2005).   
Asthma, chronic bronchitis and emphysema are all characterized by the presence of airflow 
obstruction.  Distinguishing between these diseases is difficult and may be impossible; the 
Venn diagram below (Figure 2.2) suggests that overlap syndromes occur (ATS, 1995).   
 
 
 
Figure 2.2.   Venn diagram shows overlapping clinical conditions (URL 2) 
 
2.3.1 Progression from Other Respiratory Illnesses 
 
In this regard, there are two major concepts that seek to explain COPD pathogenesis; the Dutch 
hypothesis and the British hypothesis.  Orie and his team put forward a concept of genetically 
influenced hypersensitivity of bronchial airways in COPD (Orie and Sluiter, 1960).  They also 
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suggested that the various forms of airflow obstruction are different expressions of a single 
GLVHDVHHQWLW\DQGLQWURGXFHGDWHUPFDOOHG³FKURQLFQRQ-VSHFLILFOXQJGLVHDVH´&16/'2Q
the other hand, the British hypothesis (Stuart-Harris et al., 1953; Scadding, 1959) stated that air 
pollution and repeated chest infections are the main causes that contributed to the pathogenesis 
and progression of the disease.   
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Figure 2.3.  A summary of the pathological changes that occur in COPD Lungs 
     (Adapted from: Hogg et al., 1968; Saetta et al., 2000;  Torato et al., 2001) 
 
 
 
 
 
Structural changes 
Intima thickening 
endothelial cell 
dys+smooth muscle 
leads to Pulmonary 
Hypertension 
PARENCHYMA       AIRWAYS VASCULATURE 
 
Peripheral 
<2mm 
Diameter 
Bronchioles 
Bronchioles Alveoli Arteries Capillaries 
Cells 
Macrophages 
T lymphocytes 
CD8 
PATHOLOGICAL CHANGES IN COPD 
 
Proximal 
>2mm 
Diameter 
trachea/ 
bronchi 
Veins 
 
Cells 
Macrophages 
T lymphocytes 
CD8 
Few 
Neutrophils 
Few 
Easinophils 
 
Cells 
Macrophages 
T and B 
Lymphocytes 
CD8>CD4 
Lymphoid 
Follicles 
+Fibroblasts 
 
 
 
Cells  
Macrophages 
T lymphocytes 
CD8 
Structural 
changes 
+Goblet cells 
+Submuscusal 
glands 
+Mucus 
hypersecretion 
Squamous 
Metaplasia 
Structural changes 
Air wall thickening 
Peribronchial 
Fibrosis 
Luminal exudates 
Bronchiolar 
narrowing 
and exudates. 
Centrilobular 
 
Common in 
smokers 
Dilatation and 
destruction of 
bronchioles 
Panacinar 
 
Common in A-
1 AT 
destruction of 
alveolar sacs 
and 
bronchioles. 
 
Structural Changes 
Alveolar destruction 
Apoptosis of endothelial 
and epithelial cells 
  
 
16 
However, both hypotheses are probably acceptable as studies have suggested that bronchial 
hyperactivity, irritant exposure and chest infections all play important roles in the pathogenesis 
of COPD.  Figure 2.3 summarizes the pathological changes that occur in COPD.  
 
 
2.4   Factors Influencing the Pathogenesis and Progression of COPD. 
 
Although COPD is known to be a preventable and a treatable condition, the airflow limitation 
that occurs in COPD is not completely reversible (Pauwels et al., 2001; Celli et al., 2004).  The 
most important cause of COPD in the world is cigarette smoking (Churg et al., 2008; Jordan et 
al., 2011; Mannino et al., 2007).  In some individuals environmental and occupational 
exposures to fumes, gases, vapours and dust are the major risk factor (Trupin et al., 2003).  
Additionally exposure to domestic or biomass smoke (Guoping et al., 2010; Smith et al., 2003; 
Kiraz et al., 2003), malnutrition (Bargon & Muller, 2001; Ferreira et al., 2000), childhood 
infection (Shaheen et al., 1995), genetic predisposition (Lomas and Silverman., 2001), 
hyperresponsiveness of the airways and asthma (Scichilone et al., 2006) are also regarded as 
important causes of COPD particularly in the developing world i.e. the regions where cigarette 
smoking is less prevalent.  Some important exposures (Smith et al., 2003) that influence COPD 
progression are presented in figure 2.4. 
 
Figure 2.4.  Risk factors of chronic obstructive pulmonary disease (URL 3) 
(Adapted from GOLD 2009) 
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2.4.1  Smoking and COPD 
 
Smoking is the major cause of both development and poor outcomes in patients with COPD 
due to its influence on the progression of COPD in individuals irrespective of their smoking 
status.  Non-smokers are defined as subjects who have not smoked 100 cigarettes in their life 
time.  Disease progression may also differ in patients with different smoking status; however, it 
has been suggested that complete smoking cessation may be beneficial even in older and more 
advanced COPD patients (Zielinski et al., 2010).   
 
There are various observed and published articles which confirm the association of smoking 
status with disease severity, progression, and mortality (Fletcher and Peto, 1977).  One study 
showed that COPD patients who continue smoking have a significantly impaired health related 
quality of life (HRQL) as compared to those who stop smoking (Prigatano et al., 1984).  On the 
other hand, current smoking has been associated with better HRQL in the study by Wijnhoven 
and colleagues (2001).  The explanation given was that subjects who do not stop smoking 
might be those with a less severe stage of the disease and therefore less health status 
impairment. The present study also examines the effect of both active and passive smoke on 
disease progression.   
 
It has been also suggested that an undefined genetic makeup of heavy smokers may minimize 
or maximize the chances of developing COPD in later life.  The gene ADAM33 has been 
connected with asthma and studies suggest that patients with asthma and emphysema (a 
permanent dilatation of the air sacs of the lungs accompanied by destruction and loss of 
elasticity alveolar walls) are more prone to develop COPD if they smoke (Sadeghnejad et al., 
2009).   
 
 
2.4.2 Tobacco Smoke (Passive Smoking) 
 
Passive smoke (also called second hand smoke) is smoke that mainly comes from two different 
sources -- mainstream smoke or indirect cigarette smoke which is exhaled by an individual 
during smoking, and a side stream smoke or a direct smoke emitted directly from the end of a 
burning cigarette (Leader, 2008; Coultas, 1998).  Studies have suggested that both types 
contain the same toxic substances (US Department of Health, 2006; Oberg et al., 2010). 
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Studies have also confirmed that tobacco smoke is one of the major sources of indoor pollution 
both in developed and developing countries. PM2.5 which is a small particle emitted from 
combustion, including cigarette smoking, has a substantial effect on deaths/year.   According to 
a UK Government report, a 6% increase in death rate occurred in western European and North 
American populations after a modest increase in the ambient annual average level of PM2.5 of 
about 10micrograms /m3.  Where solid domestic fuel combustion is common concentrations 
can easily be raised by this amount (Department of Health, UK, 2005).  It is also indicated that 
before the smoking ban in Irish workplaces, fine particulate  pollution, PM2.5 levels in Dublin 
restaurants and pubs were almost 6 times higher than in the outdoor environment (Goodman et 
al., 2007).  This later decreased by 84% when the smoking ban came into effect.  This strongly 
suggests that second hand smoke is the major indoor source of PM2.5.   Eisner and colleagues 
(2006) have studied the direct impact of second hand smoke on health outcomes and showed 
that the highest tertile of urine cotinine in COPD patients was longitudinally associated with 
severe dyspnoea, COPD severity, and a worsening of  health status in these patients (Eisner et 
al., 2006).   
 
Elastin, a fibrous protein is a target for injury in COPD and plays an important role in 
pathogenesis of COPD (Deslee et al., 2009) and a recent study (Slowik et al., 2011) suggests 
that a degradation of body elastin occurred in lungs due to second-hand smoke exposure which 
possibly leads to lung structure damage resulting in the development of COPD.   
 
The above discussion of the global burden of disease attributable to second-hand smoke 
suggests that in order to achieve substantial health improvements, attempts should be made by 
extensive and effective public health programmes, awareness and clinical interventions to 
reduce and to avoid passive smoking worldwide.   
 
 
2.4.3 Exposure to Other Pollutants (Mainly Air, Occupational & Environmental) 
 
 
The airway obstruction in COPD is generally progressive and is linked with an abnormal 
inflammatory response of the lungs to harmful gaseous particles and primarily to cigarette 
smoke.  Because various kinds of air pollutants are commonly known as risk factors for COPD 
(ATS, 1995), it appears that occupation and indirect smoke (maybe passive smoke) are likely 
to play an important role in COPD occurrence, progression and complication.   
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Environmental air pollution is another factor that influences both the development and 
progression of COPD (Blanc et al., 2004, Trupin et al., 2003).  But there may be other causes 
such as in-house smoke released from biomass fuel (wood) used for cooking purpose (Osman 
et al., 2007) and this is becoming an increasing problem in third world countries. Another 
study suggested that both indoor and outdoor exposure to air pollutants may exacerbate COPD 
(Liu et al., 2008) and thus influence outcomes. 
 
Occupational and environmental exposure to chemicals found in the environment may 
potentiate or aggravate the inflammatory effect in the lung airways of COPD patients 
(Meldrum et al., 2005; Christiani, 2003).  There is a possibility that heavy smokers and non-
smokers who are not exposed to such pollutants exhibit no pathological changes in the airways 
and are relatively safe.  Lastly, there are varieties of cigarettes available in the market with 
different brand names and there may be some specific brands that are responsible for COPD. 
To date, such substances are not known. Substances including Beedi, Cigar, Hookah and Pipe 
that are common in some parts of the world may be responsible for the development of COPD 
(Malik 1977; Jindal et al., 2006).  Biomass burning in both rural and urban habitations may 
affect both men and women (Torres et al., 2008; Tan et al., 2008) and could lead to the 
development of chronic lung disease later in life.  
 
The use of biomass substances for cooking and heating is a major source of  indoor pollution in 
the developing world.  This smoke contains high levels of organic chemicals released into 
spaces that are poorly ventilated, particularly in developing and poorer countries. However, 
evidence-based findings are needed to draw any final conclusion.  Therefore there is a need to 
investigate its effects on patients with established obstructive lung disease including its impact 
of lung function impairment and on the clinical course of obstructive  pulmonary disease 
(Eisner et al., 2007) particularly in developing countries. 
 
In addition, Osman and co-workers (2007) have suggested that nitrogen dioxide (NO2) another 
major indoor pollutant yielded from combustion, during the operation of gas heaters or gas 
stoves may be associated with COPD.  However, it is also suggested that NO2 exposure is not 
consistently associated with worsening respiratory symptoms or lung function impairment 
(Eisner et al., 2002, Jarvis et al., 1998, Moran et al., 1999, Blance et al., 2005).  Therefore, 
further research will be needed to explore the influence of indoor NO2 on pulmonary function 
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(Lagorio et al., 2006).  On a global scale, a large burden of obstructive lung disease  symptoms 
is attributable to indoor combustion (Ramirez-Venegas et al., 2006).   
   
It has been documented that occupational exposure to some substances such as silica and 
cadmium also increase the risk of COPD.  Occupational related exposure in coal miners, 
construction workers, metal workers, motor mechanics, cotton workers and shipyard workers 
have also been reported as factors (Hendrick, 1996; Boschetto et al., 2006) that potentiate the 
adverse events related to COPD including worsening of symptoms, hospitalisation and 
disability.   
 
 
2.4.4 Family and Genetic Predisposition 
 
 
Deficiency of alpha-1-antitrypsin is the only known genetic factor that is widely accepted to 
predispose both smokers and non-smokers to COPD (Lomas and Silverman, 2006).  Damage to 
peripheral airways and alveoli is thought to occur when there is an imbalance between 
proteinases (e.g. elastase from polymorphonuclear neutrophils) and anti-SURWHLQDVHV Į1 
antitrypsin being the most important). Alpha1 antitrypsin deficiency is a recessive disorder with 
prevalence in the UK estimated higher than other European countries (Hutchinson, 1998; 
Blanco et al., 2006).  It is important to screen these individuals at birth as recurrent lower 
respiratory tract infections and cigarette smoking accelerate the development of emphysema.    
 
Studies also suggest that some single nucleotide polymorphisms (SNPs)-human DNA sequence 
variations are more common in COPD sufferers who smoke than in smokers without COPD 
(van Diemen et al., 2005).  Patients with a family history of respiratory problems (suggestive 
of parental emphysema, asthma, autoimmune disease, any genetic defect or COPD sensitivity), 
a past history of recurrent chest infections and childhood asthma are more prone to develop 
COPD later in life, which can be earlier and more severe in those who smoke. Some studies 
have also suggested that tobacco expressed as pack years correlates weakly with FEV1 (Marcus 
et al., 1988; Sadeghnejad et al., 2007).  
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2.4.5 Gender and COPD 
 
Gender plays an important role in the development of COPD.  Generally, COPD is more 
prevalent in males, and this may be the result of smoking habits and occupational exposure to 
certain chemicals.  However, during the last decade the prevalence of smoking has increased 
among women and some evidence suggests that women are more prone to damage their lung 
function than men (Chapman et al., 2001).   
 
COPD in non-smoking females is more prevalent than in non-smoking males and this may be 
explained by the difference in size of their lungs (Sorheim et al., 2010).  Female lungs are 
smaller than male lungs and the smaller cross-sectional dimensions of the airways may 
contribute to airflow limitation.  This accords ZLWK3RLVHQLOOH¶VODZZKHUHUHVLVWDQFHLQDWXEH
is proportional to the fourth power of the radius. 
 
Many studies have highlighted the importance of gender in chronic diseases and its relationship 
with mortality (de Torris et al., 2009).  It is also suggested that frequent exacerbations are more 
prevalent in females than men. Women are also at a higher risk of malnutrition (Leader, 2011).  
Furthermore, the data of the Rotterdam Study that addresses  the important issue of a 
remarkably high incidence of COPD in young women, suggests a further shift toward 
females in the sex distribution of COPD (van Durme et al., 2009).  However, despite 
this inconsistency in the gender predominance, mortality remains higher in males  (de Torres et 
al., 2009). 
   
In relation to HRQL in COPD, lower HRQL among women has been widely described 
(Belloch et al., 2003, de Torres et al., 2005 and 2006).  It remains unclear whether this is due to 
differential reporting patterns, or whether there is a real difference in their health status.   
Gender is therefore important for COPD susceptibility and progression (Kirkpatrick et al., 
2009). 
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2.4.6 Age and COPD 
 
As with most chronic diseases, the prevalence of COPD is strongly associated with age 
(Halbert et al., 2006).  This is one of the most important personal characteristics known to have 
an impact on progression, health, mortality and morbidity.  Data collected in a general Italian 
population showed a progressive increase of the prevalence of chronic bronchitis and 
emphysema with age in both genders (Viegi, 2001).   
 
Blake and his co-workers reported that ageing is related to the decline in health related quality 
of life (HRQL) especially in its physical aspects (Blake et al., 2000), which could lead to 
disability and death.  
 
2.4.7 Body weight and Body Mass Index in COPD 
The phenomena of loss of weight together with muscle weakness and loss of muscle mass in 
patients with COPD are not clear. However, experts (GOLD, 2009) have suggested a number 
of factors that potentially cause loss of weight and muscle tissue which, in turn, influences 
progression and assessment in these patients (Bargon et al., 2004). 
These factors may include: 
x Breathing and any other physical activity in these patients requires more energy thus 
more nutrients are needed to produce more energy.   
x Drugs such as oral corticosteroids may be needed as a treatment option and may 
influence the breakdown of muscle tissue. 
x Loss of appetite as they feel depressed due to their breathing symptoms.  Additionally, 
some drugs used to treat depression may cause loss of interest in food (Chavannes et 
al., 2005).   
x These patients have less oxygen available to diffuse into the blood which affects the 
ability of the body to metabolize food properly.    
x Postprandial (after eating) effect on breathing, as a full stomach may exert pressure 
on the diaphragm (muscular partition between thorax and abdomen that supports lungs 
and helps breathing) therefore, make it difficult to breathe (Palmer and Hiiemae, 2003). 
Furthermore, chewing or swallowing of food, particularly solid food requires breath 
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holding which may not be comfortable, particularly if the patient has breathing 
difficulties. 
x COPD patients are generally elderly and live alone or with a carer (Pinnock et al., 
2011).  Therefore, they may not take in quality food or balance their diet on time.  This 
is especially true for those who belong to a limited income group as this potentiates 
poor eating habits.   
 
If patients with COPD lose weight e.g. when fat free mass (FFM) falls below 16 kg/m2 or the 
body mass index (BMI) falls below 21, increased mortality has been found (Marti et al., 2006).  
So, in addition to FEV1, BMI has proved useful in predicting outcomes, such as survival, and 
several authors have recommended that it should be evaluated in all patients (Schols, 1998; 
Landbo, 1999).  BMI is an easily measured index calculated by dividing total body weight (in 
kg) by height squared (in m2).  A value of less than 25 kg/m2 is associated with increased 
mortality (Marti et al., 2006; Yang et al., 2010). 
 
Patients with COPD who demonstrate a significant weight loss do not only have a worse 
prognosis but also develop peripheral muscle weakness (Arora and Rochester, 1982). This 
leads to exercise limitation and health impairment (Vandenbergh et al., 1967; Dowson et al., 
2001) and these factors act as an important cause of disability.  Chen and colleagues (2000) 
found that a BMI < 20 and a BMI > 28 among male and female subjects respectively were 
associated with an increased prevalence of COPD.  De Angelis (2001) reported hypercapnia 
during sleep in COPD patients with a high BMI (De Angelis et al., 2001).  Later studies 
documented that men with a low BMI are at an increased risk of developing COPD (Raida et 
al., 2002).  Another interesting study carried out by Guerra and co-workers (2002) concluded 
that patients with chronic bronchitis are more likely to be obese whilst patients with 
emphysema are underweight.  
 
Thus, until 2002, studies have documented the prognostic value of low and high body weight 
in patients with COPD as well as in the general population.  However, it was unclear whether 
low body weight is a risk factor for COPD or a consequence of the disease.  But, research 
carried out by Gronberg and co-workers (2005) concluded that dietary problems are common 
in the group studied, and related to smoking habits and gender. Chavannes and his team (2005) 
suggest that, in primary care, depressive symptoms in COPD seem to be related with female 
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gender, high BMI and dyspnoea.  Patients with COPD have a high metabolic rate that is not 
balanced by high dietary intake, and thus results in low body weight.   
 
 
2.4.8 Life style and COPD 
 
Lifestyle is also an important factor and this varies in different parts of the world. If we 
consider western society, smoking is common in males and hence their female partners are 
exposed to passive smoke (Gupta et al., 2002).  
 
Another study suggested that culture and ethnic origins may also influence COPD progression 
and should be investigated further (Siu et al., 2009).   
 
Education is important in the sense that education leads to people becoming aware of general 
symptoms and how and when to seek medical advice.  Thus earlier diagnosis can prevent 
disease progression.   
 
Smoking marijuana and opium may be a precipitating factor for airway inflammation as well 
as air pollution and this is seen across the world (Tan et al., 2009).  Psychosocial and economic 
status may be related to the use of these addictive substances (Leader, 2008).  But there is an 
uncertainty regarding its impact on progression in patients with COPD and this area needs 
further attention particularly in developing and poor income countries where the addiction to 
these drugs are more common.   
 
Furthermore, significant social and occupational inequalities are found in men between 20-64 
years of age. Those engaged in unskilled manual occupations are at more risk (14 times) of 
dying from COPD than those involved in professional occupations (BTS, 2006). 
  
Thus at a personal level, each individual has specific risk factors influencing progression of the 
disease based on economic conditions, psychosocial status, attitude towards disease 
management and improved health, work related exposure, family and life time medical and 
drug history.  The present study will evaluate some of these markers and their role in COPD 
progression. 
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2.4.9 Low Socioeconomic Status and COPD 
 
The association of a high prevalence of COPD with low socioeconomic status has been 
reported in many epidemiological surveys (Thorn et al., 2007; Eisner et al., 2011).  Economic 
difficulties have also been identified as a marker of poor disease course (Antonelli-Incalzi et 
al., 2007).  It has also been found that with patients aged 70 years or above hospitalisation due 
to exacerbations are more prevalent (Antonelli-Incalzi et al., 2007).   
 
Populations of poor countries are exposed to indoor air pollutants that result from the 
combustion of solid fuels in poorly ventilated work or living spaces, which significantly 
influence the burden of COPD-related diseases, particularly in (non-smoking) women (Liu et 
al., 2008).  However, preventive strategies may vary between countries that particularly need to 
improve air-cleaning technology, air quality legislation and information dissemination together 
with greater provision and installation of improved cooking stoves.  Therefore a co-operative 
effort is needed from both governments and society to improve COPD related outcomes.   
 
In low income countries, both the amount of food and quality of the diet is influenced by 
income, which may lead to malnutrition or insufficient nutrients.  One study has suggested that 
poor socioeconomic status plays an important role in the development, progression and other 
life threatening manifestations of COPD (Tan and Ng, 2008).  Moreover, sufferers do not 
consult a physician because they neither have the money to pay the doctors nor to buy 
prescribed medicines.  It also appears that diet influences self-immunity (e.g. antioxidants) 
(Nelson, 2009) and thus delays inflammatory responses to certain inhaled substances.  
 
Clinically, a viral infection (mainly adenovirus) within the lungs heightens inflammation and 
hyperactivity of the bronchial passages but the role of viruses in the pathogenesis of COPD 
remains controversial.  Nevertheless, it has been proposed that childhood respiratory symptoms 
and a history of recurrent respiratory infection could lead to COPD in adulthood (Barker et al., 
1991, Shaheen et al., 1994, Sethi, 2000, GOLD, 2004). 
 
Irrespective of gender and age, there are several other proposed risk factors.  These risk factors 
include gestational age, weight at birth, smoking and smoke exposure from both mother and 
father throughout gestation and several other irritants throughout adulthood.  Family history 
may also be important to rule out chances of airway disease development.  Additionally, the 
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ERG\¶V VHOI DQG DXWRLPPXQH UHVSRQVH WR FHUWDLQ FKHPLFDOV PD\ EH RI UHODWLYH LPSRUWDQFH
suggesting an autoimmune nature of COPD (Nunez et al., 2010).  Several studies also suggest 
that, irrespective of smoking status, older patients with a low BMI are statistically associated 
with COPD.  In both factors, education and poverty have a role.  
 
Moreover, epidemiological studies have played an important role in the characterization of the 
disease at a population level, pointing to potential causes and assessing its impact on the 
patient, individually and on the society collectively.  But more research is needed to explore 
factors that influence progression that in turn, could lead to more comprehensive strategies to 
overcome poor outcomes in these patients. 
 
 
2.5 COPD Outcomes 
 
COPD is one of the major causes of preventable disability and death.  In the UK, COPD is the 
2nd commonest condition for emergency hospital visits and the 5th commonest cause of hospital 
readmission.  Thus COPD becomes very costly both for patients as well as for health care 
providers (Department of Health, UK, 2010).  
 
The chronic, progressive and irreversible nature of COPD will lead to outcomes that impact 
upon both patients with COPD as well as their care providers. 
 
 
2.5.1 Mortality 
 
COPD causes approximately 26,000 deaths every year in England and kills more females than 
breast cancer and more men than prostate cancer (Royal College of Physicians of London, 
British Thoracic Society (BTS) and British Lung Foundation (BLF), 2008).  
 
Worldwide, at least 2.5 million deaths from COPD were recorded in 2000 and approximately 
half were in the Western Pacific Region especially China. In the United States, COPD causes 
death to someone every 4 minutes (COPD Foundation, 2008). Furthermore, 12 million people 
have diagnoses of COPD, and it is estimated that 2 million cases still remained undiagnosed 
(NHLB, 2009).  In other industrialized countries more deaths due to COPD occur and the 
regional prevalence of COPD in adults varied from 0.5% in parts of Africa to 3±4% in North 
America in 2000 (Lopez et al., 2006).  More recently, the mortality data published by Gener
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Register Office of Scotland (GROS) indicates that the annual number of deaths due to COPD 
in males fell from 79-52 per 100,000 to 34% between 1981 and 2006 and increased from 21.2 
to 40.9 to 93% in females (Scottish Public Health Observatory, 2011). In the UK, annually, 
approximately thirty thousand people die of COPD and the majority of those are aged over 65 
years (Britton et al., 2003). People dying from other diseases (cardiovascular, lung 
malignancy) often have COPD as a comorbid condition (Hensell et al., 2003).  COPD related 
mortality also shows a strong rural and urban gradient (Eberhardt et al., 2001) especially in the 
Northern part of England (Hansell et al., 2003).  
 
Mortality in severe COPD due to acute exacerbation of COPD ranges from 36%-59% and this 
FRPSDUHV  XQIDYRXUDEO\ ZLWK FDQFHU SDWLHQWV µWKH -year relative survival rate for persons 
diagnosed with cancer is 62.7%, with variation according to cancer site and stage at the time of 
GLDJQRVLV¶*ORHFNOHUHWDO 
 
In the UK, pulmonary pathologies are the third commonest cause of chronic sickness in the 
working age population (aged 45-64 years). In contrast to cardiovascular and other chronic 
illnesses, deaths from COPD are predicted to rise substantially as reported by Center for 
Disease Control (CDS) in 2008 (COPD Alert Fact Sheet, 2010) (Figure 2.5).   
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Figure 2.5.  Mortality trends of different chronic illnesses in the US (URL 4) 
 
 
2.5.2 Exacerbations 
 
 
Exacerbation, which is defined as a worsening of the severity of the disease or its signs and 
symptoms, is very common even in mild stages of disease (Hurst et al., 2010).  The recurrent 
attacks are caused by smoking or infection and often require emergency (hospital at home or 
hospital care) treatment (BTS Guideline Development Group, 2007) and in a significant 
proportion of patients may lead to respiratory failure. 
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2.5.3 Impaired Quality of Life  
 
Health status impairment is also common in these patients.  Considering a chronic illness and 
long standing breathlessness, functional impairment is also common even in those with a mild 
stage of the disease (Miravitlles et al., 2009).   
 
 
2.5.4 Co-morbidities 
 
Comorbidities are also common in patients with different stages of COPD (Feary et al., 2010; 
European Lung Foundation, 2011).  These patients are at higher risk of premature disability 
and death from cardiovascular causes and stroke.  More importantly, deaths in patient with a 
milder form of COPD are more likely due to other associated comorbid conditions than the 
COPD itself (Feary et al., 2010). 
 
 
2.5.5 Anxiety and Depression 
 
The prevalence of anxiety and depression are very common in patients with COPD.  This 
psychological condition can have a significant impact not only on patients, but also on  their 
families, carers,  society, and the ultimately the progression of the disease (Maurer et al., 2008) 
due to its influence on treatment adherence, disturbed sleep and appetite and self-care.  
 
Therefore, the key reasons for the poor outcomes seen in patients with COPD are poor 
symptom recognition, late diagnosis of COPD and insufficient or maybe inappropriate methods 
of assessment of its progression and management and further research should be carried out to 
overcome the overwhelming burden of the disease and its outcomes. 
 
 
2.6  Complexities in the Progression of COPD 
 
It has been suggested by Mannino and co-workers (2000) that COPD is usually in the moderate 
to severe stage by the time clinical signs become obvious and the patient seeks medical advice 
(Mannino et al., 2000).  
 
COPD is a very complex and heterogeneous disease with various clinical presentations 
(Nishimura et al., 2012; Decramer et al., 2008; Pistolesi et al., 2010).  In the early stages of 
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COPD, patients appear to be symptomless and may not visit a physician until the condition 
becomes worse and reaches an advanced stage (Van Schayck et al., 2000; Clotet et al., 2004).  
Around the age of 40, people with COPD experience a mild cough with or without sputum. 
During their middle to late 60s, shortness of breath on exertion becomes more troublesome, 
specifically if they continue smoking.  There are a number of reasons for this delay in the 
appearance of symptoms (Celli et al., 2004).  Firstly there may be no sudden episodes of chest 
symptoms such as chest tightness, breathlessness, cough and/or wheeze that might alert the 
patient, as occurs in patients with asthma (Van den Boom et al., 1998).  Secondly, a delay in 
recognition of the true impact of COPD might occur because the disease usually develops at 
that time of life when people generally begin to modify their leisure and recreational activity to 
less strenuous pursuits.  Therefore, we can assume that a damaging process has been started 
long before the time when a patient usually seeks medical advice for their symptoms.   
Pneumonia and other lung infections occur more often as the disease advances. In severe 
stages, patients become short of breath even at rest and/or modest activity, which sometimes 
requires a course of antibiotics and/or steroids possibly with hospital admission (Bahadori et 
al., 2009).  
Patients with COPD particularly in severe cases often complain of disturbed sleep (Omachi et 
al., 2010) because they are unable to breathe easily in a lying down position therefore they 
sleep in a semi-sitting position or need to sit up to cough (Omachi et al., 2010). 
COPD also presents with various kind of both pulmonary and extra-pulmonary manifestations. 
These manifestations commonly include weight loss, loss of appetite, anxiety, depression, 
osteoporosis, cardiovascular problems and finally lead to impairment in overall quality of life 
and health status (Dourado et al., 2006; Barnes et al., 2008; Smith, 2009).  In most severe 
cases, it may lead to circulatory and respiratory failure.  This emphasizes the necessity for 
comprehensive monitoring and assessment of all the aspects of disease progression in patients 
with COPD and to utilize a multidimensional approach to assess these patients.   
 
If COPD is allowed to progress there are more hospitalisations and unscheduled visits to 
emergency departments or GP surgeries.  These are all expensive and will require medication 
and other expensive interventions to manage these COPD related consequences.  There is also 
DVRFLHWDOFRVW LQ WHUPVRISDWLHQWV¶ UHVWULFWLQJ WKHLU OHLVXUHDFWLYLWLHVDQGGURSSLQJRXWRI WKH
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work force.  This burden may be lessened if the condition is diagnosed earlier and monitored 
effectively. 
 
A patient ±centred, and evidenced based report published recently (2010) by the Department of 
Health (DH), England) is a very comprehensive document which recognises that potentially 
there are substantial gaps with respect to COPD disease management.  They recognise that 
there is significant scope for improvement in the prevention, diagnosis, management and 
assessment of progression of COPD, and propose a fundamentally new approach to reducing 
the COPD burden (Kearney et al., 2010). 
 
However, identifying and filling those gaps could play a vital role in driving up quality and 
delivering significantly better outcomes in these patients.   
 
 
2.7 Measurement and Assessment of Progression (Natural History) & Severity of 
COPD 
 
Studies suggest that the natural progression and history of COPD involves very complex 
cellular, microbiological and biochemical events in the small airways and adjacent alveoli 
which may lead to loss of elastic recoil (Saetta et al., 1997 & 2000; Petty et al., 1987).  As a 
result, the lungs enlarge but the airways become narrower leading to early spirometric airflow 
limitation (Burrow et al., 1987).   
 
Therefore, it is essential to understand the development of healthy and diseased lungs with 
aging and also the gender related differences that may be associated with pulmonary 
impairment in order to plan strategies to monitor and treat different lung pathologies such as 
COPD (Cosio & Agusti, 2010).  
 
The Fletcher-Peto model (1976) explains the natural history of COPD and uses an FEV1 based 
model to describe the natural history of COPD (in males) (Fletcher & Peto 1977).  This finding 
is the most important finding in the field of COPD as it established the impact of smoking on 
COPD and significance of smoking cessation at different stages of COPD (Anthonisen et al., 
1994).  This model demonstrates that lung function declined progressively over time and that 
the rate of decline is associated with ageing (Figure 2.6).  This study also showed a slower rate 
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of FEV1 decline in non-smokers and, surprisingly, many smokers who seemed highly resistant 
to be influenced by adverse effects of smoking on their lungs.  In contrast, there are smokers 
who are susceptible to lose FEV1 at faster rate and are highly prone to develop clinically 
significant obstruction of the airways. It was also found that in smokers who stop smoking 
(exsmokers), the expected rate of lung function decline may revert to normal. Fletcher and Peto 
concluded that both hypersecretion of mucus and bronchial infections does not influence lung 
function deterioration.  That concluding remark from Fletcher and Peto made development and 
progression of COPD more controversial and the subject become the focus of all investigations 
regarding disease progression. 
 
Figure 2.6.  Fletcher±Peto Curve indicating effect of smoking by age on lung functions 
     (Adapted from Fletcher Peto, 1977) (URL 5) 
 
 
More recently (Kohansal et al., 2009) revisited with a larger cohort consisting of both males 
and females for the first time.  They were followed up for 23 years and put forward some novel 
findings related to the natural history and progression of COPD.  They found that the rate of 
lung function deterioration was smaller in healthy never smokers (in both genders) than 
suggested previously (20 vs 30 ml/year).  Another important finding was the damaging effect 
of smoking on the lung function decline rate which was similar in males and females.  They 
also underlined the significance of respiratory symptoms that helped them identify a 
population of smokers particularly susceptible to develop obstruction.  Additionally, the study 
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suggested that quitting smoking earlier is more protective and preventive in slowing down the 
progression of airflow limitation (Kohansal et al., 2009).  
 
Severity of disease is another term used in parallel to disease progression.  In COPD it is 
measured on the basis of FEV1 predicted value cut off points however proposed cut-off ranges 
to determine severity in all recommended guidelines (ATS, 1995; BTS, 1997; GOLD, 2010; 
National Institute of Clinical Excellence (NICE), 2010) are not evidence-based and do not 
correlate  with some of the outcomes.  Therefore, the current trend is in favour of the use of 
multidimensional indices of severity such as BODE, DOSE and ADO (Celli et al., 2004; Jones 
et al., 2009; Puhan et al., 2009) however, these indices have some limitations  and therefore 
have not yet been included in guidelines published (NICE, 2010).  Esteban and colleagues 
(2009) compared them as prognostic indicators and found that BTS system of classification 
was slightly superior but that none of the guidelines was closely related to 5 year mortality.   
 
Hence, FEV1 which plays a role in all these multidimensional indices contributes to the 
variability in patient severity scores, depending on the cut-off points used. However the current 
recommendation emphasises (NICE, 2010) the use of classification criteria developed by 
GOLD (GOLD, 2011) which is based on deterioration in lung functions and may not 
completely reflects the burden of disease in these patients.   
  
 
2.8  THE NEED TO MEASURE PROGRESSION 
 
The literature review to date suggests that COPD has been the focus of research related to 
respiratory diseases, for many years, with studies addressing a number of different issues 
LQFOXGLQJ WKH LGHQWLILFDWLRQ RI LWV¶ FDXVH $JXVWL HW DO  	  PHFKDQLVPV IRU WKH
improvement of care and management (Brusasco et al., 2003; Yang et al., 2011, Qaseem et al., 
2011); identification of new markers for the diagnosis of COPD (Celli et al., 2004; Cote et al., 
2005; Funk et al., 2009) together with markers for the progression of the illness (Celli et al., 
2004 & 2009; Puhan et al., 2009; Esteban et al., 2010) and prediction of survival (Funk et al., 
2009; Puhan et al., 2009).  Despite extensive research, mortality of patients with COPD has 
risen (Ekstrom et al., 2011).   
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Furthermore, the current methods of assessment of clinical outcomes in patients with COPD 
mainly rely on physiological measurements combined with the use of health assessment 
questionnaires.  The review has considered commonly used outcome measures in COPD such 
as lung function, breathlessness, health status, exacerbations, exercise capacity, physical 
activity, dyspnoea, comorbidities and mortality.  Based on current studies (Celli et al. 2004, 
Puhan et al., 2009, Jones et al., 2009), this review provides a comprehensive overview of the 
principle objectives, strengths and weaknesses with particular emphasis on their limitations and 
opportunities that should be recognized when assessing and interpreting their use (Glaab et al., 
2010).   
However, it is estimated that in England 842,100 of 50 million people have COPD at some 
point in their lives (Simpson et al., 2010) and the burden of COPD is still on the rise (WHO, 
2011).  Therefore urgent action needs to be taken to reduce this rising trend and also to explore 
and re-examine relevant physiological and psychological factors that directly or indirectly 
influence diagnosis, progression, treatment response and other COPD outcomes. 
 
 
2.9 MECHANISMS FOR THE ASSESSMENT OF COPD PROGRESSION 
 
 
2.9.1 PHYSIOLOGICAL ASSESSMENT 
 
a. Lung Function Deterioration  
FEV1 is regarded as an important indicator of COPD progression and the most accurate clinical 
measure of lung function. To date, smoking cessation has been the only intervention that has 
been conclusively shown to alter the rate of decline in FEV1 (Godtfredsen et al., 2008).   
The original findings from TORCH (TOwards a Revolution in Chronic obstructive pulmonary 
disease) study (Calverley et al., 2007) demonstrated that treatment with salmeterol/fluticasone 
propionate resulted in a trend towards a reduction in all-cause mortality, although the mortality 
benefit did not reach statistical significance.  In addition, the study confirmed that treatment 
with salmeterol/fluticasone propionate provides improvements in lung function over three 
years and improves COPD outcomes (Calverly et al., 2007).   
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Spirometry is the most commonly used test in COPD patients. It provides an overall measure 
of the functional status of the lung.  Post-bronchodilator spirometric values are the gold 
standard for the diagnosis and classification of COPD. However, during screening it is not 
believed to be ethical to give a drug to an individual who does not exhibit any symptom of 
disease or may simply be at risk.  Using a drug will add cost and potentially may adversely 
affect some subjects.  Spirometry provides values for FEV1 and FVC and obstruction is 
identified by a lowered FEV1/FVC ratio (Sterk, 2004). However, there is a criticism of using 
FEV1/FVC ratio based on the fact that it may over-diagnose COPD in older populations and 
under-diagnose it in younger (Pownall, 2010; Shirtcliffe et al., 2007; Hnizdo et al., 2006).  
Studies have suggested that age in years is directly associated with physiological changes that 
influence respiratory function in males and females (Janssens et al., 1999).  Several other 
studies found that the cut-off point for an impaired FEV1/FVC ratio in healthy non-smokers 
depends upon their age and sex (Enright et al., 1993; Hankinson et al., 1999).  Therefore, the 
use of the fixed ratio of 0.70 as a cut-off point may lead to a misdiagnosis of COPD in the 
middle-aged and elderly population, irrespective of their genders.  Realistically, this finding 
has been demonstrated in various studies (Roberts et al., 2006; Shirtcliffe et al., 2007; Hnizdo 
et al., 2006). 
 
Furthermore, Schermer and colleagues (2008) found that symptoms in these patients are 
important, and if a patient is asymptomatic, his/her FEV1 value becomes irrelevant. They also 
suggested that there are chances that an individual with an FEV1 of less than 70 percent of 
predicted may always had an FEV1 at that level.  Therefore, other related factors such as 
symptom history, smoking history and history of occupational exposure have to be considered 
in order to assess and treat as patients with COPD.   
 
Nevertheless, the Cardiovascular Health Study suggests that a FEV1/FVC ratio of <0.70 may 
identify patients who are at greater risk for death and hospitalisation from COPD, even among 
older adults (Mannino et al., 2007).  It has been shown that the FEV1/FEV6 ratio (FEV6 is 
forced expiratory volume exhaled after full inspiration in the first 6 seconds) is as valid as 
FEV1/FVC ratio (Jing et al., 2009) but does not represent an advance for globally accepted 
guidelines such as NICE and GOLD.  The GOLD Guidelines assess disease severity on the 
basis of the degree of airflow obstruction, whereas the NICE Guidelines place greater emphasis 
on multi-dimensional assessment (Gruffydd-Jones & Loveridge, 2011).  
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Generally, spirometric classification has proved useful in predicting health status (Ferrer et al., 
1997), utilization of health care resources (Friedman et al, 1999) development of exacerbations 
(Burge et al., 2000) and mortality (Anthonisen et al., 1986).  Therefore, lung function is not 
only diagnostic for COPD but also helps in determining the disease stage, exacerbation, and 
can predict mortality (Schunemann et al., 2000). 
  
The Fletcher-Peto model (1976), based on forced expiratory volume in one second (FEV1) is 
the classical description of the natural history of COPD (in males).  However, systemic 
influences, including BMI (body mass index), and subjective and objective measures of 
exercise tolerance have also been recognised as important for COPD prognosis (Celli et al., 
DQGZHUHQRWFRQVLGHUHGLQ)OHWFKHU¶VVWXG\ 
 
Furthermore, the correlations between lung function and HRQL have been shown to be weak 
in a number of studies (Stahl et al., 2001).  In contrast, the relationships have been shown to be 
significant in a recent trial study (Kurashima et al., 2009) but the relationship shown was 
greatly influenced by the treatment interventions given.   
 
Therefore, more research is needed to further explore the issues surrounding lung function 
volumes including the best method of calculating reference/predicted values that are used to 
diagnose and classify the severity of COPD considering different physiological features such 
as gender, height and ethical origin.  There is also a need to examine the relationship of lung 
function with other COPD related outcomes in order to draw firm conclusions. 
 
Considering the multidimensional consequences of COPD, lung function should be assessed 
alongside other parameters related to COPD and the present study considers lung function as a 
component of the proposed BOD index and as an independent variable examines its role in 
predicting COPD outcome.   
 
 
b. Other Physiological Measurements that should be considered when Assessing 
COPD 
The diagnosis of COPD is dependent on demonstrating limitations of airflow with spirometry 
and may be made if the ratio of the forced expiratory volume in the first second (FEV1) to 
forced vital capacity (FVC) is below 0.70 or the lower limit of normal (LLN) (Swanney et al., 
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2008).  Furthermore, the degree of impairment of FEV1 has been utilised to classify the 
severity of airflow obstruction in various guidelines (GOLD, ERS/ATS, NICE 2011).   
Spirometric measurements are markedly affected by age (Teramoto et al., 1999).  However, 
height and anthropometric indices are also affected by age (Perissinotto et al., 2002).  Height 
loss may be indicative of osteoporosis and could affect the linear relationship between height 
and predicted forced expiratory volume in one second (FEV1).  This in turn may lead to a 
misdiagnosis and misclassification of COPD.  
The prevalence of osteoporosis is increased in smokers. (Law et al., 1997; Cornuz et al., 1999) 
and osteoporosis is a known co-morbidity associated with COPD (Barnes et al., 2009; Fabbri et 
al., 2008 and 2010).  Thus, using current height for predicting values of FEV1 may mean that 
the degree of impairment of FEV1 is subject to confounding and underestimation in an elderly 
population.  Other measures that could be used include: 
 
 
(i)  Body Composition 
 
Nutritional abnormalities are common in COPD and in smokers (Agusti, 2003; Shiozawa et al., 
2010).  These may present as weight loss, skeletal muscle loss and dysfunction and obesity 
(Franssen et al., 2008).      
Body mass can be divided into two compartments: fat mass and fat free mass (FFM) (Vestbo et 
al., 2006).  The first serves as a storage form of energy, whereas the latter contains the 
metabolically active organs and tissues, among which skeletal muscles are the largest part. 
Body composition can be determined using several methods; however, estimation with 
bioelectrical impedance analysis (BIA) is more convenient and can be carried out within a 
minute.  Alterations in body composition can occur in COPD patients in the absence of 
clinically significant weight loss as the development of obesity can conceal loss of fat free 
mass and bone mineral content.   
In other words, a normal balance of lean body mass and fat is associated with better health.  
Imbalance or higher fat content in relation to lean body mass leads to a condition that can 
greatly increase the risk of other life threatening conditions such as cardiovascular and other 
endocrinological disorders such as diabetes.  BIA helps early detection of a potential 
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nutritional imbalance of body composition and this allows an earlier intervention and possibly 
prevention.  BIA also provides the measurement of fluid and body mass that can be a critical 
assessment tool for a current health status. 
Improving or maintaining BIA measurements in patients with COPD may help the body to 
function properly and effectively and therefore may reduce risk of illness.  BIA results can help 
in determining and recommending specific requirements on an individual basis such as a 
personalised exercise plan, and a nutritional and lifestyle plan to help support good health and 
wellbeing. 
 
(ii) Body Weight and Body Mass Index   
 
 
Furthermore, significantly reduced body weight in advanced COPD is associated with 
decreased exercise performance and increased mortality.  Some previous studies (Schols e t al., 
1993; Mador, 2002) found that the reduction in fat-free mass without a reduction in body 
weight was seen in 24 of 255 patients (9.4%).  A reduction in body weight without a reduction 
in fat-free mass was seen in 23 of 255 patients (9.0%).  Thus, discrepancies between measures 
of body weight and measures of fat-free mass are not uncommon in this patient  population. 
Reduction in fat-free mass is a better predictor of peak exercise performance than the body 
mass index (Baarends et al., 1997).  It is possible that decreased fat-free mass may be a 
predictor of poor exercise performance independent of body weight.  However, the author is 
unaware of any studies to date that highlight this issue.  
 
Although the effect of nutritional status on exercise performance is established (Gray et al., 
1989, Hallin et al., 2010) little attention has been given to its effect on HRQL, disease 
progression and mortality. The present study examines the effect of nutritional status over time, 
change in BMI and lean body mass / fat free mass (FFM) and its relationship with other 
physiological measurements as a measure of the progression of the disease. This research also 
investigates how any change in FFM affects health status, muscle strength, co-morbid 
conditions, physiology and overall progression of COPD.   
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(iii) Inflammation and Muscle Wasting 
 
Muscle weakness is considered to be one of the leading coexisting problems in patients with 
COPD.  7KHUHDVRQ WKDW WKLVFRXOGEHUHVSRQVLEOHIRUSDWLHQWV¶SRRUERG\FRPSRVLWLRQ LV the 
lack of use of peripheral muscles (accessory muscles of inspiration such as intercostal muscles)  
among COPD patients (Decramer et al., 1997).  In the present research, BMI is one of the main 
components of the proposed BOD index and this study provides further evidence of how this 
measurement could be beneficial in predicting COPD outcomes and its management  
 
  Loss of muscle mass and muscle dysfunction are now recognised as important features of 
COPD which contribute to poor prognosis and additional symptoms. Initial studies revealed 
that such limitations were due to dyspnoea (Agusti et al., 2003).  In 1992, a study demonstrated 
that patients with COPD have limited exercise capacity owing to muscle dysfunction and 
skeletal muscle fatigue (Killian et al., 1992).  Consequently, this observation fuelled extensive 
research in the field and many studies have since confirmed the role of skeletal muscle 
dysfunction in the pathogenesis of COPD (Gosselink et al., 1996; Demedts et al., 2006) but 
there is still a need for detailed research in relation to the impact of muscle weakness on health 
status.   
 
COPD impairs peripheral muscle force (ATA / ERS 1999).  Peripheral muscle weakness may, 
in turn, result in reduced exercise capacity (Gosselink et al., 1996), higher use of health care 
resources (Decramer et al., 1997) or decreased survival (Decramer et al., 1996, Marquis et al., 
2002).  Sarah Bernard (1998) suggests that muscle weakness in COPD is due to muscle 
atrophy and her study also suggests that prolonged inactivity and muscle deconditioning are 
important factors in the loss of muscle mass and muscle strength in patients with COPD 
(Bernard et al., 1998). 
In 1998, Rantanen and co-workers launched a study that suggested that higher age reflects 
decreased strength.  This study also reported that chronic conditions such as stroke, diabetes, 
arthritis, coronary heart disease and COPD are associated with weight loss. Rantanen (1998 & 
2003) also found that hand grip strength is a powerful predictor of total mortality in older 
women.  In addition, it is also documented that poor hand strength as measured by handgrip is 
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a predictor of disability in older people (Giampaoli et al., 1999) but the study was just confined 
to elderly men (age range 71-91) with different chronic illnesses such as osteoarthritis. 
     
Therefore, the present study can be distinct in this aspect as it considers hand grip strength, 
dominant hand grip strength and dominant hand grip strength % predicted normal of age and 
sex) (Sunnerhagen et al., 2000) as a determinant of COPD outcome and the present study 
evaluates its influence in predicting COPD related measurements such as SMWT and 
outcomes such as health status and change over time.  
 
 
2.9.2 SYMPTOMATIC AND FUNCTIONAL ASSESSMENT 
 
 
a. Breathlessness 
 
The predominant complaint of patients with COPD is dyspnoea during physical activity (Witek 
HWDO6HYHUHG\VSQRHDZKHWKHUDFXWHRUFKURQLFDIIHFWVDSDWLHQW¶VIXQFWLRQDOVWDWXV
and quality of life as well as other aspects of the patient's life (Moody et al., 1993).  
Many studies have demonstrated various clinical techniques for rating dyspnoea including the 
modified Medical Research Council (MRC) scale (Bestall et al., 1999, Calverly et al., 2003; 
Pitta et al., 2005).  All are significantly correlated and virtually identical in evaluating 
dyspnoea in patients with COPD. 
Dyspnoea (shortness of breath) is a complex subjective sensation of functional disability in 
patients with different forms of cardio-respiratory diseases (Stenton, 2008).  There are various 
tools available for assessing dyspnoea.  For example, the measurement of dyspnoea with 
activities of daily living using clinical dyspnoea ratings such as the Medical Research Council 
05& WKH 0DKOHU¶V '\VSQRHD ,QGH[ 0', ZKLFK LV FRPSRVHG WR two parts Baseline 
Dyspnoea index (BDI) and Transitional Dyspnoea Index (TDI) (Mahler et al., 1988), the 
Oxygen Cost Diagram (OCD) (Chhabra et al., 2009)  and the measurement of dyspnoea during 
exercise using the Borg scale, which is a RPE (Rate of Perceived Exertion) scale to rate degree 
of breathlessness, uncomfortableness and fatigue level after an exertional activity such as a 
walk test (Burdon et al., 1982). 
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Every tool has its own advantages and disadvantages.  For example, MDI is a complex and a 
very time consuming questionnaire both for researchers and for patients but at the same time it 
has proved more sensitive for assessing short term changes in the degree of breathlessness in 
patients with COPD (Ansari et al., 2009; Chhabra et al., 2009).  Studies also suggest that the 
BORG scale is relatively costly and needs instruments, time and space. It cannot be applied to 
every subject as not all patients with COPD can perform the exercise test.  
In the 1950s, Fletcher and co-workers invented a tool to evaluate the degree of functional 
disability in subjects who have shortness of breath.  The full version of the questionnaire with 
its scaling system was published in 1959 (Fletcher et al., 1959).  Several versions are available. 
The version utilized in the present study is the five point scale demonstrated in table 3.2 
(chapter 3) (Scale from 1-5).  However, the modified version of MRC (MMRC, Scale from 0 
to 4) is virtually identical and appears to be more logical as absent breathlessness is scored 
zero.  The MRC scale is one of the most validated and widely used instruments to assess the 
degree of impairment due to shortness of breath in COPD (Bestall et al., 1999), bronchiectasis 
(Koulouris et al., 2003) and idiopathic pulmonary fibrosis (IPF) (Papiris et al., 2005).  It has 
also been used in other systemic illnesses that cause breathlessness such as sickle cell disease. 
(Declaux et al., 2005).  Patients with COPD predominantly complain of dyspnoea during 
physical activity.  The severity of dyspnoea and its correlation with various pulmonary 
physiological tests in COPD have been published (Mahler et al., 1988; Eltayara, 1996; Bestall 
et al., 1999).  Studies have also demonstrated that the MRC scores are significantly correlated 
with walking distance and mortality (Celli et al., 2004; Nishimura et al., 2002).   
As the MRC is sensitive when assessing long term changes in the degree of dyspnoea (Bestall 
et al., 1999, Calverly et al., 2003; Pitta et al., 2005; Ansari et al., 2007), this is the assessment 
of choice when measuring functional impairment in patients with COPD due to shortness of 
breath.   
 
The MRC scale is recommended as complimentary to spirometric measurements (FEV1) in 
describing functional disability in COPD patients and is used worldwide (Stenton, 2008).   
The MRC scale is an easy to fill questionnaire that requires only a few seconds.  It can be self- 
administered by asking the subject to choose the statement (out of 5) that best describes their 
clinical condition.  It can be administered by an interviewer with all the options of the MRC 
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scale framed in the form of questions/statements.  No additional resources such as space, 
equipment or any training is required to fill in this questionnaire.  Additionally, there is no 
copyright issue involved and it is readily available to use for clinical and research purposes.    
The only disadvantage of the MRC scale is its relative insensitivity to acute and sub-acute 
changes of disease status.  For example, change in disease status can be demonstrated after 
lung volume reduction surgery (LVRS); however, it is unlikely that all patients who undergo 
LVRS will demonstrate any significant improvement or deterioration in their entire MRC 
grades. The insensitivity may be due to a certain ambiguity in the MRC grading system, such 
that any subjects who can leave the house but can only walk 100 yards or less does not clearly 
fall into either Grade 4 or Grade 5.  Breathlessness during dressing and undressing is an 
additional indicator of severity.      
In the present research, dyspnoea is one of the vital components of the proposed BOD index 
and this research evaluates its significance in predicting COPD outcome and its change over 
time with respect to disease progression.    
 
 
b.  Exercise Test  
 
Patients with COPD often become severely inactive in their activities of daily living (ADL) 
such as housework, cooking, eating, bathing, dressing, grooming, and leisure (Katz et al., 
1983).  This inactivity leads to deconditioning and muscle weakness because of disuse. 
Several laboratory tests are available for the objective evaluation of functional exercise 
capacity, such as cardiopulmonary exercise testing, the Shuttle Walk Test and the 6-minutes 
walking test. Cardiopulmonary exercise testing is considered the gold-standard in the 
evaluation of patients with pulmonary diseases as it is monitoring, breath by breath, several 
cardiopulmonary variables, including maximal oxygen uptake, pulmonary output of CO2, 
minute ventilation, and cardiac frequency.  However, cardiopulmonary exercise testing 
requires dedicated laboratory equipment and expertise and it is difficult to perform in general 
clinical settings (Papaioannou et al., 2009).    
Pulmonary rehabilitation proved to be an effective intervention for the management of COPD 
(George & Monica, 2011; ZuWallack, 2007) and the six-minute walk test (6MWT) is widely 
used as an outcome measure in pulmonary rehabilitation programs (Jenkins et al., 2010). 
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Studies suggest several factors influencing the 6MWT in patients with and without COPD. 
There are various co-founders that can alter test results particularly in elderly individuals.  
These factors include age, body weight, mental health, and comorbidities (Enright et al., 2003).  
Poor nutritional state (Palange et al., 1995 and 2003) and breathlessness are manifestations of 
COPD that can also reduce 6MWT (Marin et al., 2001; Oga et al., 2002).  Muscle strength in 
the lower limbs has previously been shown to be an important factor in determining the 6MWT 
(Gosselink et al., 1996).   
Despite the number of confounding subjective and objective measurements, this test has gained 
importance globally and has been found to be reliable, safe and easy to apply.  The 6-minute 
walking distance (6MWD) has been shown to be an independent predictor of mortality in 
COPD patients, as shorter walked distance was confirmed to be associated with a higher 
mortality. (Cote et al., 2007, Enright et al., 2010).  Another report (Calverly 2007) has shown 
that the 6MWD declines over time and that this decline is most important in patients with 
severe airflow limitation (i.e. FEV1 < 50% predicted).  Interestingly, in patients with severe 
COPD the decrease in FEV1 over time has been shown to be relatively small, suggesting that 
decline in exercise capacity occurs independently of changes in lung function.  Studies also 
suggest that the six minute walk test is a good predictor of mortality in patients with interstitial 
lung disease (Eaton et al., 2005), pulmonary hypertension (Miyamoto et al., 2000), and acute 
respiratory distress syndrome (ARDS) (Herridge et al., 2003).   On the basis of above 
discussion, it is evident that this test plays a significant role in detecting changes and 
improvement which cannot be detectable in spirometry results especially in severe and very 
severe COPD.   
The exercise test has some disadvantages that may limit its application to all disease population 
and its use in all clinical settings (ATS 2003; Reybrouck 2003).  In terms of its application to 
COPD patients, not all patients can perform a meaningful walk test.  Also, considering the fact 
that COPD patients are generally over 60 years of age, it is likely that patients may have any 
DVVRFLDWHGFRPRUELGFRQGLWLRQWKDWPD\FRQIRXQGWKHUHVXOWRULQIOXHQFHSDWLHQWV¶SHUIRUPDQFH
in carrying out this test (Enright et al. 2003). For example, it will not be comfortable for a 
patient with osteoarthritis or osteoporosis to carry out this test.  
Additionally, for patients with severe COPD; a six minute walk test may be relatively unsafe as 
these patients have a severe form of impaired gas exchange, such patients when challenged 
with an increase in demand (as in six minute walk test), have a higher risk of oxygen 
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desaturation (Hadeli et al, 2001).  Another study suggested that patients with severe COPD are 
at higher risk of developing arterial hypoxemia during exercise and during daily routine 
activities (Garrod et al, 2000). Therefore, close monitoring of oxygen saturation and arterial 
blood gases may be needed during the exercise test.  Another study observed oxygen 
desaturation in 90% of the study participants during a six minute walk test (Ozalevli et al, 
2007). 
 
The exercise test is time consuming and therefore not performed in primary care where the 
components of BOD are routinely recorded (Puhan et al., 2009).  
 
 
c. Duration of symptoms 
 
A symptom is a subjective representation of a disease. There are two types of symptoms.  
Sudden RQVHWDQGVKRUWGXUDWLRQLVWHUPHG³DFXWH´ZKHUHDVJUDGXDORQVHWDQGORQJVWDQGLQJLV
WHUPHG ³FKURQLF´  $FXWH V\PSWRPV FRPPRQO\ RFFXU LQ FDVHV VXFK DV FKROHF\VWLWLV
appendicitis or acute gout that require immediate therapeutic or surgical treatment. On the 
other hand, chronic symptoms are common in conditions such as rheumatoid arthritis, 
osteoarthritis and chronic obstructive pulmonary disease that require long term treatment, 
regular monitoring and follow up with other secondary interventions to minimize disease 
SURJUHVVLRQDQGWRFRQWUROSDWLHQWV¶V\PSWRPVDQGWKHLUQHJDWLYHLPSDFWVRQSDWLHQWV¶OLIH,Q
very severe cases, surgical intervention may be applied.   
 
As the symptoms in patients with COPD are usually not very prominent, a typical pathway for 
COPD patients is that it is initiated generally after 10 years of cigarette smoking when 
V\PSWRPV DSSHDU WKDW FDWFK WKH SDWLHQW¶V DWWHQWLRQ OHDGLQJ WR WKHP VHHNLQJ D SK\VLFLDQ¶V
advice.  Patients with COPD generally develop a symptom of chronic cough accompanied by a 
small amount of sputum. It is also very unusual that patients, with COPD, complain of 
shortness of breath, during exertion, below the age of 40, after that age breathlessness becomes 
more common and may well be recognised by the age of 50 years.  
To date COPD is often undiagnosed or misdiagnosed (Black, 2009) until it is advanced.   
Earlier diagnosis could markedly reduce systemic manifestation, comorbidity, disability and 
improve health status (Jones, 2006).  Key areas for improvement include enhanced case 
identification, improved quality and interpretation of findings on spirometry, and increased use 
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of tools such as differential diagnosis questionnaires and in order to achieve optimal outcomes, 
there is a need to explore every aspect of the disease to establish a firm diagnosis, which will 
lead to the development of methods for monitoring progression more effectively in these 
patients. 
 
7KH OLWHUDWXUH UHYLHZ UHSRUWV WKDW ³V\PSWRPV´ RI SDWLHQWV ZLWK &23' DQG WKHLU UHODWLRQVKLS
with other COPD outcomes have not been studied as yet.  Thus the present study examines the 
duration of symptoms in patients in relation to COPD outcomes.   
 
 
2.9.3 HEALTH ASSESMENT 
Globally, the conditions with a target impact on health status are arthritis, COPD and heart 
failure (Alonso et al., 2004) Therefore,  there is  a need to understand the relative contribution 
of respiratory impairment,  physical disability, comorbidities, coping, age and physiological and 
psychological variables on understanding health status in patients with COPD. 
 
 
a.  Health Related Quality of Life 
 
7KHWHUP³4XDOLW\RIOLIH´LVGHILQHGDVWKHJDSEHWZHHQGHVLUHGDQGDFKLHYDEOHSHUVRQDODQG
social activities (Jones et al., 1991).  Quality of life may be difficult to measure accurately.  
Patients with COPD experience a reduction in HRQL, which includes reduced ability to work 
and to participate in physical and social activities (Stahl et al., 2003).  This concept is 
encapsulated by the term "health-related quality of life" (HRQL).  
 
There are two types of questionnaires available for assessment of health related quality of life 
LQSDWLHQWVZLWKUHVSLUDWRU\LOOQHVV³*HQHULFTXHVWLRQQDLUHV´DUHXVHGWRSHUIRUPFRPSDUDWLYH
assessments between populations of patients.  However, some of these types of questionnaires 
such as the Sickness Impact Profile or Short Form 36 may be rather insensitive to changes in 
health or vary over time (Jones et al., 1997).  The other available types of questionnaires are 
³WKH GLVHDVH-VSHFLILF 4XHVWLRQQDLUHV´ WKDW PDLQO\ LQFOude Chronic Respiratory Questionnaire 
&54*X\DWWHWDODQG6W*HRUJH¶V5HVSLUDWRU\4XHVWLRQQDLUH6*54-RQHVHWDO
1992).  The CRQ attempts to overcome some of the potential difficulties when using generic 
questionnaires.  In CRQ the questionnaires are customized to the individual patient so that they 
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can compare their current state of health with their previous ones.  The SGRQ is however the 
most widely used questionnaire to assess health status in these patients and has the advantage 
of allowing direct comparison between different patient populations and treatment groups and 
has been shown to be responsive when used for these comparisons (Jones et al., 1991, Jones et 
al., 1994).  Because of their subdivision into different components i.e. symptoms, activity and 
impact; in-depth analysis of the health status impairment are possible in these patients. The 
SGRQ is also effective in assessing changes over time in health status and a 4-unit change in 
the scores considered as clinically significant (Jones, 2002).  Some recent studies have 
supported the use of SGRQ in patients with COPD by showing its relationships with other 
systemic biochemical parameters (Broekhuizen 2006, Garrod et al., 2007, Seemungal et al., 
2007). 
  
The present study looked at health status in two ways.  Firstly its relationship with other COPD 
markers, including multidimensional indices and secondly, its change over time in patients 
with COPD.  The present study also attempted to enhance this assessment by introducing 
psychologically influenced wellness status in these patients. 
 
2.9.4 HEAMATOLOGICAL ASSESSMENT 
 
It has been suggested that anaemia could be a significant factor that influences prognosis in 
COPD patients as decreased haematocrit and haemoglobin levels in these patients are 
associated with frequent hospitalization and therefore increased mortality (Chambellan et al., 
2005). 
 
 
a. C Reactive Protein (CRP) 
 
C Reactive Protein (CRP) is an acute phase plasma protein elevated particularly during 
exacerbations of COPD patients (Hurst et al., 2006, Wilkinson et al., 2006). A high 
concentration of CRP 2 weeks after an exacerbation predicts the likelihood of recurrent 
exacerbation (Perera et al., 2007).   
 
However, plasma concentrations of CRP in stable COPD patients are related to mortality in 
patients with mild to moderate disease (Dahl et al., 2007), but no association are found in 
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severe and very severe patients (de Torres et al., 2008). Elevated levels of CRP are also 
associated with a worsening of COPD outcomes, such as impaired health status and exercise 
capacity.  Another study suggests CRP as a significant predictor of body mass index 
(BMI) (Broekhuizen et al., 2006).  There is a controversy about the relationship of CRP with 
FEV1.  In cross-sectional studies CRP is related to FEV1 whereas no association was found in 
longitudinal studies (Fogarty et al., 2007) with the progressive decline of FEV1.  
 
This study investigates the role of CRP concentration as a marker of prognosis in COPD 
patients and to examine the possible correlation between CRP concentration and other COPD 
markers of progression. 
 
 
2.9.5 PSYCHOLOGICAL ASSESSMENT 
 
Our understanding about identification, diagnosis and management of the clinical signs and 
symptoms of COPD has considerably improved during the last decade but its psychosocial 
burden is often underestimated, unrecognised and may be neglected (Kelly & Lynes, 2008; 
Bauldoff, 2009).   
COPD generally involves progressive deterioration in pulmonary function which results in 
increased shortness of breath and reduced ability to perform activities of daily living (ADLs). It 
also involves variation and alterations in the social roles of patients, their relationships and 
self-perception and so necessitates continual psychological assessments and adjustment. (Kelly 
and Lynes, 2008). Thus the prevalence of conditions like anxiety, depression and mental 
impairment may be increased in COPD patients and ultimately may impair their illness 
severity, prognosis and natural wellness.     
Considering the slow progression of COPD, and the need for patients to maintain a good 
quality of life, it is imperative that any psychological issues are not only recognised but also 
managed effectively.  These psychological issues need to be explored however no assessment 
tool is available for the evaluation of the factors that precipitate mental stress and other 
psychological problems in these patients. Some of the major psychological issues common in 
patients with COPD are discussed below:   
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a. Anxiety and Depression 
 
Depression is a psychological disorder that is characterised by mood variation, physical 
function and social interactions whereas anxiety is defined as a feeling of apprehension and 
fear characterized by physical symptoms such as palpitations, sweating, and feelings of stress.  
Both terms are commonly used together as patients with depression usually have some degree 
of anxiety and vice versa.  The incidence of anxiety and depression is more common in COPD 
patients than in patients with other long standing impairments as well as in the general public 
with no obvious disease (Putman-Casdorph & Mc Crone, 2009).  However, little attention has 
been given to psychiatric comorbidities in these patients.  Compromised breathing may be the 
key cause of depression.  Other known causes that are linked with anxiety and depression in 
COPD patients are increased mortality, decreased functional status and impaired HRQL. 
However, there may be some other risk factors that cause anxiety and depression in these 
patients that have not yet been studied.  These risk factors may include socioeconomic status, 
illness perception, wellness level, smoking status, passive smokers, body mass index, lean 
body mass, and muscle strength together with occupational history and medication.  Mental 
and psychological factors are components that describe the level of wellness.  The present 
study investigates the possible correlation between level of wellness and COPD outcome.  By 
focussing on wellness related issues in treating COPD, patients can minimize the frequency of 
exacerbation.  There may also be improvements in the outcome of acute exacerbations.  
Recently a study (Funk et al., 2009) showed that BODE index is higher-up than GOLD (Global 
Initiative for Obstructive Lung Disease) to explain anxiety and depression in patients with 
COPD.   
Thus, overall the role of psychological health is an important factor in achieving a balanced 
attitude to the effects of their illness for the patients in order to maximize their wellness and the 
present study aimed to explore psychological status of these patients that may be helpful to 
control disease progression in COPD.  
b. Role of Wellness in and its Use as a Measure of COPD Progression / Outcome 
 
 
As opposed to illness perception and health status, there is another term used to describe 
SDWLHQW¶VKHDOWKZKLFKLV³:HOOQHVV´Travis (1978) has highlighted the variety of 
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psychological functions that can influence health status.  He viewed the current apparent state 
of existing life as being merely the tip of an iceberg with multiple levels of complexity below 
the surface (Figure 2.7).  
 
             Figure.2.7. Wellness Concept by John W Travis, 1978, 1998, 2004 .  
To understand all the factors that are responsible for supporting current health status, it is 
therefore suggested to look beyond the tip of the iceberg to consider that which is normally 
invisible and/or un-focussed as explained in the figure above.  The first level beneath current 
state of health (HRQL) is the lifestyle/behavioural level, followed by psychological, mental 
stress and motivational level and the deepest of all is the spiritual/being.  A combination of all 
these levels tends to indicate our overall state of wellness (Travis, 1970).   
 
$GHILQLWLRQRIZHOOQHVVDV³WKHGHJUHHRISRVLWLYLVPDQGHQWKXVLDVPDERXWhealthy OLIH´PDLQO\ 
comes from the capacity of an individual to manage feelings and related behaviours including 
WKHUHDOLVWLFDVVHVVPHQWDQGUHDOLVDWLRQRIRQH¶VOLPLWDWLRQVGHYHORSPHQWRIDXWRQRP\DQGthe 
ability to cope effectively with stress (Manderscheid, 2006).  This coincides with the concept 
behind the development of a wellness questionnaire for this study. 
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No specific study, in health research, has explored and analysed the role of wellness status in 
disease prevention, disease progression and disease monitoring (Schwartz and Holtorf, 2008).  
 
Wellness is a life style a person adopts to acquire the highest level of wellbeing.  It is a process 
that is responsible for developing awareness, energy and knowledge in people to realize that 
there is no end-point before death, therefore, always to try to resist with confidence whenever 
something goes wrong in your life, for example, in the event of any chronic illness. Wellness is 
an integration of a body, soul and mind. It is a kind of healthy belief (Travis, 1970).  It enables 
a person to realize that everything we observe, think, perform and feel has a great impact on 
our state of health and state of wellbeing.  Therefore, our activities of daily life including 
personal, social and spiritual aspects produce a serious impact on illness progression and 
recovery in both positive and negative ways. 
 
 
COPD follows a typical un-wellness trajectory of long-term restrictions and limitations with 
sporadic and relatively serious episodes (Murray et al., 1997) called exacerbations.  Sometimes 
the exacerbation attacks are very severe resulting in death.  However, many patients 
survive many such episodes. Studies have suggested that many of these patients experience a 
lower health status than patients without exacerbations.  Major problems arise from dyspnoea 
that, in turn, lead to immobility, dependency on others (family, friends, relatives, neighbours, 
health care workers) and lack of energy to perform daily tasks such as bathing, gardening, 
jogging and recreational activities. It could result in the social isolation of a patient (Skilbeck et 
al., 1998; Ek et al., 2008).  Therefore, it could be expected that patients with such impairments 
have numerous preferences, wishes, needs, expectations and requirements and all these factors 
may help to ameliorate their overall condition and contribute to an improvement in their degree 
of wellness.  Previous studies have suggested that patients with severe COPD believe that their 
limitations are irreparable and that the consequences are due to an irreversible damage of the 
airways that cannot be improved or repaired and therefore they do not actively express a wish 
for help.  These findings suggest that care at this stage of the disease should focus on 
improving daily lifestyle instead of simply aiming to improve the functioning of the lungs 
(Habraken et al., 2008). Additionally, another study (Monninkhof et al., 2004) consisting of 
qualitative interviews suggest that the SGRQ and possibly other existing HRQL instruments 
might fail to capture the full experience of patients in self-management studies.  The need for 
  
 
51 
more elaborate qualitative research on this subject is indicated and present research will be an 
attempt to fill this gap. 
 
2.9.6 MULTIDIMENSIONAL MODELS FOR ASSESSING PROGRESSION 
 
a. Multidimensional Assessment of COPD ± BODE, DOSE ADO, and BOD 
 
 
FEV1 is the key measure used for diagnosing, classifying and managing COPD.  Classically, 
FEV1 and age are the two vital prognostic indicators identified in patients with COPD (Fletcher 
et al., 1976, Traver et al., 1979; Anthonisen et al., 1986).  However over the last ten years 
COPD has been regarded as a multicomponent disease  and thus factors such as 
dyspnoea (Nishimura et al., 2002), malnutrition (Landbo et al., 1999), hospitalization related to 
COPD exacerbations (Soler-Cataluna et al., 2005), exercise capacity (Oga et al., 2003), 
physical activity (Garcia-Aymerich et al., 2006), pulmonary hypertension (Ostwald- 
Mammosser et al., 2006), inspiratory capacity (8), lung density measurements by computed 
tomography (Casanova et al., 2005), muscle mass(Marquis et al., 2002), HRQL (Domingo-
Salvany et al., 2002), and other markers (Cote and Celli, 2007), have also proved to be 
individual, effective prognostic indicators.  Therefore, employing several variables in the 
measurement of COPD improves its assessment, and incorporating these variables into a 
multidimensional model improves their prognostic power as compared to traditional measures 
based exclusively on FEV1. Adopting this approach, Celli and colleagues (2004) proposed a 
model to measure severity and prognosis of the disease; the model BODE (BODE ± BMI, 
airflow Obstruction, subjective Dyspnoea and Exercise test), uses a 10 point scale.  According 
to Celli and co-workers (2004), ³7KH%2'(LQGH[DVLPSOHPXOWLGLPHQVLRQDOJUDGLQJV\VWHP
is better than FEV1 at predicting the risk of death from any cause and from respiratory causes 
DPRQJSDWLHQWVZLWK&23'´ This index illustrated that this multi-dimensional assessment is a 
better predictor of the risk of death both from all causes and from respiratory causes than FEV1 
alone (Figure 2.8). The figure shows that patients with a higher quartile in the BODE index 
have the least probability of surviving for 4 years or more, this contrasts to those with a lower 
BODE quartile.   
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Figure 2.8.   The worst quartile BODE index showed a mortality of 80% in four years in a   
hospital cohort (Celli et al., 2004) 
 
 
The efficiency of the BODE index has been assessed in various studies (Ong et al., 2005; 
Imfeld et al. 2007; Lederer et al., 2007; Pampeo and Mineo 2007; Martinez et al., 2008; Cote et 
al., 2008; Holland et al., 2010; Ko et al., 2011) which support its value with respect to COPD 
outcomes including health status, anxiety and depression, hospitalization and mortality. 
However, COPD patients are mainly managed in GP surgeries and the BODE index is rarely 
used in these settings because exercise capacity (also known as the six minute walk test 
(SMWT), which is one component of the BODE index, cannot be easily performed and 
measured (Puhan et al., 2009).  In addition, the six minute walk test has various sources of 
variability which makes this test controversial. The sources of variability in SMWT include: 
SDWLHQW¶VPRWLYDWLRQKHLJKWZHLJKW JHQGHUDJHFRPRUELGFRQGLWLRQRIDSHUVRQDQGGD\ WR
day variability (ATS Statement, 2002).  Studies have also demonstrated that the SMWT is 
reduced significantly in patients with severe or very severe disease (GOLD stages 3 or 4) (Pitta 
et al., 2006; Watz et al., 2009).  BODE investigators have mainly recruited hospital patients 
with severe and very severe stages (70% of the cohort had FEV1%predicted of 50 or less).  The 
index was optimized to predict 12 months mortality and it is believed that the factors affecting 
short term survival may be different from those influencing longer term survival.  The gender 
based variation has not been explored in BODE studies. In addition, Puhan and colleagues 
(2009) found that BODE underestimated the risk of mortality in younger patients and 
overestimated in patients with mild symptoms, in their cohort. They used this study to derive 
DQRWKHUPXOWLGLPHQVLRQDOLQGH[³$'2´The ADO index is composed of Age, Dyspnoea Score 
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and Airway obstruction and is another major development in assessing COPD progression 
(Puhan et al. 2009). The ADO index, a new score for predicting a patient's risk of dying of 
COPD appears to give better results than the currently used BODE index (Puhan et al., 2009).  
However only one study (Chen et al., 2011) has assessed the ADO index and validated its 
prognostic importance in patients with COPD.  The ADO index used Swiss and Spanish 
cohorts and looked at 3 year mortality risk in these patients.  By introducing age, the ADO 
index has been criticised because age is the most important determinant of survival, 
independent of disease status and diagnosis. Age has limited value in the stratification of a 
specific disease process (Celli et al., 2009). 
 
An alternative outcome to mortality is hospitalization and Jones and colleagues (2009) 
developed the DOSE index that contains a combination of subjective and objective 
measurements i.e. dyspnoea (D), airway obstruction (O), smoking status (S), and frequency of 
exacerbation (E).  The index proved to be a simple tool to assess disease severity. However, 
this index was mainly aimed at examining its relationship with health status, future events such 
as hospitalisation and respiratory failure and also management and did not take account of 
mortality which is one of the main COPD outcomes of interest both for patients as well as for 
their health care providers. Although a recent publication in the European Respiratory Society 
(ERS, 2011) found DOSE as a valuable predictor of mortality no further researches have been 
carried out to support and/or to validate their findings.  ,Q DGGLWLRQ ³6´ LQ the DOSE index 
represents current smoking status, a clear risk factor for frequent exacerbations and not past 
smoking history (pack years) which relates to comorbidities (Eberly et al., 2003) and therefore 
mortality.   
The discussion above suggests that no index fully reflects the burden of disease and there is 
still a need to develop an index that can be easily applied to a wider population without 
limitations (NICE, 2010). NICE guidelines have also suggested that a multidimensional 
assessment tool should be evaluated with Caucasian populations and explore COPD related 
outcomes other than mortality.  The present study takes account of NICE recommendations by 
LQWURGXFLQJ D QHZ LQGH[ ³%2'´  BOD is an alternative to BODE which is more easily 
applicable in primary care.  The requirements for the SMWT may not be available in general 
practice or suitable for all patients.  Additional resources such as time, trained staff, and space 
are also needed. Furthermore the mobility of the patients can also influence the performance 
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during SMWT (NICE, 2010). Additionally, the present study consists of Caucasian males and 
females and explores their relationship with mortality, probability of longer survival and health 
status.   In other words, this study applies the BOD index to a cohort of primary care patients 
with COPD and will be discussed further in chapter 4.   
 
2.10  Confounding factors in the Assessment of COPD. 
 
COPD is one of the leading causes of morbidity and mortality in industrialized and developing 
countries. The mortality rate for COPD is rising and COPD will most likely become the third 
leading cause of death worldwide by the year 2020 (Siafakas et al., 1995; Murray et al., 2000, 
WHO Report, 2008).   
Forced expiratory volume in one second (FEV1) cut-off points established the severity of 
COPD.  Various guidelines have been published to classify the severity of disease that includes 
ATS (1995), BTS (1997), GOLD (2001) and consensus guidelines from the ATS-European 
Respiratory Society (ATS-ERS) in 2004 and Esteban and colleagues (2009) compared them as 
prognostic indicators. Although the BTS system was slightly superior, none of the guidelines 
was closely related to 5 year mortality.  The recent study shows harmonisation of the NICE 
severity grading with GOLD (Gruffydd-Jones and Loveridge 2011) that could potentially 
increase very considerably the number of patients diagnosed with the disease. However, there 
is little evidence that asymptomatic patients fulfilling the GOLD Stage 1 criteria have an 
increased risk of deterioration in health status or FEV1. Therefore, GOLD classification does 
not fully reflect the severity of the disease and therefore the recognition that assessment of 
COPD disease severity requires a multi-dimensional approach has led to the development of 
multi-dimensional indices. 
 
Therefore there was a need for a comprehensive staging system that allows for more adequate 
categorization of patients with COPD and the development of the BODE Index (Celli et al., 
2004) was the milestones in this regard.  However there are a number of limitations with 
BODE that are discussed in the next section. 
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2.10.1  Comorbidities  
 
COPD patients are associated with significant comorbid diseases with one study reporting that 
84% of COPD patients have at least one or more co-morbidities (Barnes and Celli, 2009) 
compared to comorbidities in control subjects which was reported 63% (Van Manen et al., 
2001) .  Studies suggested that Co-morbidity plays a major role in health status (Ferrer et al., 
1997; Van Manen et al., 2001) and health services utilisation independent of lung function 
measured by FEV1 (Oostenbrink et al., 2004).   
The most common comorbidities in COPD include osteoporosis, arthritis , cardiovascular 
diseases and cancer (Sin et al., 2006) in which cancer and cardiovascular disease are major the 
comorbid conditions related to high mortality (Wasswa-Kintu et al., 2005; Sin et al., 2005).  
The high prevalence of comorbid conditions may be related to malnutrition (Sin et al., 2006), 
inactivity, smoking, steroid treatment (Iqbal et al, 1999), systemic inflammation (John et al., 
2005), elderly patients, and patients with low BMI and FFMI (Gosker et al., 2002; Vestbo et 
al., 2006; Bolton et al., 2004).  However it is still not clearly understood whether comorbid 
conditions in COPD is the cause or an effect of COPD systemic consequences (Sin et al., 
2006).  Clearly more work is required to explore this and the potential link between COPD, 
mortality and comorbid conditions (Sin et al., 2006).  
To assess morbidity in COPD or any other disease, a complete medical history and full 
physical examination is needed to look for signs of any other chronic illness and record the 
finding on a Charlson Comorbidity Index which quantified the effect of comorbidities (Quan et 
al., 2011).  The overall comorbidity score reflects the cumulative increased likelihood of one-
year mortality; the higher the score, the more severe the burden of comorbidity. 
 
 
2.10.2 Exacerbations 
 
 
Exacerbations are characterised by acute patho-physiological deterioration reflected by 
worsening of COPD symptoms.  Patients with COPD are prone to exacerbations that are an 
important determinant of health status, morbidity and mortality (Wedzicha, 2002). Therefore, it 
becomes an important outcome measure in the study of therapy in COPD and a few studies 
have addressed the effect of exacerbations on disease progression, severity and health status in 
COPD patients (Seemungal et al., 1998; Aaron et al., 2002; Miravitlles et al., 2004).   
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Predicting which patients may be more susceptible to exacerbation is not a simple function of 
the degree of impairment of FEV1 (Ansari et al., 2007).Interestingly, Martin and colleagues 
(2008) found that a multidimensional score (BODE) is a better predictor. But Soler-Cataluna 
(2009) and co- workers concluded that severe exacerbation and BODE index are two 
independent risk factors for death in male COPD patients.  
 
 
2.11 Conclusions 
The literature review has shown that there is no drug therapy that significantly alters the 
progressive worsening of lung function (Michele et al., 2010).  Literature review also suggests 
that the main problems with COPD are twofold. First, its multidimensional consequences and 
secondly its development and progression that dramatically vary between individuals 
(Mannino et al., 2006) suggesting more research is necessary, focussing on an in-depth 
evaluation of measures to determine the progression of the disease.  
COPD is a chronic illness that has an impact on health status.  How well a patient actually feels 
and responds (in the presence of disease symptoms, lung function deterioration, and 
comorbidities) determines the progression and consequences of the disease on their health.  
To date smoking cessation and smoking bans in public places (particularly in developing 
countries) is the only intervention that has a substantial positive effect not only on disease 
progression but also on other COPD outcomes (Anthonisen et al., 1994; Papadopoulos et al., 
2011).  However the burden of COPD is still on rise worldwide (WHO, 2011) and therefore 
there is a need to do more in this respect to reduce the COPD burden not only for its sufferers 
but also for health care providers. Identification of the rate of progression of the disease could 
be used to improve outcomes, reduce health care utilization and cost. 
Therefore, this thesis has tried to identify those factors and/or markers in these patients. The 
ability to fight the disease may thus be dependent upon the sense of self responsibility, 
physical, emotional and mental wellbeing, potential stress related factors that make disease 
ZRUVH DQG WKHVH DOO FRPHV XQGHU WKH XPEUHOOD RI D WHUP ³ZHOOQHVV´ DQG WKH Sresent study 
explore this aspect of disease. 
    ___________________________ 
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Chapter 3 
 
 
METHODOLOGY 
 
 
 
The methods adopted in this study comprise: 
 
 
A. Quantitative Analysis 
 
- Evaluation of BOD and Other Markers of COPD Progression 
 
- Evaluation of Physical parameters that may relate to COPD. 
 
 
B. Qualitative Analysis 
 
- Evaluation of Wellness (Psychological Marker of COPD). 
 
 
 
A. Quantitative Analysis 
 
 
3.1 Study Background 
 
 
The present research is a continuation of a pilot study carried out in 1999-2002 when a 
database of 634 suspected COPD patients was assembled.  The measure used for the 
determination of COPD was spirometry.  This was carried out in general practice surgeries in 
Sunderland using British Thoracic Society Criteria (BTS, 1997). 458 subjects were deemed to 
satisfy the requirements for a diagnosis of COPD.  At that time, the measurements were carried 
out by a Respiratory Research Team at the Chest Clinic at Sunderland Royal Hospital led by 
Dr. Niall Keaney.  In the present study, it was decided to follow the surviving members of the 
original cohort.  Analysis for the study undertaken here was carried out in 2007-2008 and again 
a year later in 2008-2009 to examine the progression of the disease and its outcomes. 
 
Hence the data presented for time 1 (1999-2002) was collected by Andrea Kay and the data 
presented for times 2 and 3 was collected by the author of this study. 
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The detailed methodology of the present study including design, measurements and study tools 
is explained below. 
 
 
3.2  Study Design 
 
 
This is a longitudinal, retrospective and prospective / observational study.  
 
)ROORZLQJ WKH SXEOLFDWLRQ RI WKH %ULWLVK 7KRUDFLF 6RFLHW\¶V &23' JXLGHOLQH LQ 
spirometers were introduced in GP clinics and spirometry training was provided into the local 
primary care network.  The database was initially established for lung cancer screening under 
the supervision of Dr. Niall Keaney, Consultant Chest Physician by identifying patients who 
were at risk of developing lung cancer including smokers, those with a history of dust 
exposure, breathing related symptoms, spirometric evidence of lung function impairment).  
The patients were recruited from Asthma Clinics in primary care and information was collected 
by Andrea Kay (Respiratory Physiologist and Research Assistant to Dr. Keaney).  The 
following information was recorded during the establishment of the initial database:   
 
x Name (date of birth, NHS number) 
x Demographics (smoking status and pack years,age, gender, height, weight, BMI). 
x MRC Dyspnoea Score 
x Spirometry (FEV1, FVC, FEV1% predicted, FEV1/FVC ratio) 
x Respiratory Symptoms (cough, sputum, chest pain, breathless, wheezing) 
x Occupational history (exposure to dust/other pollutants) 
x Comorbid conditions. 
 
In the initial database there were 634 patients either with suspected COPD or at risk of 
developing the disease.  In 2007-8, the data base was reviewed by the researcher (Khalid 
Ansari) and those patients who met the spirometric evidence for COPD, as per the standard 
guidelines (BTS, 1997; GOLD, 2004) were invited to a follow up visit (n=458).  All 
participants were contacted via letter containing an invitation request, information sheet about 
the study, consent form and a slip asking if they were willing to participate and if so asking for  
their availability so that recruitment session could be scheduled.  The invitation letters were 
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sent a second time to those who did not respond to the initial letter. A telephone contact were 
also made to those whose contact numbers were available on the hospital databases.  
Therefore, all possible efforts, within ethical limits, were made to recruit as many participants 
as possible for this study.  
 
The ethical approval for the data collected between 1999 and 2002 was obtained in 1998.  
 
Ethical approval was also obtained from Sunderland Local Research Ethics Committee 
(LREC) and the University of Sunderland Ethical Committee.  Approval to carry out the 
research was granted by City Hospitals Sunderland Foundation Trust and Sunderland Teaching 
Primary Care Trust (TPCT) in July, 2007. 
 
Subsequently, ethical approval for the amendment made in relation to the assessment of 
wellness in the COPD cohort was obtained in March 2009. 
 
To relate the multidimensional indices with mortality, the particiapnts who died between 1999 
and 2010 were identified.  The names and NHS number of the subjects in the original 1999-
2002 cohort were submitted to the PCT and from the Registrar General¶V data those subjects 
that were deceased were obtained, together with their respective date and cause of death.  The 
follow up therefore for mortality was complete (100%).   
 
  
 3.3  Study Population 
 
 
At the commencement of this study there were 458 patients of the 634 originally recruited in 
1999-2002, all of whom had a clear diagnosis of COPD.  This was based on the following 
exclusion criteria (BTS 1997): 
 
1. Patients <40 years of age, as COPD below 40 is very unlikely. 
2. Patients who refused or did not have the ability to give informed consent as according to 
current ethical guidelines, it is one of the  essential requirement. 
3. Patients with any terminal illness were not contacted, as performing spirometry and an 
exercise test is not safe in individuals with terminal illness. 
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4. Patients who were on a pulmonary rehabilitation programme during the study, as it is an 
avoidable confounding factor with respect to COPD outcomes.  
5. Patients with >3 exacerbations in the past 12 months as such patients have a high mortality 
risk. 
 
Patients from the original cohort were invited to attend the Chest Clinic, Sunderland Royal 
Hospital  on two occasions; first in July 2007/2008 and  then for follow up in 2008/2009.  
There were thus three sets of data at the end of the collection phase, i.e.   
 
1. Data from 1999-2002 ± collected by Andrea Kay (Experienced Research Physiologist 
at Chest Clinic in Sunderland Royal Hospital). 
2. Data from 2007-2008 ± collected by researcher or Andrea Kay. 
3. Data from 2008-2009 ± collected by researcher or Andrea Kay. 
 
Subjects were contacted by letter with a patient information sheet about the study and their 
participation.  Once they had agreed in principle by returning their signed paper slip stating 
that they were willing to be contacted for the study, they were then contacted by telephone by 
either the researcher himself or Andrea Kay so that any queries could be raised regarding 
recruitment and/or arranging taxis between their homes and the hospital, and also to discuss 
any research related issues.  At the clinic appointment patients were given the opportunity to 
discuss the study further and then asked to sign a consent form.  They could refuse to take part 
at this point and future disease management would not be affected. 
 
    
3.4 Physical Measurements Undertaken.  
 
The following measurements and assessments were carried out on eligible patients at the chest 
clinic.  Patients were recruited one by one by the researcher using the same equipment for all 
participants. 
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The following measurements and assessments were carried out in eligible patients.  
 
a. Patient report form including name, date of birth, date of visit and other demographical 
details (mentioned below). 
b. Height 
c. Armspan 
d. Weight 
e. Body Mass Index 
f. Smoking History  
g. Historic occupation details to determine subjective pollution exposures. 
h. Current Medication 
i. Lung Function Measurements 
j. Fat Free Mass  
k. Six Minute walk distance (SMWT) 
l. Hand grip strength measured using a hand dynamometer. 
m. Clinical Examination 
n. Blood Samples 
o. Respiratory questionnaire (SGRQ). 
p. Charlson Index to evaluate comorbidities (table 3.4). 
q. Subjective disability using the MRC dyspnoea score. 
r. Wellness assessment questionnaire. (Sunderland Wellness Respiratory Questionnaire) 
 
(DFKSDWLHQW¶VSDUWLFLSDWLRQWRRNDQDYHUDJHRI-1.5 hour per session. 
 
All of the measurements were carried out by the researcher or by the other resea rch team 
member, who is a qualified, trained and experienced clinical physiologist. However, the main 
researcher/author was present at all times during the patient measurement sessions.   
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3.5 Study Instruments and Measurements  
 
a. Patient Report Form 
 
This form was completed by each participant and detailed information was recorded about the 
VWXG\ VXEMHFWV¶ GHPRJUDSKLFV DQG RWKHU UHOHYDQW LQIRUPDWLRQ LQFOXGLQJ SDWLHQW LGHQWLILFDWLRQ
number, name, date of birth, active and passive smoking history, height, arm span, weight, 
BMI, symptoms at present, symptom duration, current medication, history of exacerbation, 
history of medication, and physical examination findings. 
  
b.  Height 
 
Height was recorded using a stadiometer without shoes (with socks or stocking), heels 
together, freely hanging arms, and head in Frankfurt plane (an anatomical reference point of 
the human skull in which the superior border of an external auditory meatus is on a horizontal 
plane with the inferior border of the eye orbit).  The inclusion criteria for this part of the study 
included the inability of the patient to stand erect without support and the ability to extend both 
arms comfortably, without any spinal, vertebral deformity or other connective tissue disorder 
that makes measurement of standing height and armspan measurement inaccurate. 
 
c. Armspan 
 
Armspan is defined as the maximum distance from the tip of the middle finger of one hand to 
the tip of the same finger of the other hand with outstretched arms and the subject standing 
erect. It is measured when patients stand erect, with their back against the wall (URL 6).   All 
readings were taken to the nearest 0.5 cm using a measuring tape. 
 
d. Weight  
 
Body weight was measured with a calibrated precision scale (SECA) with subjects wearing 
indoor clothes but without coat and shoes.  The calibration was carried out by the company 
engineers on yearly basis.  
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e. Body Mass Index (BMI) 
 
BMI values were derived by dividing weight in kilograms (kg) by square of height (metres).  
 
 
f.  Smoking History 
 
Information on smoking status was obtained from each patient by asking about his/her current 
smoking status i.e. were they a current smoker, ex ±smoker or non-smoker.  If the patient was a 
smoker or ex-smoker, additional information was asked including when he/she had started 
smoking, how many cigarettes they had smoked/day and when he/she stopped smoking. 
 
Pack Year History 
 
Pack years = Number of cigarettes smoked / 20 x no of years smoking. 
 
In other words, one pack year is equivalent to 7300 cigarettes smoked (i.e. 20 cigarettes 
smoked per day for 1 year divided by 20). 
 
Passive Smoking History 
 
This was obtained by asking the patient about smoking exposure he/she has/had over their 
whole life. Therefore, questions were used to obtain this information. These were as follows. 
 
1.  Did either of your parents smoke? 
2.  Where did they smoke (inside home/living room, smoking area in home, outside home,              
garden)? 
3.  How many years had he/she lived with them? 
4.  When married, whether spouse or partner was a smoker, where they smoked (inside 
home/living room, smoking area in home, outside home, garden)? 
5.  How many years had he/she lived with his/her partner? 
6.  Information about any work-related smoking exposure and duration were also obtained. 
7. Finally, all the years he/she had been exposed to smoke were added to derive a total 
number of passive smoking years. 
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g. Historic occupation details  
 
This information was obtained by asking the patient about his/her work history and any related 
exposure at his/her work place including asbestos, chemicals and welding to determine 
industrial pollution exposures. 
 
h. Current Medication 
 
7KH LQIRUPDWLRQ DERXW PHGLFDWLRQKLVWRU\ ZDV REWDLQHG IURPSDWLHQWV¶ SUHVFULSWLRQ VOLSV DQG
inhalers that they were instructed to bring along to the recruitment session at the hospital.  
 
i. Lung Function Measurement 
 
Spirometry  
 
Spirometry was performed using a Vitalograph (Model No: 2120). Before the actual test was 
carried out the name, age, gender, date of birth, height, weight, BMI and ethnic group were 
entered in the computer.  These details were used to calculate predicted values as per the ATS 
guidelines. 
 
The calibration of the spirometer was carried out by the researcher on a daily basis. Calibration 
was performed with a 3L syringe following a standard procedure for calibration (Clausen et al., 
1982).   
  
Patients were requested not to take any long acting bronchodilators for up to 24 hours and no 
short acting bronchodilators for at least 8 hours prior to the day of visit.  After confirmation, 
the pre-bronchodilator readings were obtained, then an inhaled dose of salbutamol (400µg) via 
a spacer was administered and the spirometry repeated, after 30 minutes, to record post 
bronchodilator response of the airflow.  The bronchodilator was not given to patients with 
normal spirometry (FEV1 % predicted > 80%) and FEV1/FVC ratio >70%. 
 
Predicted values were obtained with the help of the regression equation proposed by the 
European Respiratory Society (ERS) guidelines (ERS, 1993). 
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  For Males:  PREDICTED FEV1= (4.30 x height) ± (0.029 x age - 2.49) 
  For Females:  PREDICTED FEV1= (3.95 x height) ± (0.025 x age - 2.60) 
 
During the test patients were asked to: 
 
1. Sit up comfortably and straight. 
2.  Take a deep breath in to fill their lungs completely. 
3. Place the mouthpiece of the spirometer tightly between the lips.  
4. Blow the air into mouthpiece out fast, hard and as long as possible (forced expiration).   
5. The test was performed three times and the highest value of FEV1 and FVC recorded.   
 
 
j. Fat Free Mass   
 
The fat free mass (lean body mass) was calculated with the help of a device called Bioelectrical 
Impedance (BIA). The detailed of how it works is discussed in section below:- 
 
Bioelectrical impedance Analysis (BIA) 
 
BIA is a simple procedure that can be performed at home or in the clinic in a matter of 
minutes.  The analyser calculates tissue and fluid compartments using an imperceptible 
electrical current passed through pads placed on one hand and one foot as the subject lies 
comfortably.   
 
The body composition was measured using the latest technology of Bioelectrical Impedance 
Analysis (BIA) using Bodystat 1500 MDD (Figure 3.1). This model was recommended as 
appropriate for the study (Wouters, personal communication, March 2007). 
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Features 
 
x Dual frequency 
x Self-calibrating 
 
 
 
 
Figure 3.1.  Bodystat 1500 MDD 
 
Lean tissues (muscles and bones) are better conductors of electricity than adipose tissues. So, 
when a very low electrical current passes through the body (about one tenth on an AA battery) 
the percentages of fat and muscle tissues can be calculated from the recorded impedance, body 
weight and height. 
 
The data required to measure composition were keyed into the Bodystat unit.  The disposable 
HOHFWURGHVZHUHWKHQDWWDFKHGWRWKHSDWLHQWV¶DQNOHVDQGZULVWVDQGWKH crocodile/alligator clips 
were connected to the exposed tabs on the Bodystat electrodes (Figure 3.2).  Lastly, the Enter 
key on the instrument was pressed.  The test takes no more than 20 second to complete and a 
list of values related to body composition are displayed on the LCD screen within seconds. 
 
 
Display Information 
 
x Fat Mass 
x Fat % 
x Lean body mass / Fat Free Mass 
x Dry Lean Weight 
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x Total Weight (kg, lb., st/lb.) 
x Total Body Water 
x Basal Metabolic Rate (BMR) 
x BMI 
x Waist/Hip Ratio 
$OOWKHLQIRUPDWLRQZDVWKHQWUDQVIHUUHGWRWKHSDWLHQW¶VUHSRUWIRUPLQWKHVSHFLILHGVHFWLRQRI
the questionnaire 
 
 
 
Figure 3.2.  The sites of electrodes and crocodile/alligator clips on ankles and wrists. 
 
 
The unit has built in calibration procedures. The system measures bio-impedance on a whole 
body basis. 
 
 
k. Six Minute Walk Test (SMWT)  
 
The SMWT involves measuring how far the patient can walk in 6 minutes, whilst walking at 
their own pace, resting if, when and for as long as necessary.  It is used to determine exercise 
tolerance. 
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It is usual for a subject to undertake a practice walk followed by the actual test.  After the 
practice six-minute walk test, the patient was allowed time to recover (for 30 minutes) before 
doing the second test (Celli, et al., 2004).  
 
The walk test took place in a corridor with a measured ten metre distance marked on the floor. 
Subjects walked up and down the course and the total distance and the number of times they 
stopped together with oxygen saturation and pulse rate were recorded. While resting between 
the walk tests, subjects were asked to complete the Respiratory Questionnaire, historic 
residency questionnaire, and a work history was also obtained by means of a brief 
questionnaire composed by the researcher. 
 
 
l. Hand-grip strength 
 
 
Hand grip was measured using a Jamar Hydraulic Hand Dynamometer - 12-0600 (Figure 3.3). 
The Jamar hand-grip dynamometer allows measurement of the muscle strength of both hands 
(Fess, 1987).  After explaining the importance of measuring grip strength and the proper 
method of holding the hand dynamometer, the values of grip strengths (left hand, right hand 
and/or dominant hand) of each patient were measured on three occasions and the highest value 
was recorded.  A standard position (sitting in a straight-backed chair) and procedure 
recommended by the American Society of Hand Therapists (Richards et al. 1996) was used to 
measure hand grip strength in our study subjects.  Medical reports were checked to find any 
history of joint disease, trauma or any other medical condition that could alter the values of 
hand grip measurements.  The percent predicted values were calculated for dominant hand grip 
strength, using reference values for the dominant hand according to respective age and gender 
(Sunnerhagen et al., 2000).  
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                Figure 3.3. Jamar Hydraulic Hand Dynamometer - 12-0600 
 
 
m. Physical examination  
 
A full physical cardiovascular and respiratory assessment of the patient was carried out to 
exclude any un-diagnosed or newly developed signs of any comorbidity, signs of oedema 
(pitting or non-pitting), atrial fibrillation, heart sounds, breath sounds, wheezing, crackles, 
clubbing, and anaemia). 
 
 
n. Blood Samples for High Sensitivity C Reactive Protein (High Sensitivity CRP) 
 
After explaining to participants the reason and method used to take blood samples, a consent 
form was given to the patient to sign and after obtaining the signed consent form for the blood 
test, 3 cms3 of blood was drawn from the most prominent vein in the arm or hand by inserting   
a needle.  
 
Blood Collection Procedure 
 
All recommended precautionary measures were taken before, during and after the blood 
VDPSOLQJ 7KH SDWLHQW¶V YHLQ ZDV SXQFWXUHG ZLWK D VWHULOH QHHGOH DWWDFKHG WR DQ DVSLUDWLQJ
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device.  This allows the drawing of venous blood with the least amount of patient discomfort 
and trauma.   
 
 o.  6*546W*HRUJH¶VRespiratory Questionnaire) 
 
 
Disease-specific instruments relate more closely to clinical symptoms and, as a consequence, 
may be more acceptable for clinicians (Marcia, 1996).  In recent years, several studies have 
reported results of HRQL instruments such as Chronic Respiratory Questionnaire (Guyatt et 
al.; 1987) or Seattle Obstructive Lung Disease Questionnaire (SOLDQ) (Tu, 1997) specific for 
respiratory patients. These instruments have been developed in English-speaking countries and 
include several health status measures for asthma patients (Cook et al., 1993; Hyland et al., 
1991; Marks et al., 1993), one for COPD patients (Guyatt et al., 1987; 1989), and one designed 
for use in patients with COPD and/or asthma (Jones, 1991&1992).  Most of these measures 
have been shown to be reproducible, valid and responsive, although they differ from each other 
in several respects.  The SGRQ is a validated questionnaire to measure HRQL in patients with 
COPD (Ferrer et al., 1996; Jones, 1992).  
 
 The questionnaire used in this research was arrived at after the following screening protocol: 
 
1.  Is it valid? Can its validity, reliability and authenticity be demonstrated on the basis of a 
literature review? 
2.  Is it globally accepted? As this research mostly involved elderly people, the questionnaire 
should be easily completed and short. 
3.  Is the questionnaire disease specific? The present research only involved COPD patients 
and generic questionnaires often fail to detect small differences among COPD patients. 
4.  Is an English version of the questionnaire available? 
5.   Is it likely that patients will be able to complete the questionnaire in the available time? 
 
The SGRQ appeared to be the most appropriate questionnaire according to the study protocol. 
Permission to use SGRQ has been obtained via email from its author, Professor P.W. Jones in 
6W*HRUJH¶V+RVSLWDO, London, UK.   
 
  
 
71 
The SGRQ is widely used for the assessment of health status in patients suffering from chronic 
airflow limitation. 
 
SGRQ is a pre-validated questionnaire developed by Jones (1992), which is a disease specific 
questionnaire particularly for COPD suffers (Jones, 1992).  It is used extensively to measure 
different domains: disease symptomatology, the impact of the disease on life style and activity 
levels of the patients.   
 
The SGRQ scoring system ranges from 0 (no disability / no health impairment) to 100 (severe 
disability or worst health status).   
  
 
Topics covered by the SGRQ     
        
 The SGRQ contains 50 items (covering 76 levels) divided into three components or domains: 
The first component is "Symptoms" which consists of 8 items, including questions about 
respiratory symptoms, their frequency and severity; the second is "Activity". This contains 16 
items, and the questions are related to activities impaired due to chest symptoms such as 
breathlessness; finally the third component is  "Impacts" composed of 26 questions, which 
covers a range of aspects concerned with social functioning, activities of daily living such as 
going out for shopping, gardening and psychological disturbances resulting from airways 
disease.  
 
 Each item in the questionnaire has a weight attached, which provides an estimate of the 
distress associated with the symptom or state described.  These weights were collected in 140 
asthma patients and they were shown to be applicable to a wide range of patients with asthma 
or COPD because demographic and disease-related factors had minimal influence on them 
(Jones et al., 1991).  A score was calculated for each subscale of the SGRQ and also an overall 
score was calculated following procedures and handling of missing data recommended by the 
developer (Jones, personal communication, September 2007).   
 The questionnaire has been shown to be reproducible and valid (Jones et al., 1992).  
Furthermore, in a head-to-head comparison, it was shown to be more responsive to differences 
in disease severity than the Sickness Impact Profile (SIP) which is a generic questionnaire 
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(Okubadejo et al., 1997) to measure COPD severity. In patients with COPD, who had a mean 
FEV1 of 50% predicted, SGRQ scores are normally distributed around a mean of 50, which is 
indicative of good scaling properties (Burge et al., 2000). 
        
Scores for SGRQ domains are on a 100 - point scale.  Higher scores correspond to a worse 
quality of life (Table 2).   
 
 
SGRQ Components POSSIBLE SCORES 
 
SYMPTOMS 
 
0-100 
 
ACTIVITY 
 
0-100 
 
IMPACT 
 
0-100 
 
TOTAL SGRQ 
 
             Symptoms Score + Activity Score + Impact Score 
 
  
 Table 3.1.   SGRQ domains and their score range.   
 
 
The SGRQ score ranges from 0-100 where                    
        
 HIGH SCORE suggests low Quality of life 
         LOW SCORE suggests high Quality of Life 
 
In almost all previous studies, in which the SGRQ questionnaire has been used (Ferrer et al., 
2002; Miravitlles et al., 2004; Torres et al., 2006) scores were expressed in percentages for all 
domains.   
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p. Medical Research Council Dyspnoea Scale 
 
The members of the cohort were given the scores and their definition and asked to classify 
themselves. The score they assigned to their illness was recorded. 
 The MRC is a validated tool to measure functional status of patients due to dyspnoea according 
to the activities impaired.  The MRC scores are classified into five grades on the basis of 
limited activities due to shortness of breath as shown in table 3.2.   
 
 
 
Table 3.2.   MRC Scores and activities impaired associated with each score. 
 
Bestall and colleagues (1999) investigated the usefulness of this scale in COPD patients and 
concluded that the MRC Dyspnoea Scale showed a significant relationship to exercise 
performance, health status, mortality and other outcomes being independent of lung function 
data.  The score ranges from 1 to 5.  Patients with MRC grade 5 represents maximum disability 
due to shortness of breath (Fletcher, 1960).    
 
The MRC dyspnoea score is now widely used in Britain and it is accepted internationally 
(Celli, 2004). 
 
 
MRC Score ACTIVITY LIMITED DUE TO DYSPNOEA 
1 Shortness of breath with strenuous exercise 
2 Shortness of breath when hurrying on the level or walking up a slight  hill 
3 Walking  slower than people of the same age on the level because of 
breathlessness or having to stop for breath when walking at own pace 
4 
 
 Needing to stop after walking 100 yards on the level. 
5 Too breathless to leave the house or breathless when dressing or 
undressing.   
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q. Charlson Index 
 
The index consists of a list of 19 chronic, life threatening clinical conditions as shown in table 
3.3.   Each condition has an associated score (1 or 2), taken from the original Charlson paper 
(Charlson et al., 1987, Valderas et al., 2009).  The scores are based on the adjusted risk of one-
year mortality.  
 
Any associated clinical condition can interfere with the prognosis of a patient with COPD and 
thHUHIRUHSOD\DYLWDOUROHLQGHWHUPLQLQJSURJUHVVLRQUHFRYHU\DQGLPSURYHPHQWLQSDWLHQWV¶
overall health condition. 
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Co-morbidity Present Points 
Myocardial Infarct  1 
Congestive heart failure  1 
Peripheral vascular disease  1 
Dementia  1 
Chronic pulmonary disease  1 
Connective tissue disease  1 
Ulcer disease  1 
Mild liver disease  1 
Diabetes  1 
Diabetes with end organ damage  2 
Hemiplegia  2 
Moderate or severe renal disease  2 
2nd solid tumour (non metastatic)  2 
Leukaemia  2 
Lymphoma, multiple myeloma  2 
Moderate or severe liver disease  3 
2nd metastatic solid tumour  6 
AIDS  6 
       Comments  
       Total points  ________ 
Optional Extension 
Age Present Score 
50-59  1 
60-69  2 
70-79  3 
80-89  4 
90-99  5 
        
Total combined score _________           
 
Table 3.3.   Charlson Co-morbidity Index                      
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The researcher took the detailed history and performed a physical examination of the study 
subject in order to find out any co-existing condition subjects may have and if the researcher 
found that the subject had any obvious pathology listed on a comorbidity index chart (Table 3.3) 
that column was marked and then the total score was recorded.  For example if patient has signs 
of congestive heart failure (pedal oedema, crackles) he/she possess a Charlson index score of 1 or 
comorbidity score of 1. 
 
3.6 Data Analysis  
 
All statistical analysis was carried out using Statistical software package (SPSS version 16.0 prior 
to July, 2011 and version 17.0 after that).  A p-value of <0.05 was considered significant.  The data 
used in this study have a wide range of varieties include continuous, categorical, nominal, ordinal 
and discrete and therefore various tests have been involved in data analysis.   
 
 
a. Basic Statistical Tests 
 
b. Advance Statistical Test 
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a. Basic Tests 
 
The list of tests is presented in table 3.4. 
 
Tests Parametric Non Parametric 
Difference between two groups Independent t test Mann Whitney U test 
Difference between more than 
two groups 
ANOVA Kruksal Wallis Test 
Difference between individuals 
(measured twice) 
Paired T test Two Related sample 
Difference between individuals 
(measured more than two times) 
 K Related sample 
Relationships Pearson Spearman Rank 
 
Table 3.4. Basic statistical tests used in data analysis 
 
 
b. Advanced Statistical Testing. 
 
 
b.1. Chi Square Test 
 
The Chi-Square test can be used as a test of association between the categorisation which 
allows the comparison of two attributes in a sample of data, to determine if there is any 
relationship between them.  In this research, this test was used determine the proportion of 
males and females in categories of smokers, exsmokers and non-smokers. 
 
 
b.2. Kaplan-Meier Survival Analysis (KMSA)  
The Kaplan-Meier Survival Analysis (KMSA) procedure is a method of estimating time-to-
event models in the presence of censored cases (Kaplan and Meier, 1958). Censored cases are 
those cases for which the second event is not recorded (for example, study subjects still 
survived at the end of the research study).  The Kaplan-Meier model is based on estimating 
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conditional probabilities at each time point when an event occurs and taking the product limit 
of those probabilities to estimate the survival rate at each point in time. 
In this study, the KMSA was employed to further assess the ability of different severity indices 
to predict outcomes.  KMSA curves are generally used to represent outcomes that are times to 
an event (Kaplan, 1984, Hersh et al., 2004); in this study the event is death.   In the present 
study they have been utilized to examine the probability of study subjects surviving over ten 
years and to represent the proportion of the study population continues to survive.  As the 
number of subjects in the deceased group decreases over time, the curves are more precise in 
the earlier periods (left hand side of the survival curves) than later periods (right hand side of 
the survival curves) (URL 7). 
Another important advantage of the KMSA curves is that the method can take into account 
some types of censored cases/data (when the value of a measurement or observation is only 
partially known), particularly right-censoring, which occurs if a patient withdraws from a 
study, i.e. is lost from the sample before the final outcome is observed.  In other words, 
incomplete data also contribute to the model.  On the graphs representing KM curves, small 
YHUWLFDO OLQHV DORQJ WKH GLVWULEXWLQJ FXUYHV UHSUHVHQW ORVVHV ZKHUH D VWXG\ VXEMHFW¶V VXUYLYDO
time has been right-censored. 
 
 
b3. Cox Regression 
 
This method was used to examine how multiple potential prognostic factors (such as age and 
pack years) may predict the probability of outcome-IUHH ³VXUYLYDO´ RYHU WLPH DQG WKHUHIRUH
influence the main predictor of interest. 
This helps to develop predictive scores for time-to-event data. The model produces a survival 
function that predicts the probability that the event of interest has occurred at a given time for 
given values of the predictor variables (for example BOD and GOLD scores in present study). 
The shape of the survival function and the regression coefficients for the predictors are 
estimated from observed subjects; the model can then be applied to new cases that have 
measurements for the predictor variables. It is also noticeable that information from censored 
subjects, that is those that do not experience the event of interest during the time of 
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observation, contributes usefully to the estimation of the index in presence of other potential 
indicators of the outcome of interest. 
Cox regression analysis was therefore employed as it is a useful test for modelling the time to a 
specified event, based upon the values of difference covariates. A covariate is defined as a 
variable or a group of variables that is possibly predictive of the study outcome (Last, 2001). A 
covariate may be of direct interest or it may acts as a confounder.  The analysis of the data 
shows that inclusion and/or exclusion of the covariate or group of covariates allowed improved 
estimates of the trend against time to be obtained compared to analyses which omitted the 
covariate (Fox, 2002; Cox, 1972). The potential covariates in the present study mainly include 
age, gender, smoking history and comorbidities for the different assessment models. 
 
 
b4. ROC Curves 
 
This procedure is a useful way to evaluate the performance of classification schemes in which 
there is one variable with two categories by which subjects are classified.  It is assumed that 
increasing numbers on the assessed index represent the increasing belief that the subject 
belongs to one category, while decreasing numbers on the index of interest represent the 
increasing belief that the subject belongs to the other category.  
 
In the present study, the Receiver Operating Characteristic (ROC) curves were utilized to 
determine the appropriate cut-off values of the different COPD clinical indicators of mortality. 
The sensitivity and specificity were also determined for each variable. To discriminate subjects 
who are at higher risk from those who are at lower risk, this was commonly quantified by 
PHDVXULQJ FRQFRUGDQFH WKH ³F VWDWLVWLF´ ³F´ VWDWLVWLF LV VLPLODU WR WKH DUHD XQGHU WKH 52&
curve (Hanley and McNeil, 1982).  C varies between 0.5 and 1.0 and for sensible models; the 
higher the value the greater the sensitivity of the model.  
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B. Qualitative Analysis 
 
3.7   Introduction 
The wellness study was an extension of a study examining the natural history of a cohort of 
COPD patients identified in 1999-2002.  In order to control the progression of chronic diseases 
like COPD it is believed that physical and physiological assessment are not enough to monitor 
disease progression (Han et al., 2010).  It is therefore may be necessary to assess the attitude 
and/or psychological status (wellness status) of the sufferers to control COPD progression and 
to improve outcomes.   
An initial objective in an exploration and assessment was to design a wellness questionnaire; 
the second objective was the identification of those members of the cohort who were still alive 
in December 2010, so that the questionnaire could be sent to survivors.   
 
Steps of the Wellness Part of the Study 
This part of the study involves 4 major steps aimed at designing a validated questionnaire and 
using it in a cohort of COPD patients to assess their wellness status (figure 3.4). These steps 
are described below in detail. 
Step 1.  Pool of questions 
The first step of the study was to develop a pool of questions that would be used to assess 
wellness status. These were mainly based on a literature search as well as review meetings with 
project supervisors. 
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   Figure 3.4.  Schematic Representation of the Steps taken to Design a Wellness Questionnaire 
 
Literature search for Wellness 
Concept 
STEPS IN THE DESIGN OF THE WELLNSS QUESTIONNAIRE 
Literature search for existing 
available Wellness Assessment 
Questionnaires 
Obtain various non-specific 
Wellness assessment 
forms/questionnaires 
Pools of 100 questions and 5 
themes 
Arrange Research team meetings 
to get advice and filter out 
relevant themes and questions 
Focus Group 
University Ethical Committee 
Contact Social Settings Office for 
focus group participants and 
venue 
Focus groups  
(Three) 
(Designing and to validation of 
the questionnaire) 
Induction visits to introduce 
research, researcher and research 
objectives and volunteers 
Arrange focus group volunteers, 
venue, date and time 
Decide to validate it with the help 
of Focus groups 
Analysis of Focus Group Data 
Development of the final 
Questionnaire 
Apply for ethical approval to 
Hospital and University and 
follow any committee 
recommendation 
Send questionnaires to original 
COPD Cohort and analyse the 
responses 
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Step 2.  Designing and Validation of the questionnaire 
The design opted to carry out a focus-group to examine the quality, character, reliability and 
validity of the data obtained.  In the present study the researcher took account of various 
important aspects to conduct a result oriented focus group, as indicated in previous studies 
(Morgan, 1988).  The most vital is the size of the groups.  It is recommended that 4-10 
particiapnts are the most appropriate numbers (Morgan, 1988; Kruger and Casey, 2009) 
although in developing countries focus groups tend to be larger in size (8-15 people) (Kumar, 
1987).  
 
The need, assessment, design, validation, and application of a wellness questionnaire for use in 
the study were completed in following stages: 
 
Focus Group Sessions 
 
A. Focus Group I (Age Concern, Sunderland) 
 
In the present research, before carrying out wellness study in patients, it was opted to carry out 
focus groups (Seymour, 2004).  The focus group were scheduled in neutral venues external to 
the hospitals to encourage receptivity during the sessions (Mordan & Scannel, 1998).  The 
focus group adds authenticity to the newly developed Wellness questionnaire.   
 
For this purpose, the Sunderland Age Concern office was contacted and all the details about 
the research were explained.  Initially, Age Concern Sunderland branches were attended and an 
address made lasting 15 minutes in which the research and the purpose of the research were 
explained by the author.  Then a request was made for people to volunteer for the focus 
group.  The focus group was finally arranged with those who agreed to participate and a 
later date and venue was finalized after mutual agreement between author, participants and 
administration of the Age concern Office, Sunderland. 
During the focus group, the purpose and rules of the focus group were explained to the 
participants, namely the need for a wellness assessment in COPD and the design of the 
questionnaire to evaluate this issue. 
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The opportunity was then given to each participant to introduce himself/herself to the other 
participants and moderator and also to ask about any concerns/questions regarding the 
discussion topic or any other relevant query about the conduct of the focus group. The 
participants were also informed about the audio-recording of the session and its purpose.  After 
their agreement, the formal focus group discussion commenced. 
The discussion was started with an initial question to seek the participants¶YLHZVRQKRZWKH\
feel and think about assessing wellness status as opposed to health status. 
The second question asked about their thoughts on what they believe is necessary for being 
mentally and physically healthy.  They were asked if they were aware of the reasons, solutions 
and the ways of identifying and improving their current state of health and wellbeing. 
They were asked if they considered a lifestyle was healthy because of lack of disease or if it is 
possible to have a disease and still feel well because of taking regular medication and attending 
regular follow-up medical visits.  Thus they were asked if they truly understood the concept 
of wellness. 
7KHLQIRUPDWLRQJDWKHUHGFRQFOXGHGWKDWWKHWHUPµZHOOQHVV¶HQFRPSDVVHVDZLGHUDQJHRI
parameters.   
The focus group aimed to discuss and gather general public comments from the same age range 
as the original study cohort and examined: 
 
1. Question Purpose/Themes 
2. Question Content and Wording 
3. Response Format 
4. Question Sequence 
5. Questionnaire Lay out 
 
Hard copies of the questionnaires (developed from step 1) were distributed to the participants 
with a request that they read the questionnaire (for 30 minutes) and the formal discussion was 
started once they had finished reading.  A pen or a pencil was provided to each 
participant. Tea, coffee and biscuits were also provided to the participants.  As recommended, 
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the whole focus group discussion was recorded after taking consent from each participant at 
the venue. 
In addition to audio-recording, comprehensive notes were also made during the discussion 
session.  
 
B. Focus Group II (Breathe Easy Group, Primary Care Trust, Sunderland) 
 
 After successful completion of Focus Group I at Age Concern, modifications were made to the 
wellness questionnaire based on the feedback, advice and comments of the participants; a 
reformed version of the wellness questionnaire was then developed and a second focus group 
was scheduled to discuss this modified version of the questionnaire.  This group of people had 
breathing problems such as COPD, asthma, pneumoconiosis, and mesothelioma.  This was a 
³%UHDWKH(DV\´JURXS 
The Breathe Easy group runs under the management of the British Lung Foundation (BLF).  It 
is a charity set up to raise funds and awareness for people with respiratory disease.  The group 
consists mainly of people who suffer from lung disease, such as COPD, bronchiectasis and 
pneumoconiosis. In the second phase, the modified questionnaire was presented to the 
³6XQGHUODQG %UHDWKH (DV\ *URXS´ LQ RUGHU WR JDLQ IHHGEDFN IURm a cohort with similar 
respiratory conditions to the study population.  The session was held at the Primary Care Trust, 
Sunderland. 
The purpose was to conduct a focus group in a Breath Easy setting to gather further views on 
the designed Respiratory Wellness Questionnaire.  This focus group added their views and 
general comments; this helped to validate the design, composition and contents of the 
questionnaire. 
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7KH IRFXV JURXS DLPHG WR GLVFXVV DQG JDWKHU WKH RSLQLRQ RI ³H[SHUW SDWLHQWV´ RQ different 
dimensions of the questionnaire including themes and purpose of the questions included in the 
questionnaire..    
Hard copies of the questionnaires (modified after the first focus group) were distributed to the 
participants with a request that they read the questionnaire (for 20 minutes) and the formal 
discussion was started once they had finished reading.  A pen or a pencil was provided to each 
participant. Tea, coffee and biscuits were also provided to the participants.  The whole focus 
group discussion was also recorded after taking consent from each participant at the venue.  
In addition to audio-recording, comprehensive notes were also made during the discussion 
session.  
The questionnaire was then amended based on the discussion and feedback from this group. 
 
 
C.  Focus group III (Breathe Easy Group-South Tyneside) 
 
After carrying out Focus Group I and II , the recommended modifications were made in the 
wellness questionnaire based on feedback, advice and comments of the participants; the 
reformed version of the wellness questionnaire was then developed and a third focus group 
session was scheduled to discuss the modified/final version of the questionnaire.  The main aim 
of this session was to get comprehensive and specific comments of the public with breathing 
problems on the designed questionnaire.   
For this purpose, Breath Easy group South Tyneside was contacted and an initial visit was 
made by the author of this study to introduce himself, the study and to recruit the volunteers for 
the third focus group.  The date for the focus group session was then agreed and two days prior 
to the session, the author contacted the agreed particiapnts again just to remind the members of 
the date, time and venue of the focus group session.  The session was held at Physiotherapy 
Section, South Tyneside Hospital, South Tyneside. 
All the steps of conducting the focus was followed as indicated in focus group I and II 
discussion above.  The whole session was recorded.  
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This focus group helped to further validate the contents of the questionnaire. 
 
 
Step 3:  Modifications and Amendments in the Questionnaire 
 
 
All three focus group discussions were very open, composed, result oriented and helpful and 
all the recommendations based on focus group member views were again discussed with the 
project supervisors and changes were made accordingly.   
 
Step 4:  Use of the questionnaire in the Surviving members of the cohort   
 
Ethical approval was then obtained from all of the relevant ethical approval bodies at the 
hospital as well as the University of Sunderland. 
The changes were again made as per the recommendations of the Ethical approval committees 
and a final version was developed.  The final version of the wellness questionnaire was sent to 
the survivors of the cohort to examine wellness along with an invitation to participate, consent 
form, information sheet, and instructions on how to fill in the questionnaire, together with an 
enclosed pre-paid and addressed envelope. The questionnaires were collected back from 
participants via post. 
 
The members of the group who did not respond were again contacted by the author in case they 
had not received the questionnaire or in case if they needed help.  The questionnaires were 
again sent to those who had not received it or lost it after receiving it but, were willing to 
participate.   
 
 
3.8       STUDY INSTRUMENT  
 
3.8.1 Wellness Assessment Questionnaire 
 
To determine wellness perception, a questionnaire was required. However, there is no validated 
tool for use in COPD patients.  There are many wellness forms available from different bodies 
and on different websites that are nonspecific or related to health insurance or lifestyle advice.  
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They all contain the following domains: diet habits, weight control, exercise, mental health and 
overall fitness level. None of the questionnaires addresses specific issues related to COPD.    
 
It was therefore essential that novel questions be constructed for use in COPD patients in order 
to explore the relationship between COPD and wellness that would be reliable and could be 
used in different clinical settings. 
 
7KH:HOOQHVV4XHVWLRQQDLUH WLWOH ³6XQGHUODQG5HVSLUDWRU\:HOOQHVV4XHVWLRQQDLUH´ 65:4
(see appendix 2) has been used.  This questionnaire consists of 5 thematic sections given 
below: 
 
 
1. Personal/Physical Wellness 
2. Emotional Wellness 
3. Self-Responsibility Related Wellness 
4. Mental Wellness 
5. Spiritual Wellness 
 
(DFK VHFWLRQ FRQWDLQHG  VWDWHPHQWV UHODWHG WR WKH SDWLHQW¶V ZHOOEHLQJ DQG  RSWLRQV ZHUH
given of which patients had to tick one option that they think reflected their wellness most 
appropriately and scores range from 1 to 4 were given against each response.  Therefore a 
person could score a minimum of 10 and a maximum of 40 in each domain.  A low score 
indicates a low wellness and high score reflects better wellness status on that particular section. 
 
As there are 5 sections in the questionnaire, the minimum score in total would be 50 and 
maximum would be 200.  The score towards a higher side of the scale represents better overall 
wellness status in study subjects. 
 
In addition to quantitative assessment of wellness with the help of scores, the SWRQ also 
contains empty spaces/box at the end of each section where the study subjects could write 
additional comments where necessary.  Instructions to write additional comment was given on 
the title page of the questionnaire (see SRWQ in appendix 2).  
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3.8.2 Reliability and validity 
 
The data of the focus-group can be tested for reliability very effectively by comparing the 
responses of first focus groups with the second (Bender & Ewbank, 1994).  In the present study 
this was carried out by conducting the third focus group, which was similar to the second focus 
group as well as the original study cohort in terms of their age ranges, gender mix, health 
problems and interaction among the respondents.  Therefore the responses of the third focus 
group to the designed questionnaire was helpful in validating the contents, composition and 
other important factors that are related to a newly-developed questionnaire (Bender & Ewbank, 
1994). 
 
 
3.8.3 Statistical Analysis for Qualitative Data 
 
7R DQDO\VH IRFXV JURXS GDWD ³FRQWHQW DQDO\VLV´ LV HPSOR\HG  In order to carry out content 
analysis on text (transcribed from audio files/hand written notes) that is generated as a result of 
the focus group, the text is either coded or broken down into meaningful categories on the basis 
of a word, sentence or a phrase used that makes sense and later themes can be generated on this 
basis.  The final stage is to examine the text using one of content analysis' basic methods: 
conceptual analysis or relational analysis (Bender & Ewbank, 1994).  In the present study 
conceptual analysis (which is also known as thematic analysis) was used to analyse focus 
group data.  
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The steps followed to analyse focus group data are summarized in figure 3.5. 
 
 
 
 
 
 
                                                                             
 
 
       TRANSCRPTION OF AUDIO FILES 
 
 
                                           
 
          TRANSCRIPTIONS COMPARED WITH HAND-WRITTEN AND FIELD NOTES 
 
  
                                                                              
 
           CONTENT ANALYSIS 
 
  
 
 
 
 
Figure 3.5.  Stages of Focus group analysis 
 
3.8.4 Content Analysis 
 
 
Content analysis helps to identify the frequency of certain phrases within transcribed or hand-
written notes produced from focus groups.  The identified phrases or concepts help to draw 
sensible, reasonable and meaningful conclusions with respect to research aims and objectives.  
(Weber, 1990).  It is suggested that content analysis also helps in determining the emotional 
and psychological state of an individual or groups and allow describing any behavioural 
response to communication (Weber, 1990; Berelson, 1952; Krripendorff, 2004 and 2008).   
 
STEPS OF ANALYSIS 
Descriptive Analysis  
 (Identification of Emergent Themes 
by Conceptual Analysis) 
Both Inductive and Deductive 
methodology used 
 
Interpretative Analysis 
  (Relational Analysis) 
Both Inductive and Deductive 
methodology used 
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Content analysis methodology can be carried out by following either of its two main categories 
which are closely related to each other. 
 
A. Conceptual Analysis (Thematic Analysis) 
B. Relational Analysis 
 
 
A. Conceptual Analysis (Thematic Analysis) 
 
This type of content analysis helps to identify different concepts mentioned in the text.  The 
conceptual analysis allows the researcher to identify groups of words, sentences or statements 
which lead to a specific concept, meaning or conclusion (Weber 1990; Krripendorff, 2004 and 
2008). It also gives the researcher the opportunity to look at the text content of the data related 
to a theme or area of interest, tally its frequency of occurrence in transcribed literature or hand 
written notes and enables the researcher to draw a meaningful conclusion.  
 
 
B. Relational Analysis 
 
The relational analysis mainly builds on the facts generated as a result of conceptual analysis 
examining the relationship on the basis of the concepts in the test.  Thus relational analysis is 
an interpretation of the conceptual analysis in order to find meaningful relationships between 
occurrences of meaningful concepts (Weber, 1990; Krripendorff, 2004 and 2008). 
 
 
3.8.5 Inductive and Deductive Approaches 
 
In the present study both the inductive and deductive methods are used to analyse focus group 
data.  It is recommended that the inductive content analysis is an acceptable approach in 
research where no previous studies are available that deal with the phenomenon (Elo and 
Kyngas, 2008), which is the case in the present study of wellness.  
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Similarly, the deductive approach was also utilized to analyse data because one study suggests 
that is useful if the general objective of the study was to test an existing theory in a different 
situation (Elo & Kyngas, 2008) and in the present study the phenomenon of wellness status has 
been tested in patients with COPD. 
 
,Q WKLV VWXG\ WKH UHVHDUFKHU WULHV WR H[SORUH LQ GHSWK DQ XQGHUVWDQGLQJ RI D SDWLHQW¶V
psychological behaviour and how he/she perceives his/her health in terms of wellness which 
directly or indirectly influences the clinical condition and overall health in these patients. As 
discussed above, the wellness questionnaire was developed with the help of certain themes 
gathered from the feedback of focus groups carried out during the study.  
 
Therefore, to analyse qualitative data a thematic approach was used. The thematic approach is 
the most basic yet commonly used analytical technique in qualitative data analysis 
(Krripendorff, 2004 & 2008). 
 
Thematic analysis is a rarely acknowledged but a widely-used method in qualitative research. 
(Boyatzis,1998; Roulsten,2001).  It is regarded as a foundational method for qualitative 
analysis. However, thematic analysis has not received detailed attention in terms of guidelines 
about how to carry out analysis properly (Attride-Stirling, 2001; Boyatzis, 1998).  
Furthermore, many researchers have given some really useful tips for carrying out a thematic 
analysis.  
 
Thematic analysis is not as dependent on specialised theory as some other qualitative 
techniques such as Discourse analysis or Conversation analysis (Hammersley, 2003).  As a 
consequence, thematic analysis is more accessible to new researchers who are unfamiliar with 
the relevant theory in-depth (Braun & Clarke, 2006). 
,Q WKHPDWLFDQDO\VLV LW LV WKHUHVHDUFKHU¶V MRE WR LGHQWLI\DQGGHYHORS WKHPHVRQ WKHEDVLVRI
text; the researcher has received, and/or transcribed from the study subjects. It is also the 
UHVHDUFKHU¶V UHVSRQVLELOLW\ WR Dssociate developed themes in order to address the research 
question effectively.  This is not so easy to do although the identification of a few superficial 
themes is generally quite easy, although it does not reflect the required level of analysis 
adequately.  7KH³NH\QHVV´RIDWKHPHLVQRWQHFHVVDULO\GHSHQGHQWRQTXDQWLILDEOHPHDVXUHV-
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but rather on whether it captures something important in relation to the overall research 
question (Braun & Clarke, 2006). 
As recommended in data obtained from the focus group, deviant case analysis is also important 
(Kitzinger, 1995).  In other words it is important to distinguish between group agreed points 
and an opinion raised by an individual, as it may give the researcher the opportunity to 
formulate a further hypothesis or develop a new area of research.  As an example, the section 
RQ³6SLULWXDOLW\´ZDVQRW LQLWLDOO\SUHVHQW LQ WKH TXHVWLRQQDLUHGUDIW  However, during focus 
group 1 session, one member of the group has mentioned that questions about the spirituality  
should be added in the questionnaire as an assessment of wellness, and this was later accepted 
and agreed by the other participants. (See result section of chapter 6 for details).   
 
In the present study, the wellness questionnaire was used for quantitative assessment of the 
wellness in patients with COPD.  In addition to the scores against each response, the wellness 
questionnaire also contained an empty spaces/box at the end of each section where the study 
subjects could write additional comments where necessary and these comments from the study 
participants were then to be used to perform a qualitative analysis by developing themes on the 
EDVLV RI WKHLU FRPPHQWV DQG WKHQ FRUUHODWH D SDWLHQW¶V ZHOOQHss perception to their overall 
wellness as well as health status in study subjects.  
 
    
     ______________________________ 
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Chapter 4 
  
 
A CRITICAL EVALUATION OF THE MULTIDIMENSIONAL INDEX 
BOD 
 
 
 
4.1. Introduction 
 
 
COPD is a complex disease and patients with COPD experience multiple clinical 
manifestations that significantly impair their functional, physiological and psychological 
health. It has been suggested that low body mass index (Landbo et al., 1999), loss of lean body 
mass (Schols et al., 2005, Calverly et al., 2003), hypoxaemia or hypercapnia (Cote, 2006; Nizet 
et al., 2005), UHGXFHG FDSDFLW\ IRU H[HUFLVH 2¶ Donnel & Katherine, 2008), and perceived 
breathlessness (Nishimura et al., 2002) assessed with the MRC Dyspnoea Score can all be used 
as measures of disease progression.  Because of these complexities there is a poor correlation 
between impairment (measured as FEV1%) (Pauwels et al., 2001) and disability as evidenced 
by health status, exercise capacity and dyspnoea (Figure 4.1) (Curtis et al., 1994).  Therefore 
assessment of COPD progression needs to adopt a multidimensional approach.  
 
 
  Figure 4.1.  Correlations between COPD Related Measurements (Curtis et al., 1994) 
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Primarily based on the Fletcher-Peto model (Fletcher & Peto 1977, Figure 2.6) forced 
expiratory volume in one second (FEV1) cut-off points have routinely been used to establish 
the severity of COPD and various guidelines have been published to classify the severity of the 
disease based upon this measure. These include ATS (1995), BTS (1997), GOLD (2001) and 
consensus guidelines from the ATS-European Respiratory Society (ATS-ERS) (2004).  
Esteban and colleagues (2009) compared them as prognostic indicators and although the BTS 
system was slightly superior, none of the guidelines was closely related to 5 year mortality.  
 
Recently, the National Institute for Clinical Excellence (NICE) updated its guidelines to 
improve COPD care; it recommends using a definition of COPD based on the GOLD 
classification of severity of airflow obstruction (NICE, 2010).  Therefore, in the present 
research the GOLD severity model was used to compare COPD progression and severity with 
the multidimensional index developed in this study BOD, to demonstrate its effectiveness in 
the assessment of COPD progression and mortality. 
 
Celli and colleagues (2004) have shown that a multidimensional index, of the severity of 
COPD, proved to be a better predictor of mortality than FEV1 alone.  They measured Body 
mass index, airflow ObstruFWLRQ'\VSQRHDDQG([HUFLVH WHVWDQGQDPHG WKH LQGH[³%2'(´
The scoring of the BODE index is not complex; however, the exercise test (six minute walk 
distance) requires time and space for its measurement. Subsequently, Puhan and colleagues 
(2009 GHYHORSHG DQG YDOLGDWHG DQRWKHU LQGH[ QDPHG ³$'2´ DJH G\VSQRHD DQG DLUIORZ
obstruction (FEV1). In their cohort, ADO and a rescaled BODE had a similar accuracy for risk 
prediction. Their study emphasised the need for careful  validation of prognostic indices but it 
should be born in mind that age is a confounder in a prognostic tool (Celli, 2009). 
 
The present study investigates the application of a new multidimensional index BOD (BODE 
without an exercise test) and has explored the efficacy of the BOD multidimensional index in 
the characterisation of the natural history of COPD. The results of this evaluation are presented 
in this chapter. 
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4.2. Methodology 
 
 
The proposed multidimensional index BOD comprises body mass index, airflow obstruction 
and dyspnoea score. 
 
 Body mass index was calculated from body weight and height.  
 
 Obstruction of the airway was calculated from FEV1 predicted values  
 
 Subjective severity of dyspnoea was measured by MRC dyspnoea score. 
 
4.2.1 Calculation of Assessment Models of COPD  
 
Table 4.1 summarizes the factors measured by the different models under investigation in this 
study.  All the indices presented in Table 4.1 including GOLD, BOD and BODE have been 
examined and analysed in this chapter using the members of the cohort described in Chapter 3.  
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Assessment 
Models  
Measurements Used  
 FEV1 % 
Predicted 
(%) 
BMI  
(kg/m2) 
MRC Score 
(1-5) 
Exercise Test 
(meters) 
GOLD Stages 
 
    
I >80 - - - 
II <50 to 80 - - - 
III 30 to 49 - - - 
IV င29 - - - 
BOD Scores 
 
    
0 t65 >21 1-2 - 
1 50-64 d21 3 - 
2 36-49 - 4 - 
3 d35 - 5 - 
BODE Scores 
 
    
0 t65 >21 1-2  
1 50-64 d21 3 250-349 
2 36-49 - 4 150-249 
3 d35 - 5  
 
Table 4.1.  Calculation of the Assessment Models 
 
For example, if a patient has FEV1 of 60% predicted (O=1), MRC score of 4 (D=2), BMI of 19 
(B=1), and six minute walk test of 265 meters (E=1) his/her total scores calculated from these 
models would be 2, 4 and 5 according to GOLD, BOD and BODE respectively. 
 
In the BOD model, the same scoring system (Table 4.1) is utilised as is used in BODE (Table 
3.4; chapter 3) but without the exercise component.  The range of possible scores is 0-7. For 
further analyses these scores were grouped into catogories (Table 4.2) as there were 
insufficient deaths to use individual scores to validate the index as a prognostic indicator. 
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BOD Scores Categories 
0-1 1 
2-3 2 
4-5 3 
6-7 4 
Table 4.2.  BOD Scores and their respective Categories 
 
Please refer to Chapter 3 section 3.1 for details of the methodology for each measurement.  
 
 
4.2.2. COPD and Cause-Specific Mortality  
 
In this study the effectiveness of the BOD Index has been assessed using the mortality of the 
members of the cohort. However there are a number of limitations to this approach. 
 
COPD is a clinical condition associated with high morbidity (Yeo et al., 2006; Lang et al., 
2010) and mortality (Gudmundsson et al., 2006).  It is predicted that death due to COPD will 
rise from the sixth leading cause of death to the third leading cause by 2020 (Murray et al., 
1997). A 22Ǧyr follow-up of 5,542 adults in the first National Health and Nutrition 
Examination Survey (NHANES I) found that 47.7% of patients with severe COPD at baseline 
had COPD listed on the death certificate and 23.1% had COPD as the underlying cause of 
death (Mannino et al., 2003). 
 
However, the determination of the actual cause of death in patients with COPD is 
controversial.  Hansell and colleagues (2003) carried out a study based in England and Wales 
of COPD patients and suggest that the use of underlying cause of death underestimates the 
contribution of chronic lung disease to mortality in these patients when compared with deaths 
that had resulted from myocardial infarction. 
 
In a more recent study (McGarvey et al., 2007; Ekstrom et al., 2011) explored this issue in 911 
patients with COPD and suggest that COPD and pneumonia are the most common causes of 
death in these patients (35%).  Other common causes were cardiovascular (26%) followed by 
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lung cancer (14%).  Furthermore, no consensus has been developed in relation to deaths caused 
by or related to COPD.  This contrasts to other diseases such as coronary artery disease. 
Therefore studies show a range of causes that contribute to death in these patients (Zielinski et 
al., 1997; Lange et al., 1990, Nussbaumer-Ochsner et al., 2011).  These causes mainly include 
cardiovascular disease, pneumonia and lung cancer due to the higher prevalence of smoking in 
COPD patients that in turn leads to other life threatening comorbidities such as coronary artery 
disease that lead to fatal outcomes (Zielinski et al., 1997).   
 
For this reason, death from all causes was recorded in the study participants with COPD in this 
study.  
 
 
4.2.3 Data Analysis 
 
 
There were a number of limitations to the data analysis carried out in this section of the study.  
One limitation was that data for the BODE index were not available for all three timeframes 
(1999-2002; 2007-2008; and 2008-2009).  The reason was that the initial database was 
established in 1999-2002, at a time when the BODE index had not yet been published.  Whilst 
the measurements were recorded on three occasions over a period of 10 years i.e. time 1 (1999-
2002), time 2 (2007-2008) and time 3 (2008-2009), on occasions there were some missing 
data.  Also, since data collection was undertaken over a period of 10 years, a diminishing 
sample size due to drop-outs occurring can be anticipated during the study.  The sample size 
was reduced further when data were sub-divided into survivors and deceased COPD patients 
(Table 4.13), in order to compare the assessment models of COPD severity and progression.   
 
The normality of the datasets was checked using the Kolmogorov-Smirnov test and histograms.  
Most of the tests were statistically significant (< 0.05) which suggests violations of the 
assumption of normality (Pallant, 2007).  The histogram plots are attached in the appendices 
(appendix 1) of this thesis.   
 
The paired sample t test, two related sample tests: (Wilcoxon) and K-related sample test 
(Friedman Test) were used to compare different monitors of progression (GOLD, BOD and 
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BODE) recorded on three occasions, in study subjects (including survivors with COPD and 
deceased COPD patients), measured at different times.   
Kaplan-Meier survival curves (K-M curves) are generally used to represent outcomes that are 
timed to an event, in this case the event being death (Kaplan, 1983).  In the present study they 
have been utilized to examine the probability of study subjects surviving over ten years and to 
represent the proportion of the study population still surviving.  Because the number of 
subjects in the deceased group decreases over time, the curves are relatively more precise in 
the earlier periods (left hand side of the survival curves) than in later periods (right hand side of 
the survival curves) (URL 7).   
Furthermore, Cox regression analysis was employed which is a useful test for modelling the 
time to a specified event, based upon the values of difference covariates.  A covariate is 
defined as a variable or a group of variables that is possibly predictive of the study outcome 
(Last, 2001).  A covariate may be of direct interest or it may act as a confounder.  Analysis of 
the data shows that inclusion and/or exclusion of the covariate or group of covariates allows 
improved estimates of the trend against time to be obtained compared to analyses which 
omitted the covariate (Everitt, 2002).  The potential covariates in the present study mainly 
include age, gender, smoking history and comorbidities for the different assessment models. 
 
Addionally, in this study, the Receiver Operating Characteristic (ROC) curves were also 
utilized to determine the appropriate cut-off values of the different COPD clinical indicators of 
mortality.  The sensitivity and specificity were also determined for each variable. 
Discrimination of subjects who are at higher risk from those who are at lower risk is commonly 
TXDQWLILHGE\PHDVXULQJFRQFRUGDQFHWKH³FVWDWLVWLF´³F´VWDWLVWLFLVVLPLODUWRWKHDUHDXQGHU
the ROC curve (Hanley & McNeil, 1983). C varies between 0.5 and 1.0 for sensible models; 
the higher the value the greater the sensitivity of the model.  
 
All the data were analyzed using SPSS Version 16.0.  
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4.3. Results 
 
 
A. DATA ANALYSIS OF THE COHORT STAGE 1 (1999-2002) 
 
 
4.3.1. Data Collection                                                                                                             
 
A cohort of patients (n=634) with suspected COPD was established.  They were identified 
from asthma clinics in primary care during 1999-2002. The initial search process for 
establishing a database for COPD patients was carried out by the respiratory research team 
based at the Chest Clinic of Sunderland Royal Hospital. The inclusion and exclusion criterion 
for the established database is given in the methodology section.   The patients on the database 
were again contacted in 2007 (which is the starting year of the present study) and recruitment 
visits were scheduled for those agreeing to participate in the study.  Home visits were also 
scheduled for those who were not willing or who were unable to attend hospital.   
 
Figure 4.2 shows a flow chart of the fate and involvement of the patients on the original 
database.  Out of 634 persons, only 458 fulfilled the inclusion criteria for the present study.  Of 
this 458, 118 had died in 2007 or before and therefore could not be recruited.  This meant that 
340 people from the original cohort were contacted. Of this number 158 subjects did not reply, 
were reluctant to participate or could not be contacted due to incorrect address details being 
held.  
 
Similarly, during the 2008-2009 phase of this study, only 98 subjects were recruited because 
more drop outs occurred during the third phase of the study.  However participating patients 
were able to complete the study protocol except for a small number who were not in a position 
to perform the six minute walk test either due to their illness and /or unwillingness.  
 
Detailed demographics of the study cohort are presented in section 4.3.2. All data are presented 
as mean ± SD (Standard Deviation) unless otherwise stated. 
 
The details of the recruitment phase including the number of patients that were recruited, left 
the study and died, are presented in figure 4.2. 
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   Figure 4.2.        Flow chart of the recruitment phases and subjects excluded/included. 
1999-2002 Cohort of patients with suspected COPD (Baseline) 
n=634 
Excluded (Non COPD) 
n=176 
Fulfilled Inclusion Criteria of the 
Study 
n=458 
 
 
Patients with COPD were again contacted in 2007-2008 Cohort 
n=340 
 
Recruited 
2007-2008 
n=161 
Excluded 
Not  Recruited 
(Drop outs) 
n=158 
Patients were again contacted in 2008-2009 Cohort 
n=140 
 
Survived 
2009-2010 
N=98 
 
n 
Died between 
2009-2010 
n=15 
 
Total Number of deaths in 10 years 2000-2010 
With COPD: n=154  
 
Died between 
2007-2008 
n=21 
Excluded 
Not Recruited 
(Drop outs) 
n=27 
 
Died between 
1999-2007 
n=118 
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4.3.2 Subject Characteristics 
  
The mean age of the cohort originally recruited was 64.7± 9.7 years, of whom 51% (n=233) 
were females.  87% of the cohort was either current or ex-smokers and only 13% were non-
smokers. The mean pack year history was 33.0±18.9 years.  The BMI was 26.0±5.1 kg/m2.  In 
relation to lung functions, the mean FEV1 and % predicted were 1.53±0.62 (L) and 60.9±20.0 
respectively indicating mild to moderate degree of severity in these patients. The subjective 
breathlessness as measured by MRC dyspnoea score was 2.50±1.01 showing that the cohort 
had mild to moderate degrees of functional impairment due to shortness of breath. The detailed 
baseline scores of the cohort as measured by GOLD and BOD are presented in Table  4.3 and 
figures 4.3-4.5.  
 
The histograms of the study variables of the present study (see appendix)  indicate  normally 
distributed data in terms of age, BMI, and pack year history (number of years smoked) in the 
study population in each gender.   
 
 
Baseline Demographic Characteristics of the subjects (n=458) 
Age (years)  64.7±9.7 
Gender (m/f) Male 
Female 
225 (49.0%) 
233(51.0%) 
Smoking Status Current 
Exsmoker 
Non smoker 
180 (40.6%) 
206 (46.5%) 
57(12.9%) 
Pack years (years)  33.0±18.9 
BMI (kg/m2) 26.0±5.1 
FEV1 (L) 1.53±0.62 
FEV1 % predicted 60.9±20.0 
MRC (1-5) 2.50±1.01 
GOLD (1-4) 2.19±0.75 
Median BOD Scores (Range) 1.0 (0-6) 
 
Table 4.3.  Baseline demographics for the cohort (1999-2002).  BOD scores are presented as 
median and range. 
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4.3.3 Evaluation of BOD & GOLD Models of Severity in the 1999-2002 Cohort 
 
 
 
 
Figure 4.3.  Distribution of BOD Scores in Study cohort (1999-2002) 
 
 
 
 
The cohort when recruited had mild to moderate COPD as shown in figures 4.3, 4.4 and 4.5 
representing the score distribution of the BOD index, BOD categories and GOLD stages 
respectively.  More than 75% of the cohort had a BOD score of 3 or less, BOD categories of 2 
or less and a GOLD score of 2 or less. It is also noticeable that the two severity indices, GOLD 
and BOD, indicate different degrees of severity in the same cohort. The scores observed using 
BOD are higher than those observed using GOLD.   
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Figure 4.4. Distribution of BOD Categories in Study cohort (1999-2002) 
 
 
 
                           Figure 4.5. Distribution of GOLD Scores in Study cohort (1999-2002) 
 
  
 
105 
The measures obtained for BOD and GOLD at recruitment have been analysed further using 
Kaplan Meier survival curves. 
 
In order to assess BOD as a predictor of mortality, actual BOD scores (0-7) and categories of 
BOD scores (1-4) (Table 4.2) were used to show the probability of survival with the help of 
Kaplan Meier Curves. Figure 4.6 shows that a lower BOD score represents, a higher 
probability of more than 10 years of survival as compared to higher BOD scores, of 5 and 6 
that indicate only a 60 to 40% probability of surviving more than 10 years or more 
respectively. Figure 4.7, which represents the probability of survival in terms of BOD 
categories clearly shows that patients with BOD categories scores greater than 4 have just 
under a 40% chance of surviving more than 10 years.  In contrast, patients with BOD 
categories of 0 and 1 have more than an 80 % probability of surviving more than 10 years 
(Figure 4.7). Figure 4.8 shows the probability of survival in terms of GOLD stages of severity 
(1-4), the curve shows that scores of 1-3 have 70-80% chance of surviving 10 years whereas 
GOLD stage 4 have a probability of 60% of surviving for 10 years. 
 
The difference between BOD scores, BOD categories and GOLD are that the BOD scores and 
categories discriminate far better between individual scores and the probability of survival as 
compared with the GOLD scores. 
 
As there are other factors that affect survival such as age (p<0.001), pack years (p<0...006), 
and gender (p<0...05), it was decided to plot KM curves adding these factors as covariates to 
the BOD index. 
 
The covariates have improved the predictive power of the index.   Figure 4.10 indicates that the 
patients with higher BOD scores have the least chance of surviving.  For example, patients 
with BOD category of 4 have under 30% probability to survive 10 years or more. 
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Figure 4.6. Kaplan-Meier Curve using BOD Index Scores (1999 - 2002) 
 
 
 
Figure 4.7. Kaplan-Meier Curve using BOD categories (1999-2002) 
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Figure 4.8.  Kaplan-Meier Curve using GOLD Stages (1999-2002) 
 
 
 
Figure 4.9.  Kaplan-Meier Curve Using BOD Index with Covariates (1999-2002)  
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Figures 4.9 and 4.10 indicate the effectiveness of BOD categories score and GOLD severity 
stages in predicting 10 years survival when age, gender, and pack years were added as 
covariates in the model.  Gender did not influence any of the indices significantly. The BOD 
categories 3 and 4 have lower survival curves.  They are therefore more likely to have shorter 
times to survive.  The figures also show that the sensitivity of the BOD categories in predicting 
survival improved (worst scores represents less probability of survival over time) by adding 
covariates.  On the other hand GOLD stages also improved.  However, figure 4.10 indicates 
that when covariates were added in the GOLD severity scores, they failed to differentiate 
survivors between stages 1, 2 and 3. 
 
 
Figure 4.10.  Kaplan Meier Curve of GOLD Severity Stages with Covariates (1999-2002)  
 
 
In Tables 4.4 and 4.5, the Cox model (a method used to examine how multiple potential 
prognostic factors (such as age and pack years), that may predict the probability of outcome-
IUHH³VXUYLYDO´RYHUWLPHZDVXWLOL]HGWRDVVHVVWKHDELOLW\RIWKH%2'LQGH[DQG*2/'VWDJHV
of severity to predict mortality.  In table 4.4., the p values for age and pack years were 
statistically significant (<0.001 and 0.02) with positive beta values (0.76 and 0.10).  The 
positive beta values indicate that when age (in years) increases the mortality increases and vice 
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versa.  Similarly when number of years smoked increases the mortality increases and hence the 
B value is positive.  Furthermore, BOD categories also showed a significant result (p<0.001) in 
the presence of other prognostic variables that remained in the model, these were age and pack 
years. However since BOD is a categorical variable, SPSS regards the last category (category 
4) as a ³reference category´ for the other BOD categories (1, 2 and 3).  This means that as 
compared to category 4, patients who are in other categories (1, 2 and 3) have a lower mortality 
than that of those with highest BOD category (category 4) and hence these B values are 
negative.  On the other hand, the GOLD stage (p=0.034) did not have greater significance over 
other covariates such as age (p<0.001) and pack years (p=0.030) (Table 4.5).   
 
(In order to ensure that a reliable model is build the data is split into two parts.   The first part 
(n=225) is used to build the model and the other part (n=233) is passed through the model to 
validate it. (Appendix 1).  BOD again successfully showed its superiority over GOLD in both 
derivation and validation cohort).   
 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
Lower Upper 
  Age .076 .010 54.227 1 .000 1.079 1.057 1.101 
Pack years .010 .004 4.876 1 .027 1.010 1.001 1.019 
BOD categories   20.045 3 .000    
BOD category (1) -1.649 .473 12.135 1 .000 .192 .076 .486 
BOD category (2) -1.392 .474 8.635 1 .003 .249 .098 .629 
BOD category (3) -.906 .482 3.528 1 .060 .404 .157 1.040 
Table 4.4.  The Cox regression of BOD model and covariates. 
 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
Lower Upper 
  Age .073 .010 51.987 1 .000 1.076 1.055 1.098 
Pack years .013 .004 8.862 1 .003 1.013 1.005 1.022 
GOLD Stages   8.698 3 .034    
GOLD (1) -.917 .370 6.152 1 .013 .400 .194 .825 
GOLD (2) -.862 .304 8.032 1 .005 .422 .233 .766 
GOLD (3) -.705 .322 4.796 1 .029 .494 .263 .929 
Table 4.5.  The Cox regression of GOLD stages and covariates. 
  
 
110 
 
 
 
Figure 4.11.  ROC Curve shows sensitivity and 1-specificity for GOLD vs BOD 1999-2002 
 
 
On further analysis of the suitability of the BOD index to predict mortality in COPD, ROC 
curves were used to compare the capacity of these indicators in predicting health outcome 
using BOD (Figure 4.11 and Table 4.6).  The figure and table clearly indicate that BOD works 
more effectively than GOLD in terms of predicting COPD mortality. The areas under the curve 
(AUC) for BOD and GOLD were 0.60 and 0.57 and p values were <0.001 and 0.02 
respectively. In other words, neither was very good (>0.7 is optimal) as the p-value merely 
gives an indication of how much confidence to place in the coefficient.   
 
 
 
Test Result 
Variables 
Area 
Under the 
Curve 
 
S.E 
 
p value 
Asymptotic 95% Confidence Interval 
Lower Bound Upper Bound 
BOD Index 0.62 .028 <0.001 .567 .678 
GOLD stages 
of severity 0.56 .029 0.02 .512 .624 
   
Table 4.6.  ROC for different indices of COPD severity with Mortality 
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Figure 4.12.  Number of survived & deceased members of the cohort in each BOD Scores 
 
 
 
Figure 4.13.  Number of survived & deceased members of the cohort in each BOD categories. 
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Figure 4.14. Number of survived & deceased members of the cohort in each GOLD stage 
 
 
Figures 4.12, 4.13 and 4.14 above represent the percentages of patients in the study who died 
and survived after 10 years, in each BOD index scores (0-7), BOD Index category (1-4), and 
GOLD stages of severity (1-4) as assigned during the 1999-2002 phase of the study.   
 
The figures demonstrate that the proportion of patients who survived is greater with BOD 
scores 0-3, BOD categories 0 and 1 than those with higher BOD scores 4-6 and categories 3 
and 4.  On the other hand, the proportion of subjects who died was higher with BOD scores 4-6 
and categories 3 and 4 compared with patients with BOD scores 0-3, BOD categories 0 and 1. 
The differences are statistically significant (p<0.001) for all comparisions.  In contrast, GOLD 
stages (figure 4.14) indicates that a higher proportion of survivors are in GOLD stages 1-3 
compared with GOLD stage 4 which has a higher proportion of deceased patients than 
survived. These figures (4.12, 4.13, 4.14) again show clear differentiations between BOD and 
GOLD.   
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B. DATA ANALYSIS OF THE COHORT AT STAGE 2 (2007-2008) 
 
In this section of the chapter, the results for the members of cohort assessed in 2007-8 are 
discussed.  At this time BODE has also been included in the evaluation of the cohort. 
 
 
4.3.4 Subject Characteristics 2007 - 2008 
 
Table 4.7 illustrates the demographics of the cohort at this timeframe. The cohort now 
comprises 51.6 % of females with a mean age of 69.3±9.2.  In terms of smoking status, 38% 
were current smokers and 48.4 % were ex-smokers whereas only 13.5% were non-smokers.   
The mean pack year history was 35.6±21.3.  The subjects were slightly overweight with a 
mean BMI of 27.1±6.5 (n=21 with BMI<21) and demonstrated moderate severity in terms of 
spirometry with a mean FEV1% predicted of 59.2±23.1, in terms of breathlessness with a mean 
MRC dyspnoea score of 3.05±1.2 out of 5 and in terms of BOD and BODE index scores of 
2.29±0.9 and 3.22±2.2 respectively. 
 
 
Age (years)  69.3±9.2 
Gender (m/f) Male 
Female 
77 (48.0%) 
84(52.0%) 
Smoking Status Current 
Exsmoker 
Non smoker 
59 (38.1%) 
75 (48.4%) 
21(13.5%) 
Pack years (years)  35.6±21.3 
BMI (kg/m2) 27.1±6.5 
FEV1 (L) 1.46±0.6 
FEV1 % predicted 59.2±23.1 
MRC (1-5) 3.05±1.2 
6MWT 275.0± 89.4 
GOLD (1-4) 2.29±0.9 
Median BOD Scores (Range) 2.00 (0-7) 
Median BOD categories (Range) 2.00 (1-4) 
 BODE Scores (1-10) 3.22±2.2 
BODE Quartiles (1-4) 1.91±1.0 
 
Table 4.7. Demographic Characteristics of the Cohort 2007 -2008 (n=161).  BOD category is  
presented as median and range. 
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The mean scores in GOLD, MRC, FEV1% predicted, MRC, BOD and BODE indicate that the 
cohort had a range of disease symptoms from mild and moderate to severe. 
 
Figures 4.15-4.19 show the score distribution of BOD, GOLD and BODE scores of severity in 
the study cohort. More than 75% of the cohort has a BOD score of 3 or less, BOD categories of 
2 or less and GOLD score of 2 or less.  It is also noticeable that the three severity indices, 
BOD, GOLD and BODE, indicate different degrees of severity in the same cohort.  The scores 
observed using BOD are higher than those observed using GOLD and BODE. 
 
 
 
 
           Figure 4.15.      BOD score distribution (2007-2008) 
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Figure 4.16.  BOD categories distribution (2007-2008) 
 
 
 
 
  
                                    Figure  4.17.  GOLD Score distribution (2007-2008) 
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                 Figure 4.18.  BODE Scores distribution (2007-2008) 
 
 
 
 
 
              Figure 4.19.  BODE quartile distribution (2007-2008)  
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KM curves have also been plotted in order to assess BOD, BODE and GOLD indices as a 
predictor of 3 year survival (2007-2010).   
 
Figure 4.20 shows that those with the higher BOD category of 4 have only a 50 % probability 
of surviving more than 3 years. In contrast, patients with BOD categories of 0 and 1 have more 
than a 90 % probability of surviving more than 3 years (Figure 4.20). 
 
 
 
 
 
Figure 4.20.  Kaplan-Meier Curve using BOD Categories (2007-2008) 
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Figure 4.21.  Kaplan-Meier Curve using BODE Scores (2007-2008) 
 
 
Similarly, figure 4.21 represents the probability of survival in terms of BODE quartiles which 
did not show any significant relationship between BODE and years of survival (figure 4.21).  
This is may be due to the fact that only 3 deaths were observed within the group of subjects 
whose BODE index was recorded. 
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Figure 4.22.  Kaplan-Meier Curve using GOLD Scores (2007-2008) 
 
 
Figure 4.22 represents the probability of survival in terms of the GOLD index which indicates 
that higher GOLD scores may be indicative of only 66.7% of survival of 3 or more years. 
 
Similarly figures 4.23, 4.24 and 4.25 represent the COPD severity indices when covariates 
were added in each index of severity i.e. BOD, BODE and GOLD.  Figure 4.23 shows that the 
ability of the BOD index to predict mortality did not significantly alter when covariates were 
added.   
 
The KM curve of BODE index with covariates did not show any particular trend (figure 4.24) 
because only 3 deaths were observed in patients whose BODE scores were recorded in 2007/8 
cohort. 
 
No significant effects were observed in GOLD stages 1-2 index (figure 4.25).  The ability to 
predict mortality particularly in patients with GOLD stage 4 (very severe) diminished when 
covariates were added in the model. 
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Figure 4.23. Kaplan-Meier Curve using covariates and BOD Scores (2007-2008) 
 
 
Figure 4.24. Kaplan-Meier Curve using covariates and BODE quartiles (2007-2008) 
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Figure 4.25.  Kaplan-Meier Curve using covariates and GOLD Scores (2007-2008) 
 
In Tables 4.8 and 4.9, the Cox model (a method used to examine how multiple potential 
prognostic factors such as age and pack years), was utilized to assess the ability of the BOD 
and BODE indices and GOLD stages of severity to predict mortality considering other factors 
that generally influence mortality in these patients such as gender, age and smoking history.   
BOD category scores 1, 2 and 3 (p=0.04, 0.04 and 0.05) whilst none of the other prognostic 
variables remained in the model.  Similarly for GOLD stages 1, 2 and 3 (p=0.03, 0.02, and ns 
respectively), none of the other covariates were significant predictor of outcome.  The Cox 
model for BODE index was not computed due to there being fewer deaths in the cohort. 
 
 
Multidimensional Index of Severity B SE Wald df Sig. Exp(B) 
 
BOD categories 
(2007-2008)   
7.185 3 .066 
 
BOD category 1 -1.440 .708 4.162 1 .041 .236 
BOD category 2 -1.592 .765 4.334 1 .037 .203 
BOD category 3 -1.621 1.119 3.831 1 .050 .112 
       
       Table 4.8. The Cox regression of BOD model and covariates (2007-2008) 
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GOLD Stages of Severity 
B SE Wald df Sig. 
Exp(B
) 
  
GOLD Stages 
(2007-2008)   
7.563 3 .056 
 
GOLD Stage 1 -13.95 361.6
3 
.001 1 .969 .000 
GOLD Stage 2  -1.324 .607 4.761 1 .029 .266 
GOLD Stage 3 -2.475 1.097 5.092 1 .024 .084 
 
        Table 4.9.  The Cox regression of GOLD stages and covariates. (2007-2008) 
 
 
 
 
Figure 4.26. ROC Curve shows sensitivity &1-specificity (GOLD vs BOD) 2007-2008 
 
 
ROC curves were used to analyse the suitability of the BOD index and GOLD severity stages 
to predict mortality in COPD as shown in Figure 4.26 and Table 4.10.  The figure and table 
clearly indicate that BOD works more effectively than GOLD. The areas under the curve 
(AUC)   for BOD and GOLD were 0.72 and 0.71 and p values were <0.001 and 0.002 
respectively. The p-value gives an indication that BOD is more accurate than GOLD. 
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Test Result Variable(s) 
Area under 
curve Std. Error p value 
Asymptotic 95% 
Confidence Interval 
Lower 
Bound 
Upper 
Bound 
GOLD stages (1-4) (2007-2008) .716 .057 .002 .604 .828 
BOD Index (0-7) (2007-2008) .725 .068 .001 .593 .858 
 
Table 4.10.  Area under the curve for GOLD stages and BOD scores 
 
 
 
C. DATA ANALYSIS OF THE COHORT AT STAGE 3 (2008-2009) 
 
In this section of the chapter, the results for the members of cohort assessed in 2008-9 are 
discussed. At this time BOD, BODE and GOLD were included in the evaluation of the cohort. 
 
 
 
4.3.5. Subject Characteristics 2008 - 2009 
 
Table 4.11 illustrates the demographics of the cohort at this timeframe. The cohort in 2008-
2009 comprises 50 % of females with a mean age of 70.0±9.3.  In terms of smoking status, 
58% were current smokers and 25.3 % were ex-smokers whereas only 16.7% were non-
smokers.  The mean pack year history was 30.9±19.4.  The subjects were slightly overweight 
with a mean BMI of 27.0±5.7 and demonstrated moderate severity in terms of spirometry with 
a mean FEV1% predicted of 56.4±22.2, with a mean MRC dyspnoea score of 3.20±1.4 out of 
5, median BOD score was 3 (range 0-7) and BODE index scores of 2.77±2.0. . The GOLD 
severity score was 2.36±0.9. 
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Age (years)  70.0±9.3 
Gender (m/f) Male 
Female 
49 (50.0%) 
49 (50.0%) 
Smoking Status Current 
Exsmoker 
Non smoker 
55 (58.0%) 
24 (25.3%) 
19 (16.7%) 
Pack years (years)  30.9±19.4 
BMI (kg/m2) 27.0±5.7 
FEV1 (L) 1.40±0.6 
FEV1 % predicted 56.4±22.2 
MRC (1-5) 3.20±1.4 
6MWT (n=73) 294.0± 100.0 
GOLD (1-4) 2.36±0.9 
Median BOD Scores (Range) 3.00(0-7) 
Median BOD categories (Range) 2.00 (1-4) 
 BODE Scores (1-10) 4.13±3.0 
BODE Quartiles (1-4) 1.96±0.9 
 
Table 4.11. Demographic Characteristics of the Cohort 2008 -2009 (n=98).  BOD scores and 
categories are presented as median and range. 
 
 
The mean scores in GOLD, MRC, FEV1% predicted, BOD and BODE indicate that the cohort 
have a range of disease symptoms from mild and moderate to severe. 
 
 
Figures 4.27-4.31 shows the score distribution of BOD, GOLD and BODE scores of severity in 
the study cohort. More than 50% of the cohort had a BOD score of 3 or less, BOD  
categories of 2 or less and a GOLD score of 2 or less. As in the previous time frames, the three 
severity indices, BOD, GOLD and BODE, indicate different degrees of severity in the same 
cohort.  
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Figure 4.27. BOD score distribution (2008-2009) 
 
 
 
 
                 
         Figure 4.28. BOD categories distribution (2008-2009) 
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Figure 4.29. BODE score distribution (2008-2009) 
 
 
 
       
        
     Figure 4.30. BODE Quartiles distribution (2008-2009) 
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Figure 4.31. GOLD stages of severity distribution (2008-2009) 
 
 
Table 4.12 shows the progression of the different indices of COPD (BOD, BODE, FEV1% 
predicted and GOLD) and demonstrates that all of the measurements deteriorated over time. 
However, out of these only BOD (median value) and FEV1% predicted (absolute value) 
changed significantly showing their sensitivity to change over time in this cohort. 
 
 
n=98 2007-2008 2008-2009 P value 
Median BOD Score (Range)  2.00 (0-7) 3.00 (0-7) 0.009 
BODE Score (n=56) 3.05 2.2) 4.15±6.7 ns 
Median BOD Categories (Range) 2.00 (1-4) 2.00 (1-4) 0.04 
BODE Quartiles (n=56) 1.78  ± 0.9 1.96 ± 1.0 ns 
FEV1 % Predicted 59.0 ± 22.8 56.4±22.2 0.02 
GOLD Score 2.31 ± 0.9 2.35±0.9 ns 
 
Table 4.12.  Progression of the Indices over time (12 months interval).  The BOD data are 
presented in median and range.  
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The covariates known to influence COPD outcomes were recorded in the 2007/8 cohort 
including the number of exacerbations in the last 12 months, comorbidity scores and other 
indices of severity such as BOD, BODE and GOLD.  The comorbidity scores are the scores 
obtained from the cohort in 2007/8 for other coexisting diseases the patients have, as detailed 
in chapter 3 with the help of Charlson comorbidity index.  These were compared between 
survivors and deceased subjects during the 2007-2010 timeframe (table 4.13). There is a 
significant differences were found between survivors and those who died within the next 12 
months of the study  in terms of their measured BOD scores, BOD categories (median value), 
GOLD stages and frequency of exacerbation.  But frequency of exacerbations was less in the 
deceased group than in survivors measured in the 2007-2008 cohort.  This seems to indicate 
that the mean number of exacerbations (which were less than 1/year) does not influence the 
death rate in this cohort of the present study.   Similarly, comorbidity scores as measured by 
Charlson index of severity (explained in Methodology Section in detail) and BODE (scores and 
quartiles) were not statistically significant between the two groups.  
 
 
 Survivors 
(n=98) 
Deceased 
(n=15) 
P value 
 
Age 69.0±9.1 74.3±9.9 0.009 
Pack years 33.3±20.1 40.4±21.4 <0.001 
Charlson Index 3.7±1.6 3.0±1.7 ns 
FEV1% Predicted 60.8±22.5 44.7±18.7 0.003 
Exacerbation frequency 0.5±0.9 0.1±0.4 0.04 
GOLD 2.21±0.8 2.95±0.8 <0.001 
Median BOD Scores (Range) 2 (0-7) 5 (0-7) <0.001 
Median BOD Categories (Range) 2(1-4) 3(1-4) <0.001 
BODE Scores 3.26±2.3 2.30±1.5 ns 
BODE Quartiles 1.94±1.0 1.33±0.6 ns 
 
Table 4.13. BOD, BODE, GOLD & FEV1 % as measured at 2007/8 and 2008/9 in                    
Survivors and Deceased Members of the Cohort. BOD data are presented as median and 
range. 
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The KM survival curves were not computed for 2008/9 interval because of fewer deaths in the 
members of the cohort whose BOD (n=3) and BODE (n=1) were recorded during the second 
phase of the study.   
 
The author also tried to explore the variation in BOD over this 12 month period and its 
relationship to the  relative risk of death however only 4 deaths were observed and therefore no 
conclusions were made.  However, it is noticeable that 3 out of 4 (who died) had worse BOD 
scores than at baseline.   
 
 
 
4.4 Discussion 
 
There are a variety of factors that are known to influence the prognosis and the natural history 
of COPD (Dolan et al., 2005; CDC, 2008). Some of these factors have been incorporated in the 
severity indices (GOLD, BOD, and BODE) and have been evaluated in this study in a cohort 
of 458 patients.  
 
The present study is somewhat unique as compared to other relevant studies in three aspects.  
First, the cohort of this study comprises 49% of females whereas in most other similar studies 
the proportion of females were less than this. Ko and colleagues (2011) who assessed the 
variation in the BODE index over three years had only 14% of females in their cohort.  
Similarly another study by Esteban and co-workers (2010 and 2011) that compared predictive 
capacity of multidimensional indices had only 3.9 and 2.3% of females in their two cohorts. A 
study to investigate the predictive ability of the multidimensional index BODE for anxious and 
depressive patients with COPD had 20% of females (Li et al., 2010). Moreover, the BODE 
study itself had only 8% females. One study which had similar proportion of females (50%) in 
their cohort to the current one was carried out to examine the gender difference in the 
distribution of BODE index (de Torres et al., 2007). The reason for a higher proportion of 
females in this study compared with other international cohorts may be due to a higher 
prevalence of smoking among women in the UK. The relatively high proportion of females 
does not reflect the clinical experience in the UK (Soriano et al., 2000; British Lung 
Foundation, 2005), as it is well established that primary care physicians tend to prefer a 
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diagnosis other than COPD in women when presented with a clinical scenario typical of COPD 
(Chapman et al., 2001). Nonetheless, the higher proportion of females in this study as 
compared to most of the other studies provides the opportunity, for health care professionals, to 
apply the study findings to both genders. 
 
The second uniqueness of this study is the degree of severity as measured by spirometry.  The 
present study cohort mainly consists of patients with a mild to moderate degree of lung 
function decline (60.9±20.0%) in contrast to other similar studies where the mean FEV1% 
predicted were 43.0±19.0 (Celli et al., 2004) 51.0±22.0 (Ko et al., 2011); 55.0±13.3 (Esteban et 
al., 2010); 49.7±14.6 Esteban et al., 2011); and 45.2± 16.2 and 52.4±16.2 in the two cohorts 
(Puhan et al., 2009).  Additionally Li and co-workers (2010) who evaluated the predictive 
ability of BODE in depressive patients had a mean FEV1% of 42.5±10.8 to 46.2 ±11.0 in their 
cohort.  The lesser degree of severity in this study therefore has been helpful in assessing the 
progression of the disease over a 10 year period.  The reason is probably that patients for this 
study were recruited from primary care clinics whereas the others mentioned mainly consisted 
of hospital clinic patients (Ko et al., 2011; Puhan et al., 2009; Celli et al., 2004), who are likely 
to have been admitted with a more severe condition. 
 
The last and perhaps the most significant difference of this study is its duration. There have 
been very few studies (Medalion et al., 2004; Van-Domburg et al.,  2002; Leavitt et al., 2006) 
that have examined the mortality as an outcome in patients  with mild to moderate form of 
disease (at baseline) over a 10 year period. For this reason, the findings of this study may 
attract the attention of healthcare professionals considering the longstanding nature of COPD. 
 
The results show that BOD and GOLD are different from one another in a COPD cohort over a 
10 year period.  Furthermore, when KMSA and ROC were performed between GOLD and 
Survival years and then BOD and Survival years, it was shown that BOD was more effective 
WKDQ*2/'LQSUHGLFWLQJ\HDUV¶PRUWDOLW\LQSDWLHQWVZLWK&23'6LPLOarly, when KMSA 
curves were computed to analyse three years survival, BOD was again more effective than 
GOLD.  However, few deaths occurred during three years (2007-2010). The results show that 
BOD is a better predictor of mortality in years than GOLD and BODE.  A recent study (Ko et 
al., 2011) suggests that serial changes in BODE were not significant when the 12th, 18th and 
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24th months indices were compared.  This may be because baseline BODE index was measured 
in patients within 6-8 weeks after recovery from acute exacerbation of COPD.   
The results of Cox regression analysis also suggest that BOD index is more accurate as a 
prognostic indicator than GOLD stages when confounders such as pack years and age were 
taken into account (Tables 4.4 and 4.5). Additionally, the ROC curve (figure 4.11) clearly 
indicates that BOD works more effectively than GOLD to predict COPD mortality. The areas 
under the curve (AUC) for BOD and GOLD were 0.64 and 0.58 and p values were <0.001 and 
0.01 respectively. In other words, neither was very good as the p-value merely gives an 
indication of how much faith to place in the coefficient. However, when the ROC curves were 
obtained for 3 years mortality data in the time 2 databases, the AUC improved significantly for 
both BOD and GOLD (0.73 and 0.71 respectively). 
 
Similarly when different indices of severity were compared over a 12 month period to assess 
variation in their respective scores, both median BOD scores and BOD categories were 
significantly changed over time (p=0.006 and 0.04) suggesting that the BOD index is more 
sensitive to change than BODE or GOLD.  The only other measurement that changed 
significantly over time was FEV1 % predicted (p=0.02) suggesting the role of lung functions in 
disease progression. 
 
Furthermore, when the indices were compared between deceased and survived members of the 
cohort (between 2007-2010), the results suggest that BOD as well as GOLD stages of severity 
scores are significantly higher in the deceased group. The most surprising fact is that in the 
deceased group the BODE scores were little better or lower (p>0.05) than in the survived 
group.  The reason may be that the number of patients was lower than in the assessment of 
BOD and GOLD as very few patients were able to perform the six minute walk test (a major 
component of the BODE Index).  This inability to exercise emphasizes the need for an index 
without an exercise test which could be applied to a larger group of patients. Another reason 
for a lower number of patients with measured BODE scores was that some patients were not 
willing to attend hospital and were recruited by visiting their homes.   The exercise could 
therefore not be performed. However, BOD scores were easily obtained in these patients. 
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While predicting risk of mortality may benefit health care professionals in their management of 
a patient with COPD, opportunity for survival is more likely to appeal to the patients 
themselves.  An observational study (Cote et al., 2005) has shown that completion of a 
pulmonary rehabilitation programme improved BODE scores and was associated with 
prediction of increased survival. In the present study, individuals with severe and very severe 
impairment of FEV1 (GOLD III and IV) were found to be long-term survivors. That is, they 
had around 60 % chance of survival for 10 years or more (Figure 4.8).  On the other hand, 
individuals with the worst category of BOD scores (6-7) showed only around 42% probability 
of survival for 10 years or more (Figure 4.7). When the data were adjusted for potential 
covariates including age and pack years that are known to influence mortality in these patients 
(Esteban et al., 2008; Reilly et al., 2008; Shavelle et al., 2009), both the BOD index and GOLD 
stages of severity improved their predictive power (figure 4.9 and 4.10). This reflects the 
sensitivity and predictive power of the BOD index in patients with COPD.   Demonstrating 
prognosis to individual patients may promote smoking cessation, and encourage a healthy diet 
and compliance with a programme of pulmonary rehabilitation, interventions that are required 
to improve a BOD score and by inference survival (Cote et al., 2005). 
 
Overall, the results suggest that BOD is a better predictor of progression of disease than 
GOLD. This emphasizes the multisystemic nature of the disease that not only effects lung 
functions but also produces functional impairment (measured by MRC dyspnoea score) and 
body mass (measured by BMI), and both of these are components of the new BOD index.   
 
The BOD index could be utilized to monitor progression of patients, with COPD because BOD 
is a simple tool for evaluation of the clinical impact of COPD. BOD performs effectively with 
patients seen in primary care where resources to conduct a walk test are not available and/or in 
those patients who are not able or not willing to perform the six minute walk test in a clinical 
setting due to breathlessness or any other comorbid conditions.  Its value may also be in 
helping patients realise their prognosis. 
 
The present study suggests that the BOD index is very simple to calculate and requires no 
DGGLWLRQDO UHVRXUFHV H[FHSW VSLURPHWU\ HJ HTXLSPHQW WUDLQHG VWDII VSDFH SDWLHQW¶V FRQVHQW
and time.  Because of this it is readily applicable outside the hospital setting, in primary care 
facilities for example, and in developing economies.  It yields multidimensional information on 
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each individual that relates to prognosis and therefore facilitates the planning of interventional 
therapies, including pulmonary rehabilitation.  BOD can also be used to inform patients of their 
COPD risk factors, so motivating them to alter their lifestyle accordingly. However, a much 
larger epidemiological study is needed to attach prognostic information to individual BOD 
scores and make this tool simpler to use and easier to explain to patients. Additionally, further 
studies will be needed that assess serial BOD indices to assess its variation in patients at 
regular intervals. 
 
The present study would appear to be the first longitudinal study that examines the correlation 
of BOD with COPD outcome by comparing 10 year, 3 year and one year mortality data in 
patients with COPD and the results are interestingly in its favour.  Health care professionals 
should utilize the BOD index in their clinical settings to HYDOXDWHSDWLHQWV¶SUogress and advise 
patients accordingly to improve their health. The index can also be utilized to motivate patients 
to modify their lifestyle and also to discuss the end of life care issues (Seamark et al., 2007; 
Goodridge, 2007) in these patients. 
 
However, more studies are needed to explore the factors that influence motivation and mood of 
these patients to follow instructions from their health care provider to improve health status 
and wellbeing. 
 
 
 
4.5. Conclusion  
 
This study demonstrates that BOD which is easy to apply in all primary care settings is an 
effective predictor of survival.  The results also suggest that BOD index is sensitive to changes 
significantly over time than other indices of severity and is more efficient in discriminating 
such as FEV1% predicted, GOLD, and BODE. 
 
However, further markers need to be investigated that could enhance the predictive power of 
BOD. These better characterise the full clinical picture of COPD, which may lead to improved 
understanding of disease development and as well as development of novel assessment indices 
of severity to monitor disease progression.  In turn that may further enhance the effectiveness 
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of current therapies and management protocol and make it possible to treat COPD patients on 
an individual basis depending upon the progression of the disease.   
 
Therefore, in the next chapter of this report (chapter 5); BOD improved by the addition of other 
potential indicators of COPD severity and progression has been investigated. 
 
    _______________________________ 
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Chapter 5 
 
 
AN INVESTIGATION INTO OTHER PHYSICAL MEASURES THAT 
COULD BE USED TO IMPROVE UPON BOD AS A MEANS OF 
PREDICTING COPD OUTCOMES 
 
 
 
5.1. Introduction 
 
The previous chapter has shown that BOD can be used to predict COPD outcomes; however it 
may be possible to improve upon the BOD index by the inclusion of other physical measures 
known to impact upon COPD progression.   
 
This chapter examines a range of potential indicators including FEV1, BMI, MRC dyspnoea 
index, age, smoking history, smoking status, gender and the exercise test that could be used as 
measures of COPD progression. It also investigates whether their inclusion in the BOD index 
might improve its ability to predict COPD outcomes.       
 
The measures investigated are: 
 
a. Demographics  and other non-specific Indicators            (Personal Marker)  
b. Body Composition (Fat Free Mass & Fat Mass)         (Physiological Marker) 
c. Hand Grip Strength                             (Physiological Marker) 
d.        6W*HRUJH¶V5HVSLUDWRU\4XHVWLRQQDLUH6*54          (Health Status Marker) 
e. Duration of Symptoms                 (Subjective/Symptomatic Marker) 
f. C Reactive Protein (CRP)              (Biomarker/Haematological Marker) 
g. Historical Height Measurement                                (Physical Marker) 
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5.2. Methods 
 
The detailed methodology for the listed indicators and exclusion and inclusion criteria are 
explained in the Methodology section in detail (section 3.4.). 
 
Full details of the cohort can be found in chapter 3. 
 
 
5.2.1.  Data Analysis 
 
 
The database used to analyse the different indicators of disease progression in this chapter is 
different depending upon the number of times that data were recorded.  For example SGRQ 
scores were obtained twice during the study phase, one year apart, whereas CRP was recorded 
just once.  Similarly, height and MRC dyspnoea score were recorded thrice whereas hand grip 
strength and lean body mass were recorded only twice, 12 months apart.  The lists of variables 
and number of times these were recorded are presented in table 5.1.   
 
When measurements were only recorded once or twice and when the sample size is small 
because of a high dropout rate (including reducing in numbers due to subjects dying) it was not 
possible to draw firm conclusions.  However, within these constraints, analysis below attempts 
to explore the relationship of COPD outcomes in terms of mortality, number of years of 
survival and health status with the measures investigated. 
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Table 5.1. Additional potential indicators of COPD progression and the number of times 
the measurements were recorded in this study. 
 
 
5.3. RESULTS 
 
  
5.3.1.  Baseline characteristics 
 
Altogether 161 patients were recruited for this analysis.  Table 5.2 represents the overall 
characteristics of study participant at baseline and at follow-ups in 2007/8 and 2008/9. 
 
 
 
 
 
 
 
 
 
 
Measurements 
recorded once 
Measurements 
recorded twice 
Measurements 
recorded three 
times 
Measurements 
derived from 
recorded data 
Charlson Index No of Exacerbations Age Lean to fat ratio 
Fat mass 
Comorbidities Lean body mass Height Percent predicted 
hand grip strength 
Survived and deceased Hand grip strength Smoking status 
Pack years 
Symptoms duration at 
baseline 
Survival time in years SGRQ Scores  BODE 
CRP Symptoms Duration  GOLD 
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n=161 Male 
N=77 
Female 
N=84 
Test for 
Normality 
p value 
Age  70.7±8.8 69.2±9.8 par ns 
Pack years 30.2±22.8 32.6±19.9 npar ns 
No of Exacerbations 0.55±0.88 0.52±0.90 npar ns 
Charlson Index 3.92±1.8 3.34±1.5 par ns 
MRC Dyspnoea Score (2007-2008) 
MRC Dyspnoea Score (2008-2009) 
2.96±1.2 
3.30±1.4 
3.17±1.3 
3.15±1.4 
par 
par 
ns 
ns 
SMWT (n=92) (2007-2008) 
SMWT (n=92) (2007-2008) 
288.6±85.0 
317.5±86.7 
261.1±93.5 
282.4±87.7 
par 
par 
<0.001 
<0.001 
Lean Body Mass (2007-2008) 
Lean Body Mass (2008-2009) 
     55.2±10.2 
55.0±10.5 
40.3±10.3 
38.9±9.2 
par 
par 
<0.001 
<0.001 
Fat Mass (2007-2008) 
Fat Mass (2008-2009) 
25.7±8.7 
27.3±8.8 
28.8±11.2 
29.3±9.6 
par 
par 
ns 
ns 
Lean Fat Ratio (2007-2008) 
Lean Fat Ratio (2008-2009) 
2.4±0.7 
2.1±0.5 
1.5±0.6 
1.6±1.3 
par 
par 
0.009 
0.02 
Grip Strength (% Pred ) (2007-2008) 
Grip Strength (% Pred) (2008-2009) 
77.5±20.4 
76.2±21.6 
78.5±25.1 
74.5±24.1 
npar 
npar 
ns 
       ns 
SGRQ Symptoms Score (2007-2008) 
SGRQ Symptoms Score (2008-2009) 
56.9±17.6 
53.0±17.3 
56.3±20.5 
48.3±19.7 
par 
par 
ns 
ns 
SGRQ Activity Score (2007-2008) 
SGRQ Activity Score(2008-2009) 
61.7±24.0 
62.7±22.8 
64.9±25.1 
64.3±25.2 
par 
par 
ns 
ns 
SGRQ Impact Score(2007-2008) 
SGRQ Impact Score(2008-2009) 
35.0±17.1 
33.0±18.0 
34.5±21.9 
27.9±18.9 
npar 
npar 
ns 
ns 
SGRQ Total Score(2007-2008) 
SGRQ Total Score(2008-2009) 
46.7±17.6 
45.7±17.3 
47.5±20.5 
42.3±19.7 
par 
par 
ns 
ns 
par=parametric test; npar: non parametric test 
 
Table 5.2.  Demographics of COPD male and female subjects at baseline and in 2007/8 and 
2008/9. 
 
 
  
 
139 
5.3.2. Assessment of Potential Predictors of COPD Outcomes in the 1999-2002, 2007-
2008 and 2008-2009 Cohorts 
 
 
The analyses below, which are based on Pearson and Spearman rank correlation (dependent on 
the data distribution), present the association of potential indicators recorded/measured in this 
study with a range of different COPD outcomes including mortality, number of years survived 
and HRQL (table 5.3). 
 
Outcomes Predictors  (1999-2002) Predictors (2007-2008) Predictors (2008-2009) 
Mortality Age                             <0.001 
BMI                                0.01 
Smoking status                0.02 
Pack years                     0.001 
MRC                           <0.001 
% Predicted FEV1       <0.001 
GOLD                           0.003 
BOD   Score               <0.001  
BOD  categories        <0.001  
Age                                  0.004 
BMI                                 0.006 
Smoking status              <0.001 
Pack years                     <0.001 
MRC                                0.003 
% Predicted FEV1        «0.001 
GOLD                           <0.001 
BOD                              <0.001 
 
BMI                             0.02 
SMWT                         0.04 
 
No of years 
survived 
Age                                  <0.001 
BMI                                   0.001 
Pack years                        0.002 
MRC                                <0.001 
% Predicted FEV1          <0.001 
GOLD                             <0.001 
BOD Score                      <0.001  
BOD categories            <0.001    
Age                                     <0.006 
BMI                                        0.01 
Pack years                             0.002 
MRC                                     0.004 
% Predicted FEV1                 0.001 
GOLD                                <0.001 
BOD  score                         <0.001  
BOD  categories              <0.001    
Smoking status             <0.001 
Pack years                        0.05 
MRC                                 0.01 
SMWT                              0.04 
Fat mass                            0.01 
 
SGRQ (%) 
Scores 
(HRQL) 
 Age                                    0.03           
Pack years                       0.002 
Handgrip Strength             0.01 
MRC                              <0.001 
Comorbidity Index            0.02 
SMWT                          <0.001 
Past exacerbation            0.008 
% Predicted FEV1         <0.001 
GOLD                              0.001 
BOD score                    < 0.001 
BOD categories           < 0.001            
BODE                           < 0.001  
BODE Quartiles           < 0.001            
BMI                              0.02 
MRC                        <0.001 
Comorbidity Index      0.02 
SMWT                        0.001 
Past exacerbation       0.008 
Handgrip                      0.01 
% PredictedFEV1     <0.001 
GOLD                        0.001 
BOD  score             < 0.001 
BOD categories     < 0.001               
BODE                         0.002 
BODE Quartiles      < 0.001             
 
Table 5.3.   Indicators of COPD and the statistical significance of comparison with multiple  
measures of outcomes (Red colour texts indicate negative correlations). 
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(a) MORTALITY AND NUMBER OF YEARS SURVIVED 
 
 
Table 5.3 represents the relationship of additional potential indicators of severity and COPD 
outcomes such as mortality, number of years survived and health status.  Only those variables 
that showed statistical significance (p<0.05) are presented in this table.  These variables are 
discussed below. 
 
(i) Age 
 
The results show that age is significantly correlated with mortality (p =<0.001 and 0.004) thus 
a higher age is associated with a higher probability of death in the 1999-2002 and 2007-2008 
cohort.  However, in the 2008-2009 cohort age did not show any significant correlation with 
mortality in these patients.   
 
Age is also significantly but negatively correlated with number of years survived in 1999-2002 
cohort and positively correlated in 2007-2008 cohort (p<0.001 and 0.006). 
 
(ii) BMI  
 
The results show that BMI is significantly correlated with mortality and indicates that a lower 
BMI is associated with a higher probability of death in all members of the cohort (p=<0.01, 
0.006 and 0.02 respectively) at all the time frames.   
 
BMI is also negatively correlated with number of years survived, and this correlation was 
found both in the 1999-2002 and 2007-2008 cohorts (p=0.001 and 0.01). 
 
(iii) Smoking 
 
The results show patients who were exsmokers were significantly correlated with higher 
mortality as indicated in 1999-2002 and 2007-2008 cohorts (p=<0.02, <0.001).  However, in 
the 2008-2009 cohort smoking status, either current or exsmoking did not show any significant 
correlation with mortality in these patients. Furthermore, in terms of pack year history, a higher 
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number of pack years was associated with a higher mortality in 1999-2002 and 2007-2008 
cohorts (p=0.001 and <0.001).   
 
Pack year history was also significantly correlated with number of year survived (p=0.002, 
0.002 and 0.005) at all times.   
 
(iv) MRC Dyspnoea Score 
 
The results show that the MRC Score is significantly correlated with mortality (p =<0.001 and 
0.003) and indicates that a higher MRC is associated with a higher probability of death in both 
the 1999-2002 and 2007-2008 cohorts.  However, in the 2008-2009 cohort, there was no 
meaningful correlation with mortality in patients with COPD and MRC score. 
 
The analysis also shows that the MRC dyspnoea score was significantly and negatively 
correlated with number of years survived in patients with COPD. (p<0.001, 0.004 and 0.01) 
indicating the high MRC score associated with less number of years survived. 
 
(v) Lung Function 
 
FEV1 %predicted and GOLD stages of severity also show significant correlation with mortality 
in both 1999-2002 and 2007-2008 cohorts.  However FEV1 % predicted indicates negative 
correlation with mortality. 
 
In other words, lower % predicted FEV1 associated with higher mortality in both cohorts 
(p<0.001 and 0.001).  Similarly, higher GOLD stages of severity was also associated with 
higher mortality in both cohorts (p=0. 003 and <0.001). 
 
On the other hand, both FEV1 % predicted (p<0.001 and 0.001) and higher GOLD stages of 
severity (p=<0. 001 and <0.001) were associated with higher number of years survived.    
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(vi) Six Minute Walk Test (SMWT) 
 
The SMWT only significantly correlated with mortality and number of years survived in 2008-
2009 cohort (p<0.04).   
 
(vii) Multidimensional Indices of Severity 
 
The results related to multidimensional index BOD scores and categories are already presented 
in chapter 4. 
 
 
(b) HEALTH RELATED QUALITY OF LIFE (ASSESSED BY SGRQ) 
 
 
Most of the potential indicators which are correlated with mortality and number of years 
survived are also associated with health status measurements as assessed by SGRQ. The 
indicators that are positively and significantly correlated with health related quality of life 
include age (p=0.03), pack years (p=0.03), MRC (p<0.001), comorbidity (p=0.02), GOLD 
(p<0.001) and number of past exacerbations (p=0.008) in 2007-2008 cohort.  In contrast, only 
comorbidity index (p=0.02), number of past exacerbations (p=0.008) and GOLD (p<0.001) 
found significant in the 2008-2009 cohort.   
 
Some indicators were negatively but significantly correlated with SGRQ score in both 2007-8 
and 2008-9 cohorts.  These include hand grip strength (p=0.01 and 0.01), SMWT (p<0.001 and 
<0.001), and FEV1 % predicted (p<0.001 and <0.001).  However, there were some additional 
variables which become significantly associated with HRQL in the 2008-2009 cohort.  These 
include BMI (p=0.02) and MRC (p=0.001). 
 
The multidimensional indices BOD and BODE (scores, categories, quartiles) were all 
positively and significantly correlated (p<0.001) with both BOD and BODE (p=0.002 for both 
indices) scores in 2007-2008 and 2008-2009 cohorts.   
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Table 5.3 summarizes the significant correlations of all the indicators and indices in all three 
cohorts of this study.  The most noticeable point is that lean body mass, fat mass, symptoms 
duration and CRP did not show any significant relationship with any of the COPD outcome 
variables. 
 
 
5.3.3.  Indicators that could potentially be used to improve upon the BOD Index  
 
From the correlation coefficients three indicators were significantly associated with mortality 
in patients with COPD.  These include the personal indicator age and the habitual indicators 
smoking status (smoker, ex-smokers and non-smokers) and pack years of smoking.  Backward 
linear regression analysis was carried out to identify factors that influence BOD index.  In table 
5.4 below it is shown that age and pack years were among the most significant predictors of 
BOD scores in patients with COPD (p<0.05 and 0.001 respectively).   
 
 
 
Dependant variables 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
Sig. 
95.0% 
Confidence 
Interval for B 
B Beta 
Lower 
Bound 
Upper 
Bound 
1 (Constant) .465  .347 -.505 1.436 
Age(years) (1999-2002) .015 .092 .054 .000 .029 
Pack years (1999-2002) .013 .157 .002 .005 .021 
Smoking status (1999-
2002) 
-.023 -.010 .836 -.240 .194 
2 (Constant) .448  .357 -.508 1.405 
Age(years) (1999-2002) .014 .091 .055 .000 .029 
Pack years (1999-2002) .013 .154 .001 .005 .020 
 
     Table 5.4.     Linear Regression analysis. Dependent Variable: BOD Scores (0-7) (1999-2002) 
 
 
Therefore, it was decided to incorporate these two factors into the BOD index and to examine 
whether or not the BOD scores then were better able to predict outcomes. 
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5.3.4.      BOD PLUS 
 
 
This section will evaluate potential indicators that can be incorporated into the BOD index to 
improve the ability of the index to predict COPD outcomes including mortality, number of 
years survived and health related quality of life as measured by SGRQ scores. 
 
 
1. Mortality and Number of years Survived 
 
In order to incorporate pack years and age into the BOD index, it is essential to score these new 
potential indicators so that data analysis can be carried out. For this reason the scores are given 
to age and pack years.  For age, the scores are given as recommended by a recently carried out 
study (Puhan et al., 2009) which categorized age into 6 categories (0-5).  
 
On the other hand, there is no consensus on how to categorize pack year history in patients 
with COPD and previous studies (Furberg et al., 2005; Vestbo et al., 2008; Shavelle et al., 
2009) have used different categorisation for their data some of which appeared opportunistic. 
For example Mannino and co-workers (2003) divided their cohort into three categories i.e. 
<30, 30-59 and > 60 pack years.  Another study classified pack years into never, 1-25, 25-50 
and >50 pack years (Fred et al.; 1998).  Similarly Folsom and colleagues (1998) divided pack 
years as 1-19; 20-39 and > 40 years. Additionally the influence of pack years on COPD 
outcomes varies between genders (Prescott et al., 1997) as well as subjects (Saccone et al., 
2010).  However, Hersh and colleagues (2004) stratified their COPD cohort by the categories 
of the number of pack-years of smoking to examine their predictability. They found that 
lifetime cigarette consumption [per 10 pack-years] was a significant predictor of mortality.  
Thus literature suggests that no standard recommendations are available that can be utilized to 
classify/quantify data on the basis of pack years history.  Therefore, in the present study pack 
years history has been divided into four categories (0-10, 11-30, 31-45 and >45). 
 
In the present study three possible indices were developed with the addition of pack year 
history (S) into BOD (BODS); addition of age (A) into BOD (BODA) and with the addition of 
both age (A) and pack years (S) into BOD (BODAS).  The new indices with their respective 
scores are presented in table (5.5). 
 
  
 
145 
 
 
Indices of Severity Measurements Used in different Models 
BMI 
(kg/m2) 
FEV1 %  
(%) 
MRC Score 
(1-5) 
Age 
(years) 
Pack years 
(years) 
BOD Scores (0-7) (B) (O) (D) (A) (S) 
0 >21 t65 1-2 NA NA 
1 d21 50-64 3 NA NA 
2 NA 36-49 4 NA NA 
3 NA d35 5 NA NA 
BODS Scores (0-10) (B) (O) (D) (A) (S) 
0 >21 t65 1-2 NA 0-10 
1 d21 50-64 3 NA 11-30 
2 NA 36-49 4 NA 31-45 
3 NA d35 5 NA >45 
BODA Scores (0-12) (B) (O) (D) (A) (S) 
0 >21 t65 1-2 40-49 NA 
1 d21 50-64 3 50-59 NA 
2 NA 36-49 4 60-69 NA 
3 NA d35 5 70-79 NA 
4 NA NA NA  NA 
BODAS Scores (0-14) (B) (O) (D) (A) (S) 
0 >21 t65 1-2 40-49 0-10 
1 d21 50-64 3 50-59 11-30 
2 NA 36-49 4 60-69 31-45 
3 NA d35 5 70-79 >45 
4 NA NA NA 80-89 NA 
 
 
Table 5.5.   Scores of each variable used in the newly developed indices. 
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(a) Evaluation of Multidimensional Indices of Severity BODS, BODA and BODAS in 
the 1999-2002 Cohort 
 
 
In order to assess new predictors that can be incorporated in the BOD index as a predictor of 
mortality, KMSA curves (previously explained in chapter 3 and 4 in detail) were used to show 
the probability of survival. 
 
Figures 5.1 to 5.6 represent the probability of 10 years of survival in this study cohort 
according to their scores and categories of their respective indices.  These include BODS, 
BODA and BODAS indices of severity.   
 
All of these indices show a clear differentiation of the cohort between lower and higher scores 
according to their probability of survival over time (p<0.001).   
 
Figures 5.1 and 5.2 show BODS scores and categories and their probability of survival.  The 
figures indicate that members of the cohort with BODS scores 7 or more out of 10 (category 3 
or 4 of 4) have the lowest survival probability over time (<50%) compared to those with lower 
scores, in whom the probability of survival over time was more than 80%.    
 
 
 
Figure 5.1.  Kaplan Meier Curve using individual BODS Scores (1999-2002) 
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Figure 5.2. Kaplan Meier Curve using BODS categories (1999-2002) 
 
 
 
Figures 5.3 and 5.4 show BODA scores and categories and their chances of survival.  The 
figures indicate that members of the cohort with BODA scores 7 or more out of 12 (categories 
3 or 4 out of 4) have lowest survival probability over time (<40%) compared to those with 
lower scores of 0, 1, 2 or 3 (categories 1 or 2 of 4), in whom the probability of survival over 
time was more than 80%. 
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Figure 5.3.  Kaplan Meier Curve using BODA scores (1999-2002) 
 
 
Figure 5.4. Kaplan Meier Curve using BODA categories (1999-2002) 
 
 
Similarly figures 5.5 and 5.6 show BODAS scores and categories and their chances of survival.  
The figures indicate that members of the cohort with BODAS scores 9 or more out of 14 
(category 4) have lower survival probability over time (<40%) compared to those with lower 
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scores of 0, 1, 2, 3 or 4 (categories 1 and 2 of 4), in whom the probability of survival over time 
was more than 80%. 
 
 
 
Figure 5.5.  Kaplan Meier Curve using BODAS scores (1999-2002) 
 
 
Figure 5.6.  Kaplan Meier Curve using BODAS categories (1999-2002) 
  
 
150 
To explore the data further, ROC curves were used to compare the capacity of these new 
potential indices in predicting health outcome. The curves produced using BODS, BODA and 
BODAS can be found in Figure 5.7 and Table 5.6.  The figure and table clearly indicate that 
BODAS has the highest ROC value for predicting mortality in the cohort.  The areas under the 
curve (AUC) for BODAS, BODA, BODS and BOD were 0.72, 0.70., 0.66 and 0.63 
respectively   (p<0.0001 for all indices). Thus the addition of age and smoking history to BOD 
provides an important development and this is clearly demonstrated in the K-M analysis for 
individual BODAS scores and categories (Figures 5.5 & 5.6).  BODAS is therefore a highly 
appropriate candidate for generalised use when exercise capacity of COPD patients cannot be 
undertaken.     
 
 
Figure  5.7. ROC Curve shows sensitivity and 1-specificity between indices (1999-2002) 
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Multidimensional Indices of 
Severity 
 
1999-2002 
Area under 
the Curve 
(AUC) 
Std. 
Error p value 
Asymptotic 95% 
Confidence Interval 
Lower 
Bound 
Upper 
Bound 
BOD Scores (0-7) .629 .029 <0.0001 .573 .685 
BODS Scores (0-10) .663 .028 <0.0001 .608 .717 
BODA Scores (0-12) .708 .026 <0.0001 .657 .759 
BODAS Scores (0-14) .721 .026 <0.0001 .671 .772 
 
Table 5.6.  ROC for different indices of COPD severity with 10 years Mortality 
      
 
(b)  Validation of the multidimensional indices of severity BODS, BODA and    
BODAS in the 2007-2008 surviving cohort 
 
KMSA curves have also been plotted in order to assess BODS, BODA and BODAS indices of 
severity as a predictor of 3 year survival (2007-2010).  For this analysis, categories of each 
respective index score were used, as not enough deaths were observed to represent each 
individual score (Figures 5.8-5.11).   
 
Figure 5.8 shows that those with a higher BOD category of 4 have only around 50 % 
probability of surviving more than 3 years. In contrast, patients with BOD categories of 0 and 1 
have more than a 90 % probability of surviving more than 3 years. 
 
Figure 5.9 represents BODS categories and their KMSA curve shows that subjects with higher 
category scores (of 4) have least chance of survival as compared to those with lower 
categories. However the discrimination between categories is not as clear as in the case of 
BOD categories. 
 
Figure 5.10 indicates categories of BODA and their probability of survival for 3 years or more 
and shows that members of the cohort with higher BODA categories have less chance of 3 
years survival than those with lower categories (60% vs >90%). 
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Similarly, figure 5.11 shows categories of BODAS index.  This figure also shows that patients 
with BODAS categories of 4 have less survival probability of surviving for three years than 
those with 1 or 2 category (90% vs 70%). 
 
 
 
Figure 5.8. Kaplan Meier Curve using BOD categories (2007-2008) 
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Figure 5.9.   Kaplan Meier Curve using BODS categories (2007-2008) 
 
 
          Figure 5.10.   Kaplan Meier Curve using BODA Categories (2007-2008) 
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Figure 5.11.   Kaplan Meier Curve using BODAS categories (2007-2008) 
 
 
On further analysis, the capacity of these new potential indices in predicting health outcome 
was examined using ROC as shown in Figure 5.12 and Table 5.7.  The figure and table indicate 
that BOD worked better than other indices (BODS, BODA and BODAS) in terms of predicting 
COPD mortality. The areas under the curve (AUC) for BOD, BODS, BODA and BODAS were 
0.71, 0.68., 0.70 and 0.69 respectively (and their p values were <0.003; 0.008, 0.005, 0.006 
respectively). 
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Figure 5.12.    ROC Curve shows sensitivity and 1-specificity between indices (2007-2010) 
 
 
Indices of Severity 
 
2007-2008 
Area under 
the Curve 
(AUC) 
Std. 
Error p value 
Asymptotic 95% 
Confidence Interval 
Lower 
Bound Upper Bound 
BOD Scores (0-7) .711 .070 .003 .573 .848 
BODS Scores (0-10) .688 .071 .008 .549 .827 
BODA Scores (0-12) .700 .071 .005 .561 .839 
BODAS Scores (0-14) .696 .072 .006 .555 .836 
  
Table 5.7.  ROC for different indices of COPD severity with 3 years mortality 
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The indices were not assessed either by KM survival curves or ROC curves because of the 
fewer deaths in the members of the cohort for whom BOD, BODS, BODA and BODAS scores 
were calculated. (n=3). 
 
 
2. HEALTH RELATED QUALITY OF LIFE (ASSESSED BY SGRQ) 
 
 
Most of the potential indicators that are correlated with mortality and number of years survived 
were also assessed for their association with health status as an outcome. All the indices (BOD, 
BODS, BODA, and BODAS) are similarly significantly correlated with health related quality 
of life (see appendix for results). 
  
The data of SGRQ Scores were then divided into two categories on the basis of cut-off values 
of 0-49 vs 50 to 100.  The chi-square test indicates that lower categories of indices have better 
health status and higher categories have worst SGRQ scores in all the indices (p<0.001) as 
shown in figures 5.13, 5.15, 5.17, 5.19 for all potential COPD indices. 
 
The univariate analysis shows that the mean scores of SGRQ are significantly different 
between individual scores of all the indices of severity (p<0.001) as shown in figures 5.14, 
5.16, 5.18, 5.20 for each potential COPD indices.   
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Figure 5.13. BOD categories and SGRQ Score catogories 
 
 
 
 
 
 
 
Figure 5.14. The relationship between BOD Scores and Mean SGRQ scores 
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Figure 5.15. BODS categories and SGRQ Score catogories 
 
 
 
 
 
 
  
Figure 5.16. The relationship between BODS Scores and Mean SGRQ scores 
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 Figure 5.17. BODA categories and SGRQ Score catogories 
 
 
 
 
 
 
Figure 5.18. The relationship between BODA Scores and Mean SGRQ scores 
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Figure 5.19. BODAS categories and SGRQ Score catogories 
 
 
 
  
Figure 5.20. The relationship between BODAS Scores and Mean SGRQ scores 
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5.4. Discussion 
 
 
5.4.1. Introduction 
 
This chapter has explored potential measures that could be used to improve upon BOD as a 
prognostic indicator.  Its relationship with other COPD outcomes such as mortality, number of 
years survived and health related quality of life has been explored to reflect the clinical impact 
of the disease.  
 
 
5.4.2. Potential Measures 
 
The potential measures that were assessed in this study were age, smoking status and smoking 
history, gender, FEV1 % predicted, comorbidities, number of past exacerbations, SMWT, MRC 
dyspnoea score, body mass index, body composition, lean body mass, handgrip strength, health 
status, CRP, duration of symptoms and historical height.  
 
Many studies have examined the role of age in COPD outcomes (Britton et al., 2003; Puhan et 
al., 2009); however, no firm conclusion can be made on the basis of their findings. But, age 
adjustment should always be considered in clinical research involving patients with COPD 
because of its relationship with mortality (Britton et al., 2003; Puhan et al., 2009). COPD is 
more prevalent in people > 45 years and is highest in elderly patients over the age of 65 (Hurd, 
2000, Sullivan et al., 2000).  The present study supports previous findings in terms of the age 
of COPD sufferers (mean age 69.5±8.7and 64.5±9.4 in COPD) - presented in table 5.1. Further 
analysis in the present study supports the finding of Puhan and co-workers who developed the 
ADO index (Puhan et al, 2009) consisting of Age, MRC Dyspnoea Score and Airway 
oEVWUXFWLRQ VFRUHV ZRUNV EHWWHU WKDQ D ³UHFDOLEUDWHG´ %2'( LQGH[ LQ SUHGLFWLQJ PRUWDOLW\ LQ
patients with COPD and underlines the effect of age on 3 year mortality in patients with 
COPD. When age was added as a covariate in the BOD model, however, ROC analysis was 
shown that BOD becomes more sensitive indicator of mortality when age added to the index 
(Figure 5.12 and Table 5.7). This suggests that consideration should always be given to age 
when exploring mortality in COPD and other COPD outcomes in these patients. 
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Tobacco smoke is a very well known risk factor in the development, progression, comorbidity 
and mortality of COPD and present research also shows a high prevalence of both current and 
exsmokers and a high pack-year history in this cohort.   
The present study supports previous findings (Fletcher et al., 1976; Zaher et al., 2004) that both 
ex-smoking and current smoking influenced disease progression and mortality. This is shown 
in table 5.3 where pack years of smoking significantly correlated with COPD outcomes 
including the BOD index (Table 5.4). 
 
The ROC curve improves the BOD index when the years of smoking was added in the BOD 
index.  The above findings suggest that the assessment of the smoking status of COPD patients 
is important especially in relation to exacerbation frequency as shown with the DOSE index 
(Jones et al.; 2010). This suggests that smoking cessation intervention methods should be 
promptly discussed with the patient by the primary care physician and that smoking in COPD 
is an issue that may be vital for patients.  It also suggests that larger scale research is needed in 
order to explore the impact of smoking cessation on prognosis in COPD.  The data in this study 
are related to the burden of smoking and not to when individual subjects stopped smoking. 
 
Traditionally, COPD has been associated with the male gender; however, in the last decade 
COPD has become an increasing problem among women in UK (Soriano et al., 2000) and has 
been recently shown in the Spanish population (Torres et al., 2010). In the present study the 
number of female subjects was marginally higher than males (51% vs 49%) in contrast to other 
studies where the levels are 14% vs 86% in Japan (Ko et al., 2010) and 4% vs 96% in Spain 
(Esteban et al., 2010).  Hypothetically, this changing trend of COPD is simply because 
smoking rates are now becoming higher or at least equal in women compared to men.  This is 
indicated by the demographical findings of the present study results where the pack-year 
history is 30.2±22.8 in men vs 32.6±19.9 in women. Similarly, 52% of females were current 
smokers in our cohort in contrast to 44% of males. Furthermore, in the analysis of BOD with 
mortality, the KMSA shows that BOD had the same effect in females as males, when gender 
specific analyses were performed. However, our findings could not be compared with other 
similar studies due to higher number of males in those studies. Thus it is very difficult to make 
the judgement that gender itself has a great impact on mortality as the study did not have the 
power to detect (p=0.07). As one of the potentially most important factors, it should always be 
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considered when researchers examine COPD outcomes and more research should be carried 
out to further explore any gender related difference in COPD outcomes. 
 
COPD patients have a higher prevalence of co-morbidities than other chronic diseases.  A 
previous study by Ferrer and colleagues (1997) reported 84% of patients with one or more co-
morbidities.  Another study, which compared comorbidities in COPD and controls, reported 
73% prevalence of one or more co-morbidities in COPD and 63% in controls (Sprenkle et al., 
2004) but this difference is statistically important.  In the present study, 55% of the COPD 
group had comorbidities at baseline which later rose to 79% in the 2008-2009 demonstrating 
the consequences of COPD disease over time underlining their possible impact on COPD 
outcomes.  In the present study the mean score of the Charlson Index score was 3.8 but this did 
not correlate significantly with mortality.   It has been also suggested that co-morbidity is an 
important determinant of health status in patients with COPD, independent of 
FEV1 (Oostenbrink et al., 2004; van Manen et al., 2001) and of health service utilisation 
(Oostenbrink et al., 2004).  The present study supports previous findings that comorbidities are 
significantly associated with health status as shown in table 5.3. But the use of Charlson index 
only in 2008/9 may be a confounder here. 
 
Soler-Cataluna and colleagues (2005) were the first who were able to demonstrate that the 
frequency of exacerbation influenced mortality.  Their study contained 304 men with COPD in 
6SDLQ RYHU  \HDUV DQG WKH\ VXJJHVWHG WKDW ³SDWLHQWV ZLWK  RU PRUH H[DFHUEDWLRQV KDG D
survival rate of 30% at 5 years whereas those without exacerbation had a survival rate of 80%.  
Survival rate was also influenced by the need for readmission.  Those requiring readmission 
KDGDVXUYLYDODW\HDUV´ (Soler-Cataluna et al., 2005).  The current study has recorded 
the frequency of exacerbations over one year from 2007/8 to 2008/9 in a group of survivors.  
However, too few deaths were observed during that period to reveal meaningful results.   
 
The six minute walk test (SMWT) is frequently employed for the assessment of COPD 
patients, due to its high prognostic value in terms of disability, mortality, and its usefulness in 
evaluating long-term therapeutic interventions (Celli et al., 2004, Ko et al., 2010). Furthermore, 
the test is simple to perform, inexpensive, reproducible and safe. However, it does require 
resources of time and expertise that are unlikely to be available in the primary care setting in 
the UK. Also, its application in elderly patients may be problematic where an arthritic 
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comorbidity presents.  In 2007/8 cohort SMWT correlated significantly with mortality and 
number of survival years and health status (Table 5.3). But the drawback was that not all 
patients could perform a meaningful test and some were unwilling to.  For example, this test 
requires a large area where the test can be performed and 10% of the surviving cohort was 
house-bound. This indicates the extent of the practical difficulties of performing this test in 
elderly patients with COPD in different clinical settings. On the other hand, BOD 
measurements can be taken anywhere.  However, the variation of SMWT in study subjects at 
12 months intervals was significant (p<0.001 in both genders) which shows its sensitivity over 
time in patients with COPD.   
 
BMI in BOD is a surrogate for lean body mass (LBM) because loss of muscle mass has been 
regarded as an important indicator of the systemic manifestations of COPD (Troosters et al., 
2005). In the present study, the bioelectrical impedance analysis of body composition did not 
yield any significant results in the 2007/8 cohort.  Therefore, more longitudinal research will 
EHQHHGHGWRLQYHVWLJDWHIXUWKHU/%0¶VUROHLQ&23'RXWFRPHV 
   
Hand grip strength is potentially a physical indicator of disability (Rantanen et al., 1999). 
Therefore results of this study demonstrate significant deterioration over time both in males 
and females (Table 5.2). Hand grip strength also shows significant correlation with health 
status assessed by SGRQ scores (table 5.3) consistent with the findings of Ansari and co-
workers (2007; 2012).  As a consequence, the findings support hand grip strength as an 
important factor influencing physical impairment and thus can be used as a measure of 
disability in patients with COPD and also to assess health status in these patients. However 
more research will be needed to explore relationships with COPD related outcomes. 
 
Many studies have found that the health status measurement is closely related to other markers 
of COPD outcomes such as severity, functional status and mortality.  Few studies have 
examined health status and COPD markers over time (Lin et al., 2009; Habraken et al., 
2011).In the present study, most of the SGRQ domains did not significantly change over 12 
months (Table 5.2) except the impact domain of the SGRQ which slightly improved clinically 
and statistically (p<0.05). This improvement in health status may be due to only less severely 
affected patients attending follow up visits and also because of the new therapies that are 
claimed to be effective in improving health status in these patients (Brusasco et al., 2003). 
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However in the present study, the medication history was not taken into account during the 
analysis. 
 
The present work has examined the relationship of health status of COPD patients and 
multidimensional indices (BOD, BODS, BODA, and BODAS).  The results of the present 
study provide a very comprehensive account of the relationships of SGRQ measurement with 
other markers of COPD severity, disability and progression.  The most importantly repeated 
measurements of COPD related markers and health status over time adds validity to this study 
results and also to the validity and importance of health status measurements with SGRQ. 
 
The data support the conclusion that measurement of health status by the SGRQ may be more 
useful as a prognostic tool than generic questionnaires in an elderly population with a range of 
severity of COPD. The study results also suggest the potential ability of multidimensional 
indices as a marker of health status in patients with COPD. However, more longitudinal studies 
with larger cohorts will be needed to validate and support the present study findings. 
 
Many studies in the past suggested the importance of a CRP and its prognostic value in COPD 
severity and other outcomes (Gan et al., 2004, Dahl et al., 2007).  However, the present work 
did not discover any relationship between CRP levels and other COPD outcomes apart from its 
higher value (>3mg/dl) in those with FEV1!SUHGLFWHGZKLFKPD\LQGLFDWH&53¶VUROHLQ
these patients as suggesteG E\ UHFHQW VWXG\ 6WRFNOH\  6WRFNOH\¶V VWXG\  DOVR
demonstrated that the increased level of systemic C-reactive protein was related with poorer 
health status and comorbid conditions such as cardiovascular disease, cancer and skeletal 
muscle dysfunction. 
 
The data of the present study also show that many of the potential indicators of COPD 
progression and severity are significantly correlated with COPD outcomes including mortality, 
number of years survived and health related quality of life. However there is a lack of 
consistency in some of the indicators.  For example, smoking status and pack years were only 
observed at baseline and in the follow-up cohort but not with the third cohort.  On the other 
hand, BMI was consistently recorded.  Similarly both clinical (GOLD and FEV1 % predicted)   
and multidimensional indices (BOD, BODS, BODA and BODAS) of COPD severity were 
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highly correlated with mortality at baseline and the follow up cohort but not with the third 
cohort because of too few deaths.   
 
The present study also shows that most of the potential indicators of COPD were significantly 
correlated with health related quality of life. Significant relationships of demographic data with 
HRQL were either found at baseline (age, pack years) or at follow-up (BMI).  Comorbidity 
scores, six minute walk test and number of past exacerbations were highly correlated with 
health status scores in both cohorts.  And indices of severity such as GOLD and FEV1 % 
predicted and multidimensional indices (BOD and BODS) of COPD severity were also highly 
correlated with health status scores both at baseline and in the follow-up cohort. Additionally 
percent predicted hand grip strength also turned out to be a significant predictor of health status 
in later cohorts as was found in a previous study (Ansari et al., 2007; 2012). 
 
Previous investigations (Celli et al., 2004, Ko et al., 2010) have tended to look at the 
application and relationship of their developed indices with other COPD outcomes such as 
their relationship with gender (Torres et al., 2007), depressive symptoms (An et al., 2010), 
health related quality of life (Martin et al., 2011), hospitalized patients, (Ko et al., 2011), 
patients enrolled in pulmonary rehabilitation programme (Cote and Celli, 2005) or patients 
with lung volume reduction surgery (Imfeld et al., 2006). However, the present study has made 
further attempts to improve the new BOD index with the help of other potential measures that 
could be incorporated into BOD.  The potential measures that were chosen to improve BOD as 
a result of in depth analyses of all the known and potential indicators were age and pack years 
(See section 5.3.4). 
 
 
5.4.3. BOD PLUS 
 
The information needed to calculate BOD is easily obtainable without special resources and 
readily available in all primary care settings where these patients are mostly diagnosed and 
treated. In the original cohort BOD plus measures including age and smoking years seemed 
more effective than BOD alone in terms of their relationship with COPD outcomes such as 
mortality, number of years survived and health status (Figures 5.13-5.20).  Overall, the 
findings suggest that multidimensional indices of severity are more beneficial to monitor 
COPD progression and severity as scores are consistently correlated with COPD outcomes. In 
  
 
167 
the 1999-2010 cohort, the data related to mortality and number of years survived BODAS 
worked better than the other potential indices BOD, BODS and BODA (Table 5.6). Figure 
(5.7) and table (5.6) clearly show that BODAS is the most powerful indicator of mortality as 
compared to other indices included in the analysis (BOD, BODA and BODS).  The AUC for 
BODAS was 0.72 (p<0.0001) which is almost the same as found in Celli BODE study where 
the AUC was 0.74 (Celli et al., 2004).  But in terms of its utilisation, BODAS is far superior to 
BODE as all of its variables are easily measured and /or obtainable in all settings,  and in all 
patients irrespective of their demographical representation, psychological status, or comorbid 
condition as compared to BODE where one of its components  (E-Exercise test) requires 
H[SHUWLVHUHVRXUFHVSDWLHQWV¶PRWLYDWLRQDQGabsence of relevant comorbidities.  Furthermore, 
BODAS consists of five different variables hence providing healthcare professionals with an 
opportunity to work on a range of indicators that can be modified (apart from the A-age).  
Therefore more possibilities are available for patients to take advantage of knowledge about 
their prognosis and become motivated to alter their lifestyle and behaviour.  Encouraging 
patients to make efforts to improve their scores and to participate in pulmonary rehabilitation 
for instance would help them to improve their outcome and to achieve a better health status.  
There is therefore more chance of improvement than with BODE.   
 
The findings could not be compared with other studies and no previous study has examined 
these potential indicators by means of an index. Therefore further investigation of longer 
duration and with larger cohort would be needed to support and validate this study finding. As 
age and pack years are routinely recorded in primary care settings, it should be possible to 
obtain this information with no additional staff, resources, or time required to get this 
information.   Overall, the study suggests that the BODAS significantly influences both 
mortality and HRQL.  The BODAS scores of an individual could possibly be utilized to 
motivate patients to make the necessary effort to improve their scores by life style 
modifications.  
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5.5. Conclusion 
 
Findings suggest that there are many potential indicators that need examination in order to 
further enhance COPD assessment and improve the prediction of COPD outcomes.   
The results also suggests that the addition of pack years smoking history scores (S) in BOD 
scores improves its accuracy by 4%.    
However, none of indicators tested were able to provide total assurance that could lead to their 
incorporation into a new BOD index with the exception of pack year history.  
Therefore, there is a need to explore other factors beyond conventional indicators such as 
SDWLHQWV¶SV\FKRORJLFDOVWDWXV7KLVPD\KHOSWRLPSURYHSDWLHQWV¶OLIHVW\OHDQGLPSURYHWKHLU
attitude which may assist them as they battle against the negative consequences of the disease. 
 
 
                                   ______________________________ 
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Chapter 6 
 
 
PSYCHOLOGICAL MARKER OF COPD PROGRESSION 
 
 
6.1. Introduction 
 
,WLVVXJJHVWHGWKDWDSDWLHQW¶VKHDOWKUHODWHGTXDOLW\RIOLIH+54/LVYLWDOLQLPSURYLQJ&23'
outcomes (Jones et al., 2002) which may mean that an improvement in HRQL could lead to 
improvements in other COPD related measures.  However, it is essential to understand all the 
factors that may be responsible for supporting and improving current health status (Daudey et 
al., 2010).  This could be achieved by assessing the degree of psychological status and 
wellbeing of an individual.  In the context of mental illness Manderscheid and colleagues 
(2010) define wellness as a separate aspect of an illness which refers to the degree of positive 
attitude and enthusiastic behaviour about healthy life.  
 
It is believed that the level beneath current state of health (HRQL) is the lifestyle/behavioural 
level, followed by psychological, mental stress and motivational levels and the deepest of all is 
the spiritual being (Travis, 1970; Figure 2.9).  A combination of all these levels describes 
overall wellness. Wellness assessment is believed to help in exploring feelings of an individual 
in an event or during a course of chronic disease. As a result, psychological intervention may 
be developed that could help to improve the overall natural and physical health of these 
patients. This in turn may influence COPD outcomes and may intercept or slow down the 
progression of COPD in these patients.   
 
The purpose of this section of the thesis is to describe the development of a wellness 
assessment questionnaire and to apply this to study participants to investigate the role of 
wellness in patients with COPD and its relationship to clinical status and health status of the 
disease.  
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6.2. Methodology 
 
An overview of the steps used to explore the concept of wellness and to design and validate the 
wellness questionnaire is given in Chapter 3 (section 3.8)  
 
 
6.2.1.    Steps in the Development of the Wellness Questionnaire  
 
 
The aim and objectives related to this part of the study were to explore the views on the need 
for assessing wellness and to design an appropriate questionnaire that comprehensively reflects 
the wellness status of the study cohort. Therefore in the first phase, numerous examples of 
existing wellness questionnaires were reviewed to identify generally accepted domains, 
categories and most suitable questions used to assess wellness and from these a draft 
questionnaire (see appendix 2) was designed. Ethical approval was then gained from the 
Committee at Sunderland University.  The three community settings (Age Concern and 
Breathe Easy, Sunderland and South Tyneside) were approached to seek their views about the 
concept of wellness and the questionnaire. Of importance were the ease of comprehension and 
the relevance of questions to our target population of COPD patients with mild, moderate and 
severe disease.  Following feedback from the focus groups, together with discussion with the 
research team the questionnaire was modified and finalised. 
 
Following approval by the NHS, LREC and the Sunderland University ethics committees, 
questionnaires were sent to COPD study participants by post, including a prepaid envelope and 
a covering letter, asking them to fill in the questionnaire and return it to the University of 
Sunderland. A consent form to confirm their voluntary participation in the study and an 
information sheet about how to complete the questionnaire were included together with contact 
details in case there were any concerns to discuss.  If necessary a home visit or hospital 
appointment would be made DWWKHSDWLHQW¶VUHTXHVW 
6.3 Qualitative Data Analysis 
 
 
7R DQDO\VH IRFXV JURXS GDWD ³FRQWHQW DQDO\VLV´ LV HPSOR\HG  In order to carry out content 
analysis on text (transcribed from audio files/hand written notes) that is generated as a result of 
the focus group, the text is either coded or broken down into meaningful categories on the basis 
of a word, sentence or a phrase used that makes sense. Later themes can be generated on this 
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basis.  The final stage is to examine the text using one of content analysis' basic methods: 
conceptual analysis or relational analysis (Bender & Ewbank, 1994). In the present study 
conceptual analysis (which is also known as thematic analysis) was used to analyse focus 
group data. The details are presented in section 3.8.3 (chapter 3). 
 
 
6.4. Results 
 
After critically analysing the literature, a questionnaire was initially derived consisting of 
potential themes/domains that would be appropriate to assess wellness status. Five domains 
were identified initially. These include Personal, Self-Responsibility, Daily Stress, Stress 
Management, and Physical wellness (See appendix 2).  The researcher then attempted to 
H[SORUH LQ GHSWK SDWLHQWV¶ SV\FKRORJLFDO EHKDYLRXU DQG KRZ WKH\ SHUFHLYHG WKHLU KHDOWK LQ
terms of wellness and whether this directly or indirectly influences the clinical condition and 
overall health in these patients. As discussed above, the wellness questionnaire was developed 
using themes gathered from the literature search and the feedback gained from the focus 
groups using thematic analysis. 
 
 
6.4.1. Development of the Wellness Assessment Questionnaire  
 
a. General Characteristics 
 
FocuVJURXSVDQGZHUHDUUDQJHGDW³$JHFRQFHUQ´³*ULQGRQ/DQH3ULPDU\&DUH&HQWUH
6XQGHUODQG´DQG6RXWK7\QHVLGH+RVSLWDO6RXWK6KLHOGVUHVSHFWLYHO\,QWKHILUVWIRFXVJURXS
there were 8 participants, of whom 7 were females.  The other details regarding focus group 
particiSDQWV¶FKDUDFWHULVWLFVDQG venues are presented in table 6.1.  The participants in all focus 
groups were Caucasian. 
The steps followed and the major outcomes of the focus group sessions are presented in table 
6.2.     
 
 
  
 
172 
Characteristics Focus group 1 
(F1) 
Focus group 2 
(F2) 
Focus group 
(F3) 
Source Age Concern, 
Sunderland 
Breath Easy group, 
Sunderland 
Breath Easy group, 
Sunderland 
Induction Venue Nursing Homes 
Hendon and 
Seaburn 
Primary Care 
Centre, Sunderland 
6W*UHJRU\¶V5&
Church, 
South Shields 
Session Venue Age Concern, 
Sunderland 
Primary Care 
Centre, Sunderland 
South Tyneside 
Hospital, South 
Shields 
Number of  
Respondents 
(R) 
8 6 6 
Gender (m/f) 1/7 5/1 3/3 
Age range 45-75 60-75 60-75 
Health issues None COPD, 
Emphysema, 
Bronchiectasis. 
COPD, 
Emphysema, 
Bronchiectasis. 
Motivation of 
participants 
Enthusiastic, 
highly motivated 
and enthusiastic. 
Enthusiastic, highly 
motivated and 
actively took part 
in the discussion. 
All were vocal, highly 
motivated and 
interested to discuss 
the questionnaire 
therefore actively took 
part in the discussion. 
Table 6.1.  Characteristics of Focus group participants and the session venues. 
 
b. Sources of Analysis 
 
o Audio transcripts 
 
o Hand written notes by the Researcher 
 
o Thematic analysis 
 
 
The sources used to develop the questionnaire, number of domains and questions and the major 
outcomes of each step are  summarised in table 6.2 a detailed account is presented in the next 
section.   
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Questionnaire Initial Draft First Version  Second Version  Third Version 
Sources Literature Review 
Research Team 
Meetings 
Focus Group I Focus Group II Focus Group III 
 
Domains 
Included 
5 5 5 5 
Questions 
Included 
101 101 40 40 
Action Taken  Removed, added   
and amended 
Questions and 
merged domains 
Removed, added   
and amended 
Questions 
No major 
changes made 
Major 
Outcomes 
Initial draft 
prepared and 
focus group 
sessions arranged 
Substantial 
reduction in the 
length of the 
questionnaire. 
Identified new 
theme 
³6SLULWXDOLW\´ 
 
Validated first 
version of the 
questionnaire 
from people 
with respiratory 
problems 
Preparation of 
the final version 
of the 
questionnaire 
from people 
with respiratory 
problems.   
Table 6.2.  Development of the Wellness Questionnaire  
 
c. Themes Included in the Questionnaire 
The results presented in this section are based on focus group participants views about 
assessment of wellness and potential themes that could improve the initial draft of the 
questionnaire.    
7KH WKHPHV VRXJKW IURP WKH IRFXV JURXSV ZLOO EH SUHVHQWHG WRJHWKHU ZLWK UHVSRQGHQWV¶ 
transcribed data for each section.   
 
Theme 1: Personality  
 
In the initial draft 5 questions were included.  
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However, during the first focus group sessions, members were in agreement that this section 
should be included in the questionnaire.  However, they criticized some of the questions as 
itemised below.     
 
4XHVWLRQVDERXWSK\VLFDODSSHDUDQFHVKRXOGQ¶WEHDVNHGEHFDXVH,GRQ¶WNQRZKRZWRUHVSRQG
(F1R7).    
 
$QRWKHUPHPEHUDGGHG³,GRQ¶WZDQWWRDQVZHUWKLVTXHVWLRQ´)5 
 
Another suggested an alternative to this question and said, 
 
³, WKLQN ZKDW \RX IHHO LQVLGH LV PRUH LPSRUWDQW WKDQ ZKDW \RX IHHO DERXW \RXU SK\VLFDO
DSSHDUDQFH´)5 
 
 
Theme 2: Self-Responsibility Related Wellness 
 
7KHVHFRQGGRPDLQLQWKHLQLWLDOTXHVWLRQQDLUHGUDIWZDV³6HOf 5HVSRQVLELOLW\´ZKLFKFRQVLVWHG 
of 10 questions. 
 
7KHRQO\TXHVWLRQUHPRYHGIURPWKLVVHFWLRQZDV³,I,ZHUHWRKDYHDQHPHUJHQF\ZLWKP\FDU
,ZRXOGEHSUHSDUHG´ 
 
As most members either use public transport or do not drive, it was decided to remove this 
question.  Some of the questions were modified for clarity. 
  
A consensus was found among focus group members and therefore no major changes were 
made in this domain.   
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Theme 3: Daily Stress  
 
This domain initially contained 15 questions.  However, the focus group discussion reduced 
this number by identifying stress factors that patients with respiratory problems commonly 
faced.   
For example, 
  ³7RPHPDQDJLQJILQDQFHVLVH[WUHPHO\VWUHVVIXO\RXNQRZZKDW,PHDQ´)5 
Several members gave reasons for the different worries about their overall health and 
wellbeing which may contribute to making their lives stressful. 
³«TXHVWLRQRQPHQWDO ZHOOQHVV DQG VWUHVVEHFDXVHRIKRXVHZRUN , GR EHOLHYH \RX FDQDGG´
(F2R5). 
 
Another interesting fact that came out is that the diagnosis of COPD is also a stressing factor 
for patients particularly when the patient had to share this bad news with their family or 
relative. 
 
A member quoted concerns of one of her colleagues that had breathing problems and said,  
 
³,NQow a woman; she is not with us today. She said that when she was diagnosed she was kind 
RIREVHVVHGE\KHUIDPLO\EHFDXVHWKH\ZHUHVRZRUULHGDERXWWKDW´)5 
 
 
Theme 4: Stress Management 
 
This was the most common domain found in the literature in relation to wellness.  However, a 
substantial reduction was made after the focus group discussion as the participants suggested 
that the section was too long and also that most of the questions were hard to answer and not 
appropriate to an assessment of wellness.  It was also suggested that these questions should be 
merged into the ³'DLO\6WUHVVVHFWLRQ´ 
 
One participant said, 
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³,WLVLPSRUWDQWWREHLQJRRGKHDOWKEXWLWLVQRWWKHHQG2U,ZRXOGVD\WKHUHLVPRUHWREHLQJ
in good health than just basic mind and body care umm and to me mental, physical emotional 
ZHOOEHLQJLVDOVRYHU\LPSRUWDQW´F1R1) 
³)XOO TXHVWLRQV ZRUN EHWWHU WKDQ VWDWHPHQWV IRU H[DPSOH WKH TXHVWLRQ DERXW DOFRKRO ³, GRQ¶W
GULQNDOFRKROLQH[FHVV´FRXOGEHUHSKUDVHGDV³DUH\RXWHPSWHGWRGULQN"´)5 
 
 
Theme 5: Physical Wellness 
 
This domain of the questionnaire initially had 4 questions.  However after the focus groups the 
questions were modified for clarity. 
 
For example a question that asked ³$UH\RXZLWKLQRI\RXULGHDOZHLJKW?¶¶ was felt to be 
very difficult to calculate and answer.  Therefore the question ZDV PRGLILHG WR ³GR \RX
PDLQWDLQDGHVLUDEOHZHLJKW´" 
 
Similarly, more questions were generated as a result of the focus group views. Areas included 
were: 
³,GHFLGHGWRGRrHJXODUH[HUFLVHWREHILWDQGZHOOEXWXQIRUWXQDWHO\P\DJHGRHVQ¶WDOORZPH
to do so as and when I need to. However, when I heard about somebody who is trying hard and 
struggling to become physically fit just like me, it PRWLYDWHGPHWRGRVR«´)5 
 
Another important source of stress was found to be the weight gain which is a common 
problem with the elderly particularly due to inactivity, lack of exercise or comorbidity.   
For example, a member stated, 
 ³:HOOP\PDLQFRQFHUQLVZHLJKWDQG,WU\WRILQGZD\VWRORVHZHLJKW\RXNQRZ«EXW,IHHOD
ELWORZDWWLPHVEHFDXVHRIWKLV«\RXNQRZ«LVWKDWZKDW\RXPD\FDOOZHOOQHVV""´)5 
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³, DP WKH NLQG RI SHUVRQ ZKR LV D ELW OD[ DERXW H[HUFLVH« «PPP«DQG ORVH P\
HQWKXVLDVPVXGGHQO\«««ZHOO«,NQRZLWLVLPSRUWDQWIRUP\KHDOWK\OLIHVW\OH«WKDW\RX
PD\FDOOZHOOQHVV««\RXNQRZ´)5 
Another said, 
³«, WKLQN ZHOOQHVV LV UHIOHFWHG IURP ZKDW \RX DUH HDWLQJ \RXU FRQFHUQV DERXW ZHLJKW
««XVLQJQXWULWLRQDOVXSSOHPHQWVDQGOHLVXUHJURXSVRIDOOVRUWVDQGLf not, something wrong 
LV JRLQJ RQ««««« PD\ EH DQ\ KHDOWK SUREOHP RU DQ\ RWKHU VWUHVV RU ZKDW , PD\ FDOO
³:HOOQHVVGLVWXUEDQFH´WKDWFRQWULEXWHVWRORVWLQWHUHVWLQVXFKDFWLYLWLHV´)5 
³,XVHZDWHUWDEOHWV´ 
³,KDYH,%6´ 
 
³,KDYHQRSUREOHPZLWKP\ERZHls, but I take tablets for combatting water retention, this can 
cause some stress, if I need to pass water and I do not have access to a toilet. My breathing is 
RIWHQDIIHFWHG%XWLWLVXVXDOO\2.DIWHUUHOLHYLQJP\VHOI´ 
 
Underlining the importance of other related symptoms, patients with COPD may have, that 
influence their disease progression. 
 
In the present study, the research found that patients with COPD understand the role of diet in 
their disease progression; however, they need proper guidelines and support.  One respondent 
comments in the section related to dietary intake and states that..  
 
³,GRQ¶WNQRZZKDWLVWKHEHVWIRRGWKDWLPSURYHVP\EUHDWKLQJ´ 
 
This statement shows that patients do realize that it is not only the weight that needs to be 
controlled but that dietary modifications may also be needed to control symptoms, disease 
progression and overall wellbeing in these patients. However, this area needs to be explored 
further. 
 
Environment is another important theme identified during the focus group discussions. The 
participants clearly expressed their views on environment and its role on health.  
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For example, a member of the focus group stated, 
³««P\ERG\V\VWHPDQGP\EHOLHIKHOSVPHILJKWDJDLQVWJHUPVDQGOLYHLQKHDOWK\FOHDQ
and mmm geUPVIUHHHQYLURQPHQW,ZRXOGVD\´)5 
 
The group members also identified potential factors that makes environment worse and put 
SHRSOH¶V KHDOWK DW ULVN DQG DOVR KLJKOLJKWHG VWHSV WKDW FRXOG EH WDNHQ WR ILJKW DJDLQVW WKRVH
negative consequences that are harmful to health. 
 
³,WU\WRPDLQWDLQDJRRGK\JLHQHSHUVRQDOO\DVZHOODVWRP\VXUURXQGLQJV«WDNLQJVKRZHU
daily, wash my hands whenever use toilets, touching doors or touching any dusty things, before 
eating meals and also for shaking hands with others and for a good oral hygiene, brushing my 
WHHWKDQGDOVRZHDULQJFOHDQFORWKHV´)5 
 
³&OHDQHQYLURQPHQWLVDOVRYHU\LPSRUWDQW«DVLWKHOSVPDLQWDLQLQJSK\VLFDOKHDOWKHVSHFLDOO\
DQGSUHYHQWERG\LQWHUDFWLRQZLWKWKHJHUPV´)5 
³,KDYHEHJXQDGiet (3 weeks ago) in order to lose weight to help breathing. I will persevere as 
,UHDOL]HKRZLPSRUWDQWLWLV´ 
 
 
d. New Theme Identified During the Focus group Session 
 
Spirituality was a theme that emerged in the first focus group discussion. It had not initially 
been included in a first draft of the questionnaire as the literature did not suggest it as a 
potential factor to assess Wellness or health.   
 
 
Theme 6. Spiritual Wellness 
 
At the end of the first focus group session, the group was asked as if there was any other issue 
that could be incorporated in the questionnaire to assess wellness, three female members of the 
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group initiated a discussion considering spirituality as a wellness indicator and were supported 
by other members. 
 
As, one member stated, 
³,WHQGWRJRWRFKXUFKZKHQ,DPZHOODQGILWDQGWKDWJLYHVPHDIHHOLQJRIUHOD[DWLRQ´)5 
Supported by another participant and said, 
 
 ³««\HV/RWRISHRSOHIHHOJUHDWZKHQWKH\JRRXWIRUZRUVKLS´)5 
Participants also expressed their feelings about nature. One said, 
³,IHHOHQWKXVLDVWLFDQGHQMR\HYHU\DVSHFWRIOLIHDQGQDWXUH)5´ 
 
Participant also shared their views about spirituality and its role in daily life.   
 
A member said, 
 
³, WKLQN VSLULWXDOLW\ LV OLNH D VHQVH RI EHORQJLQJ WR our creator and it really helps when you 
EHOLHYH WKDW WKHUH LV DELJJHUSRZHUXS WKHUH WRKHOS\RX WKURXJK \RXUSUREOHPVDQGSDLQV´
(F1R2) 
The comment of F1R2 was supported by another member of the group.  
She said, 
³, DJUHH DQG VSLULWXDOLW\ DQG EHOLHIV become more important when you are going through 
difficulties and then you want to get help from God and your beliefs get stronger and stronger, 
,WKLQN´)5 
 
Some believe that spirituality helps in reducing stresses in life.  In this regard one participant 
stated, 
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³,PRVWO\WU\WRXWLOL]HP\EHOLHIVLQFRSLQJDQGGHDOLQJZLWKP\SDLQP\LOOQHVVDQGJHQHUDO
VWUHVVHVRIP\OLIHDQGLWUHDOO\KHOSV,IHHO´)5 
 
It was further said, 
 
³,WHQGWRJRWRFKXUFKZKHQ,DPZHOODQGILWDQGWKDWJLYHVPHDIHHOLQJRIUHOD[DWLRQ´ 
( F1R1).   
 
Participants also considered faith and beliefs as a mean of coping and positive hope. 
One member stated, 
 
³«EHOLHIJLYHVDQHZKRSHWRFRSHZLWK\RXUSUREOHPV«)5 
The participants also identified meditation as a source of relaxation.  
 
For example, one participant said, 
 
 ³««WRPHWKHPDLQVROXWLRQWR\RXUPHQWDOZHOOEHLQJLVPHGLWDWLRQ,GRLWUHJXODUO\DPPP
DQG,WKLQNLWDOVRKHOSVLQNHHSLQJ\RXEXV\DQGPHQWDOO\ILW«««´)5 
 
Meditation is a method of relaxation that helps to overcome or re-shape the physiological and 
psychological reactions to the illness or stress.  The focus group members also discussed 
advantages of being a firm believer or having faith or participating in regular worship.  
 
Finally the consensus was that spirituality was important to include. 
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The major themes incorporated in the final version of the questionnaire are presented in table 
6.3 with the keywords used by the participants.   
 
 
Wellness Related Issues/ 
Emergent Themes 
Key words used 
Personal/Physical 
Wellness 
lack of exercise, Weight gain, what to eat, nutritional 
supplements, best food 
Self-Responsibility 
Related Wellness 
Germ Free environment, healthy and clean 
Emotional  
Wellness 
very angry, ³,JHWVWUHVVHGE\my family, frustrated about DIY 
in a house, share feelings 
 
Mental Wellness Stress due to Family, stress due to Finance, Lack of Exercise, 
Age, hate drugs, body pain, and loss of interest. 
Spirituality Mediation, Church, God, Prayers, Many people go to church 
Table 6.3. Themes generated for Wellness Questionnaire. 
 
 
6.4.2.   Views on the design of the Respiratory Wellness Questionnaire 
 
This section presents the focus group views on other aspects of the questionnaire.  These 
include differing dimensions of the questionnaire such as contents, wordings, length, response 
format, sequence of the questions and the lay out.   
 
Initially, participants were asked to comment on the design and type of questions asked 
including choice of questions. The views of the participants on the questionnaire design were 
very clear and mostly in support. However some criticisms and suggestions were also made.  
 
Participants responded by suggesting that the questionnaire was too long and therefore time 
consuming.  
A member said, 
 
³7KHTXHVWLRQQDLUHVHHPHGWREHWRRWLPHFRQVXPLQJ),5DQGDOOSDUWLFLSDQWVH[SUHVVHGWKHLU
agreement by nodding their heads) which is supported by other members of the group as they 
WKRXJKWWKDW³LWLVPRVWLPSRUWDQWWREHDGGUHVVHG´)5 
 
Participants also criticized a few questions included in the questionnaire.   
  
 
182 
As one participant said, 
 
³6RPHSDUWLFLSDQWVDOVRPDGHYDOXDEOHFRPPHQWVRQWKHZD\WKHTXHVWLRQVZHUHZULWWHQ¶¶.   
 
The participants were then asked to comment on the lay out and format of the questionnaire. 
The members again showed their interest and the following responses were made. 
 
A member said,  
³«TXHVWLRQQDLUHORRNVILQH´)5 
 
Another said, 
 
³«TXHVWLRQVDUHYHU\JRRG´)5 
 
and another said, 
 
³([FHOOHQW´)5RU³«WKHVHDUHQLFHTXHVWLRQV´«)5 
³<HDK , WKRXJKWZHUHJUHDWTXHVWLRQV«, WKLQNWKHZKROHH[HUFLVHVDUHZHOO ODLGRXWUHDOO\
(F2R1) 
 
The participants not only commented on the layout but also the language used.  
 
As one member stated, 
 
³7KH\DUHSUHWW\VWUDLJKWIRUZDUGTXHVWLRQVUHDOO\««´)5 
 
Another said, 
³,WFRYHUVTXLWHDZLGHDUHDZKLFKLVLPSRUWDQWUHDOO\´)5 
 
Interestingly, the group members of each focus group also commented on the response format 
suggesting a sliding scale of 0-10 or 0-4 or Likert scale which they felt would be better than an 
analogue scale or a line. 
 
A participant stated, 
³)RUVFRULQJ6OLGLQJVFDOH-ZRXOGEHEHWWHURUDOLQH´)5 
 
³'LIIHUHQWVHFWLRQVFRXOGEHVFRUHGGLIIHUHQWO\7KDW LVRQDVFDOHRI WR WR or other 
RSWLRQDOPHWKRGWRUHFRUGUHVSRQVHV´)5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³,OLNHWKRVHRSWLRQV´)5 
Furthermore, when participants were asked to comment on the layout of the questionnaire a 
positive response was obtained.. 
 
For example,  
³«IDLUO\YHU\ZHOOODLGRXWJHQHUDOO\«´)5 
 
and 
 
³«)DLUO\VWUDLJKWIRUZDUG««´)5 
Another said, 
³«JUHDWTXHVWLRQV«ZHOOODLGRXWUHDOO\´)5 
 
A participant also stated, 
³«FHUWDLQO\WKHTXHVWLRQQDLUHLVH[FHOOHQWDQGVRPHTXHVWLRQVZKHUH\RXKDYHWRVD\PRUH
and WKHUHDUHDGGLWLRQDOVSDFHVZKHUH\RXFDQDGG´)5 
 
As noted earlier where the criticism was made by the first focus group members that the 
questionnaire seemed too long, the author asked the third focus group (F3) if participants 
thought that the questionnaire is still too long.  
 
The following responses were made from members of focus group 3. 
 
³1R´)5 
 
 ³,WFRYHUVDZLGHUDQJH´)5 
 
 ³1RWUHDOO\,WKLQN´)5 
 
A consensus was therefore derived from the focus group members suggesting the questionnaire 
was well designed, well-structured, easy to understand and covers a reasonable range of health 
and wellbeing related issues. 
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6.4.3. Interpretative Analysis 
 
 
The preceding sections show that the focus group participants were very interested in the 
discussion topic.  Many members of the groups expressed their views and their daily life 
experiences openly and in a friendly way with explanations where needed and/or requested. 
 
Overall, participants were fully aware and understood the importance of assessing Wellness 
and its role in their overall health and wellbeing.   
 
The discussions suggested that people are no longer relying on doctors or hospitals to make 
them better, if they get mildly sick. Instead, their approach has been changed to disease 
prevention by taking self-responsibility, for instance in making their environment clean and 
pathogen free.  Additionally, they try to maintain or improve their current health status to a 
maximum level.   
 
Overall, the focus group discussions were focused, composed, helpful, and results oriented.  
For example, the major new theme of spirituality emerged as a result of the focus group 
discussions TXHVWLRQV DGGUHVVLQJ ³6SLULWXDOLW\´ ZHUH initially not in the questionnaire. The 
literature (Sulmasy et al., 2006; Puchalski, 2001) also supports the role of spirituality in health 
outcomes in different diseases. However, no previous study has examined its role in patients 
with COPD.  In discussing this domain, it was felt that questions asked should be capable of 
being answered by those with no declared faith or belief in a god as well as those in practising 
religion.  
 
The first two focus groups highlighted a number of strengths, some areas for improvement, and 
some significant comments to be made.  The third focus group helped to validate the 
questionnaire contents, in a very comprehensive manner, by making comments on each and 
every statement using the different phrases and key words presented in table 6.3.   
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6.4.4. Use of the Wellness Assessment Questionnaire in COPD Subjects 
 
 
The names and NHS number of the subjects in the original 1999-2002 cohort were submitted 
to the PCT and from the registrar general data of those subjects that were deceased was 
obtained.  The final version of the questionnaires was sent to survivors (n=134) together with a 
letter of invitation, patient information sheet, consent form and a postage-paid envelope for 
returning the completed questionnaire.  Completed questionnaires were returned by only 27 
subjects. A further four had died in the intervening period, 14 were returned as undeliverable 
and 10 sent refusals.    
 
Qualitative analysis was carried out on the 27 questionnaires using thematic analysis based on 
additional comments made by study subjects relating to any aspect or section of the 
questionnaire.  It is interesting to note that many comments were made in various sections of 
the questionnaire and these comments have been used to develop themes and codes and to 
identify and explore the psychological impact on diseasH RXWFRPH DQG WKH SDWLHQW¶V FOLQLFDO
condition.  
 
The baseline demographics of respondents are presented in table 6.4.   It shows that the 
respondents have a severe clinical condition, as indicated by their FEV1% predicted of 
45.4±19.2, with a mean MRC score of 3, but with an optimal health status having a total SGRQ 
score of 44.1±19.6.   
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Baseline Demographic Characteristics of the COPD Respondents (n=27) 
Age (years)  68.8±9.3 
Gender (m/f) Male 
Female 
15 (56%) 
12(44%) 
Pack years (years)  39.0±17.9 
BMI (kg/m2) 27.6±5.7 
FEV1 % predicted 45.4±19.2 
MRC (1-5) 3.21±1.35 
GOLD (1-4) 2.75±0.90 
Median BOD score (Range) 3.00  (0-7) 
Median BOD category (Range) 2.00  (1-4) 
Median BODAS Score (Range) 6.00  (2-13) 
Median BODAS category (Range) 3.00 (1-4) 
SGRQ Total% 44.1±19.6 
   
  Table 6.4. Baseline characteristics of COPD subjects (Respondents).The BOD and     
BODAS data are presented as Median (range). 
 
 
Table 6.5 shows the percentage of responses for those respondents who indicated  agreement 
with the statements of each domain (5 domains; 10 statements in each domain; 50 statements in 
total) divided into those representing high or low wellness.  The results indicate that the 
majority of COPD subjects show dichotomy in their responses which means they either marked 
the first two options of the Likert scale (rarely or sometimes) or the last two options (most of 
the time/always) in response to a written statement, of the questionnaire. For example, all 
SDWLHQWV UHVSRQGHG DV HLWKHU ³PRVW RI WKH WLPH´ RU ³$OZD\V´ DJDLQVW WKH VWDWHPHQW ³,
H[SHULHQFHPRRGLQHVVDQJU\RXWEXUVWVEHFDXVHRIP\LOOQHVV´ 
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Wellness Domains High Wellness Low Wellness 
PERSONAL / 
PHYSICAL 
WELLNESS 
I have good appetite & enjoy my food 
(89%) 
I rarely engage in vigorous exercises 
(71%) 
My liquid intake is adequate (93.3%) I have negative or critical feelings 
about myself (52%) 
 
EMOTIONAL 
WELLNESS 
 
I am flexible and adopt or adjust to 
change in a positive way. (85%) 
I use alcohol as a means of helping me 
forget my problems (90%) 
I experience moodiness/angry outburst 
because of my illness (100%) 
I asses my current state of health and 
stress level on daily basis rarely. (78%) 
 
SELF 
RESPONSIBILITY-
RELATED 
WELLNESS 
I believe my life is in my hands and I 
control it. (94%) 
I am aware that I am responsible for 
every aspect of my life (58%) 
I believe the way I live is important in 
improving my health. (93%) 
I take a variety of supplements or 
alternative therapy to help maintain my 
health rarely (84%) 
 
I believe I am a major force in 
determining my rate of recovery from 
an illness. (94%) 
I try to perform at least one good deed 
every day. (74%) 
I am keen to maintain a healthy 
lifestyle and healthy diet. (80%) 
 
MENTAL 
WELLNESS 
I have good sense of wellbeing about 
my health (70%). 
I feel tired or have low energy. (84%) 
I manage my time rather than time 
managing me. (84%) 
I am stressed by my family (90%) 
I am stressed because of my finances. 
(89%) 
I am stressed because of house work 
(88%) 
I feel stressed when I go shopping. 
(95%) 
I feel generally stressed by my bowel 
habits. (100%) 
I am stressed by having to rely on 
others. (84%) 
 
 
 
SPIRITUALITY 
I believe life is a precious gift. (90%) 
 
I rarely go to church or other place of 
worship. (85%) 
I engage in acts of caring and good 
will without expecting something in 
return. (85%) 
Practicing my faith rarely occupies an 
important part in my life. (89%) 
I do not pray for better health. (82%) 
Table 6.5.Records of the participants who scored each statement (3-being agreed or 4- strongly 
agree) 
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The quantitative analysis of the wellness questionnaire (Table 6.6) with Spearman correlation 
indicates that a significant correlation was found between Physical/Personal Wellness and 
other markers of COPD progression such as GOLD (0.006), FEV1% (0.01), health related 
quality of life (0.009), multidimensional BOD score and category (0.003 and 0.02) and 
BODAS score and category (0.02 and 0.002) suggesting the possible role of wellness 
assessment in these patients and its impact on disease progression. However, other domains of 
the questionnaire did not show any relationship with any of the relevant and known COPD 
outcomes measures. 
 
Wellness domains COPD markers of progression 
Personal/ physical wellness GOLD stage               0.006 
SGRQ score               0.009 
FEV1 %                      0.01 
BOD score                 0.03 
BOD categories         0.02 
BODAS Score           0.02 
BODAS Categories   0.002 
Emotional wellness Not significant 
Self-Responsibility related wellness Not significant 
Mental wellness Not significant 
Spiritual wellness Not significant 
Total wellness Not significant 
        Table 6.6.  Relationship of Wellness domains with COPD markers 
 
 
6.5. Discussion 
 
Manderscheid defined wellness as mentioned in the introduction of this chapter but wrote 
about it in terms of its relationship to mental health.  Daudey and colleagues (2010)  have 
discussed the SGRQ as an illness measure and have stated that it does not include other aspects 
related to health status in COPD.  The Wellness Questionnaire is an attempt to bridge this gap.  
Following a literature review and discussion within the research group it was decided to use 
focus groups to aid in the development of the wellness questionnaire.   
 
Prioritization in health research topics, are mainly driven by professionals.  Decision making is 
LQIOXHQFHGE\WKHLUDUHDRILQWHUHVWDYDLODEOHUHVRXUFHVIXQGLQJDQGWLPH+RZHYHUSDWLHQWV¶
involvement in considering and selecting research topics proved to be very useful where 
patients are considered as expert in that they are experienced in facing, analysing and living 
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with a disease. Their observations about both apparent and out-of-sight consequences of the 
disease may be reliable, particularly in chronic illnesses such as COPD. 
 
A focus group is one approach to collecting rich data (McLafferty, 2004) in which the 
investigator/moderator/researcher/interviewer poses different questions related to the research 
topic (in the present study questions were about the need for assessing Wellness) to get further 
XQGHUVWDQGLQJRIWKHIRFXVJURXSPHPEHUV¶SHUVSHFWLYHRQWKHWRSLFRIGLVFXVVLon (Wong et al., 
2008). During the focus group discussions, the interaction of the participants with the 
moderator as well as with other group members was encouraged.   
 
Initially, the researcher met with the members of Age Concern and this proved valuable in 
LGHQWLI\LQJ ³6SLULWXDOLW\´ DV DQ LPSRUWDQW FRPSRQHQW RI WKHLU understanding of a concept of 
wellness.  Subsequently, patients with respiratory problems were the resource relied on and 
their knowledge, enthusiasm and support for the project was invaluable.  The outcome of all 
the deliberations was the development of the questionnaire.  
 
Unfortunately when the questionnaire was distributed to the members of the cohort only 27 of 
134 forms were returned and hence discussion of the results is limited. 
 
Table 6.6 shows that only the physical/personal Wellness domain correlated significantly with 
the known markers of COPD prognosis.  Out of those, BODAS again showed superiority over 
other indicators.  However, other domains of the questionnaire failed to show any significant 
association.  This may be due to the small sample size. The results suggest that more studies 
will be needed to validate these findings and  to draw any firm conclusions.    
 
 
6.6. Conclusion 
 
This study needs to be considered as a unique addition to research in the field of COPD in that 
it introduces an assessment of wellness into the management of this illness.  However, these 
results should be regarded as pilot data in that the response rate was very low. 
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The questionnaire needs to be extensively applied in the clinical environment to further 
evaluate its relevance and to refine the questions in the various domains.   
      
       ________________________________ 
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Chapter 7 
 
            
DISCUSSION 
 
 
 
As the findings of each chapter have been discussed at the end of the relevant chapters this 
final discussion will take an overview of the work presented in the thesis. 
 
 
7.1 Introduction. 
 
 
COPD is a complex chronic disease with systemic consequences.  These in turn lead to 
disability often accompanied by comorbidity (Yeo et al., 2006; Lang et al., 2010) and high 
mortality rates (Gudmundsson et al., 2006).  In addition, for spirometric staging of severity 
discrepancies and controversies exist in relation not only to diagnosis and classification 
(Harrison 2011), but also to treatment and management (Rabe and Wedzicha 2011). By not 
hDYLQJDFOHDUXQGHUVWDQGLQJRI WKHVWDJHRI WKHGLVHDVHSDWLHQWV¶ZHOOEHLQJFRXOGEH DW ULVN
and healthcare costs could be increased (Bridevaux et al., 2008) with a greater burden put on 
both hospital and health care workers. However, no clear alternative to impairment of FEV1 as 
the marker of severity has yet been defined. 
  
There is therefore a need to adopt a multidimensional approach to the evaluation of COPD 
patients which also includes an assessment of their inner state of mind including their wellness 
status. Attitude to the illness appears to play a vital role in the progression of any disease, 
LQFOXGLQJ&23'DQGKHOSVWRPRGLI\SDWLHQW¶VDWWLWXGHWKLQNLQJDQGFRSLQJEHKDYLRXUGXULQJ
their illness.   
 
The use of a combination of all of these assessment tools may lead to an improved outcome in 
these patients and provide health practitioners with a range of tools for the better management 
of COPD. 
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7.2.  Cohort Evaluated in this Study. 
 
The present study is unique in several aspects in terms of the cohort used to examine COPD 
markers.  Firstly, the number of female participants in this study (49%) was higher as 
compared to other relevant studies (Ko et al., 2011; Esteban et al., 2010 and 2011, Li et al., 
2010; de Torres et al., 2007). The higher proportion of females in the present study may be due 
to the increased prevalence of smoking among women in UK. Nonetheless, the higher 
proportion of females in this study provides the opportunity for health care professionals to 
consider the findings of this study in relation to both genders.  
 
Another unique feature is the degree of severity as measured by lung function.  In the present 
study the cohort had a mild to moderate degree of lung function decline (60.9±20.0%) in 
contrast to other similar studies where the mean FEV1% predicted were either severe or very 
severe ranging from 42.5±10.8 to 55.0±13.3 (Celli et al., 2004; Ko et al., 2011; Esteban et al., 
2010 and 2011; Puhan et al., 2009; Li et al., 2010; Celli et al., 2004).  The lesser degree of 
severity provided the opportunity to monitor progression from mild to severe disease and their 
association with other outcomes including mortality and health status.   
 
Patients for this study were recruited from primary care clinics whereas other studies mainly 
recruit patients from hospital wards or clinics (Ko et al., 2011; Puhan et al., 2009 Celli et al., 
2004). 
 
The long term nature of this study also makes it unique.  There have been very few studies 
(Trevor et al., 1979; Leavitt et al., 2006) which examined mortality as an outcome over a 10 
year period. Furthermore, the data on historical heights 8-10 year apart were measured and 
ZHUHQRWEDVHGRQSDWLHQWµV UHFDOORQ WKHLUKLJKHVWKHLJKW7KLV WKHUHIRUHDGGVYDOLGLW\ WR WKH
study findings as regards the use of height as a potential marker.  
 
 
7.3. Development and Use of Multidimensional Indices 
 
In relation to the assessment of the multidimensional nature of COPD, a major advancement 
came through a study carried out in 2004 when Celli and colleagues (2004) presented data 
showing that their multidimensional grading system had a significant advantage over the 
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Fletcher-Peto model, the classical study used  to explain the natural history of COPD.  Celli 
and co-workers (2004) established the BODE index (BODE ± BMI, airflow Obstruction, 
subjective Dyspnoea and Exercise test; a 10 point scale) (Celli, 2004) which proved to be a 
better predictor of the health outcomes than FEV1 alone. Later, Puhan and colleagues (2009) 
developed another multidimensional index (ADO) composed of Age, MRC Dyspnoea index 
and Airway Obstruction.  The index proved as useful as BODE for prognostic assessment in 
COPD patients.  However, by introducing age, the ADO index is compromised because age is 
the most important determinant of survival, independent of disease status and diagnosis, 
although its role in any assessment of disease prognosis should not be discarded. Other indices 
also developed were of limited use.  For example Jones and colleagues (2009) developed the 
DOSE index that contains four COPD related measurements i.e. dyspnoea (D), airway 
obstruction (O), smoking status (S), and frequency of exacerbation (E).  The index proved to 
be a simple tool to assess disease severity and probability of hospitalisation.  There are number 
of indices developed in the past incorporating various other markers (Van Dijik et al., 2011).  
Altogether, the indices used 3-8 predictors only one study did not use FEV1 as a part of the 
index (Omachi et al., 2008) and only two studies (Omachi et al., 2008; Jones et al., 2009) 
reported the change over time of the index and the associated outcome.   
 
The present study examines the change over time in the BOD index and other physical 
markers.  Other rarely used markers include blood oxygen (paO2), knee extensor strength, rate 
of exacerbations and comorbidities.  However, some of the potential (easily measured) markers 
have not been studied effectively yet; these include smoking status and smoking intensity, lean 
body mass, hand grip strength and duration of symptoms. This study has investigated some of 
them and attempted to develop indices that could improve assessment of COPD. To date, only 
one study (pilot) actually implemented a prognostic COPD index in patient care, without 
showing significant improvements in health (care) (Gruffydd-Jones et al., 2010). As the 
practical abilities of COPD indices remain untested, they fail to tackle the current need to 
improve treatment programs (The Health Foundation, 2007; Schunemann, 2009; Wildman et 
al., 2007).   
 
 
The present study has evaluated BOD (BODE without the exercise component) and the results 
indicate that it is a suitable marker for the measurement of COPD progression and to use in all 
healthcare settings as well as in the community and/or house bound patients.  BOD is a better 
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marker as many patients particularly with severe COPD are unable to walk.  Also, the walk test 
is not useful in assessing COPD patients with mild disease as they may have normal or above 
normal exercise capacities (Smith, 2011).  It also means that the test cannot be carried out in a 
primary care setting.  
 
However, there are many other physical measures made on COPD patients and the present 
study examined a number of other potential clinical, physiological, physical, symptomatical 
and habitual markers and measurements that could improve the ability of the BOD index to 
predict COPD outcomes over time. Other potential markers of COPD outcome examined 
included smoking history, lean body mass, hand grip strength, health status assessment, 
duration of symptoms, CRP and most importantly the assessment of wellness status which is 
the new way of evaluating the mental status of these patients. 
 
An initial evaluation of a range of indicators demonstrated that the following were suitable for 
inclusion in the new index of physical measures developed in this study: 
 
Age 
Pack years 
Gender 
 
Many studies have examined the role of age in COPD outcomes (Britton et al., 2003; Puhan et 
al., 2009, but no firm conclusion has been made.  However, age adjustment should always be 
considered in clinical research involving patients with chronic illnesses because of its 
relationship with mortality (Tran DD et al., 1990) in general and COPD in particular (Britton et 
al., 2003; Puhan et al., 2009).  COPD is more prevalent in people > 45 years and is highest in 
elderly patients over the age of 65 (Hurd S., 2000, Sullivan et al., 2000).  The present study 
supports previous findings in terms of years of age of COPD sufferers (mean age 69.5±8.7and 
64.5±9.4 in COPD) presented in table 5.2.  Our data suggest that patients >73 years of age are 
highest in the deceased group whereas patients with <57 years are highest in survivors.  Further 
analysis in the present study partially supports the finding of Puhan and co-workers who 
developed ADO index (Puhan et al, 2009) consisting of Age, MRC Dyspnoea Score and 
Airway obstruction scores which works better than the validated BODE index in predicting 
mortality in patients with COPD and underlines the effect of age on 10 year mortality in 
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patients with COPD. However, age does not alter our principle model of BOD index when age 
was added as a covariate in the model. However, the current study suggests that consideration 
should always be given to age when exploring mortality in COPD and other COPD outcomes.  
The present study successfully proved the value of age which enhances the effectivity of 
multidimensional assessment when incorporated in BOD.   
 
Tobacco smoke is a well-known risk factor in the development, progression and mortality of 
COPD and the present research also shows a high prevalence of both current and exsmokers 
and a high pack-year history in patients with COPD.   
 
The present study supports previous findings (Fletcher et al., 1976; Zaher et al., 2004) that both 
ex-smoking and current smoking influence disease progression and mortality.  
 
However, avoiding smoking is not sufficient to prevent COPD and the risk factors are not self-
same.  In eastern countries, the approach to minimize COPD should be different from western 
countries (Murray et al., 1996).  Each individual person has specific risk factors based on 
economic background, psychosocial status, work related exposure, family and life time 
medical and drug history.  
 
The findings of the present study thus suggest that the assessment of the smoking status of 
COPD patients is an essential element and smoking cessation interventions should be promptly 
discussed with the primary care physician.  Therefore, smoking in COPD poses a serious threat 
to medical world and larger scale researches are needed in order to reduce the impact of this 
debilitating disorder which influences disease prevalence, prevention, management, treatment, 
complications, disability and death.   
 
Traditionally, COPD is associated with the male gender; however, over the last decade COPD 
has become an increasing problem among women (Torres et al., 2010). However, in the 
present study the numbers of female subjects were higher than males (51% vs 49%) in contrast 
to other studies such as 14% vs 86% (Ko et al., 2010) and 4% vs 96% (Esteban et al., 2010).  
Hypothetically, this changing trend of COPD is simply because smoking rates are now 
becoming higher or at least equal in women compared to men as reflected by the 
demographical findings of the present study results where the pack-year history is 33.3±25.7 in 
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men vs 31.1±18.6 in women. Similarly, 52% of females were current smokers in our cohort in 
contrast to 44% of males. Furthermore, in the analysis of BOD with mortality, the KMSA 
shows that BOD worked better for females (only over 10 year time-frame) when gender 
specific analyses were carried out however our findings could not be compared with other 
similar studies due to the higher number of males in those studies.   
 
Thus it is very difficult to make the judgement that gender itself has a great impact on 
mortality.  However, it is one of the most important factors and should always be considered 
by exploring the gender based phenotypes of patients with COPD whenever researchers 
examine COPD outcomes such as mortality, health status and wellness status. 
 
Lean body mass was another potential marker that was evaluated in this study.  Unlike 
previous studies that underlined the role of lean body mass in COPD and other chronic diseases 
(Schols et al., 2005; Coxon et al., 2004; Engelen MP et al., 1994; Schols et al., 1993). In this 
regard, however the findings are inconclusive.  Reid and colleagues (1992) found a correlation 
of lean mass with bone mass density (BMD) particularly in postmenopausal females (Reid et 
al., 1992); however the present study did not consider BMD as an outcome.   
 
Patients with COPD may be quite inactive, not only because of their age but also due to 
breathing difficulties, a very common subjective complaint in patients with COPD.  This 
problem further leads to impairment in activity which in turn causes muscular atrophy and 
muscle weakness (Schols et al., 1993, Rantanen et al., 1998).  It has been proposed that 
systemic inflammation has a role in perpetuating damage to muscle (Remels et al. 2007) and 
exacerbations of COPD are characterised by increased systemic inflammation. (Remels et al., 
2007).  Also treatment of an exacerbation with oral steroids may contribute to further muscle 
wasting (Wouters, 2006). 
 
The present study also evaluated handgrip strength as a potential marker of disease progression 
but it did not appear to be as effective as age and pack years history.  Furthermore, this study 
demonstrated that hand grip strength deteriorates significantly in patients with COPD when 
measured 12 months apart. The study also found a significant correlation of percent predicted 
grip strength with some components of Health related quality of life scores measured by SGRQ 
which is consistent with the findings of previous researches (Ansari et al., 2007).  However, 
  
 
197 
more longitudinal studies are needed in future to evaluate this association, which would really 
be beneficial with respect to health status, progression and mortality in patients with COPD.   
 
The study suggests that BODAS is the most powerful indicator of mortality as compared to 
other indices (Figure 5.7 and Table 5.6).  The AUC for BODAS was 0.72 (p<0.0001) which is 
similar to BODE in the Celli study (AUC was 0.74) (Celli et al., 2004).  In practice, the 
utilisation of BODAS has an important advantage over BODE. Due to the nature of the 
indicators included in the BODAS index which are easily obtainable and measurable in 
primary care settings and in all patients without any limitations.  In contrast, BODE has as one 
of its component E-Exercise test which requires H[SHUWLVHUHVRXUFHVSDWLHQWV¶PRWLYDWLRQDQG
an ability to walk without discomfort.  Furthermore, BODAS consists of five different but very 
basic variables, most of which are modifiable there is therefore more chances of improvement 
than with BODE.   
 
Thus the addition of age and smoking history to BOD provides an important development and 
this is clearly demonstrated in the K-M analysis for individual BODAS scores and categories 
(Figures 5.5 & 5.6).  BODAS is therefore a highly appropriate candidate for generalised use 
when exercise capacity of COPD patients cannot be undertaken.  However, the performance of 
BODAS was not as DQWLFLSDWHGLQWKHFRKRUWEHFDXVHRIHYHQWV³GHDWK´REVHUYHGGXHWR
a smaller sample size and shorter period of observation (Table 5.7). 
 
Overall, the study suggests that BODAS which consists of five different indicators of COPD 
progression significantly influences risk of mortality and is also related to HRQL.  But it is 
difficult to inform patients about their chances of survival.  However, the scores could possibly 
be utilized to encourage and also to motivate patients to make efforts to improve their scores 
by life style changes in order to avoid or to delay any worse possible outcomes and to live 
healthy life as long as they can.  
 
The present study suggests that age and smoking history could play a vital role in assessing and 
monitoring progression of COPD particularly when incorporated into the BOD index.  On the 
other hand, the results related to other combinations of markers were not as convincing and 
therefore further studies may be needed to explore their influence in disease progression and 
outcomes. 
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The SGRQ which is the most widely used health status marker in patients with COPD was 
examined in these patients over time suggesting again that SGRQ is consistently associated 
with most of the physiological variables and multidimensional assessment indices over time. 
 
$QRWKHU VXEMHFWLYH PHDVXUHPHQW ³'XUDWLRQ RI V\PSWRPV´ ZDV DOVR H[DPLQHG LQ WKH SUHVHQW
study and demonstrates that this measurement may play an important role in predicting COPD 
outcomes.  However no standard, reproducible and validated instrument is available to 
accurately record this information that may provide clinically relevant information about the 
development, progression and outcomes.   
 
The findings of this study suggest a potential phenotype of COPD patients that exhibit no 
symptoms even in the presence of severe airflow obstruction as measured by spirometry.   
Similarly, there is another phenotype that has more than 20 years of symptoms.  However, no 
airflow obstruction has been suggested in such a group of patients however no study was found 
in support of this finding and further research is needed to validate the present study findings.   
 
$ELRPDUNHU³&53´WKDWLVNQRZQWREHDQLPSRUWDQWLQGLFDWRURI&23'SURJQRVLVZDVVWXGLHG
in this thesis but the results were not clear and its role in monitoring COPD progression could 
not be justified. Many studies in the past have suggested the importance of a CRP and its 
prognostic value in COPD severity and other outcomes (Gan et al., 2004, Dahl et al., 2007).  
However, the present work did not discover any relationship between CRP levels and other 
COPD outcomes apart from its elevated level in the COPD groups (on the basis of FEV1%) 
with high CRP value (>3mg/dl) in those with FEV1 > 60% predicted which may indicate 
&53¶V UROH LQ WKHVH SDWLHQWV DV VXJJHVWHG E\ D UHFHQW VWXG\ 6WRFNOH\  $OWKRXJK
6WRFNOH\¶V VWXG\  DOVR GHPRQVWUDWHG WKDt the increased level of systemic C-reactive 
protein was related with poorer health status and comorbid conditions (e.g. cardiovascular 
disease, cancer and skeletal muscle dysfunction).   
 
In order to examine the relationship, various means have been used to investigate the 
relationship.  These included considering CRP as a continuous variable and dividing it into 
quartiles and cut off values, but in all cases it did not show any significant relationship with 
any of the COPD outcomes except lung function (when divide CRP values into cut off points 
of >3 and <3) including health status, multidimensional indices BOD and BODE, MRC, 
history of exacerbation or death.   
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The study also examined the influence of height variation (loss) on spirometric diagnosis of 
COPD over time and found that height loss may not only under-diagnose some of the 
borderline COPD cases particularly in the elderly but also misinterpret the severity of the 
disease (mild, moderate and severe as per NICE classification of severity) in some cases. 
 
Although many multidimensional indices have been developed and proved useful no consensus 
has been found as to the use of the most appropriate index to manage patients in primary and 
secondary care.  In other words many indices have been developed for clinical use, as yet, 
however, these indices lack impact studies to demonstrate effects on patient outcome and 
health care when implemented in daily patient care. The indices may improve population-based 
predictions of the natural course of COPD compared to looking at airway obstruction (as 
measured by FEV1%) alone, in terms of mortality, hospitalizations and exacerbations. The 
diversity in populations, (the weighting of) predictors and (the definition of) outcome, strangles 
any overall recommendations on which index to prefer for predicting prognosis in patients with 
COPD and how these patients can be motivated to improve their disease.   
 
Clearly, there is a need to explore a patient-centred approach where psychological status comes 
into play.  The present study used this approach and attempted to examine the mental status by 
means of assessing overall wellbeing including stress factors, their attitude and beliefs and way 
of thinking when dealing with disease consequences.   
 
7.4. Wellness Status 
 
To date the majority of indices developed for the evaluation of COPD have concentrated on 
physical, physiological and biochemical measures (van Dijik et al., 2011) however a SHUVRQ¶V 
attitude towards their illness can often impact upon the outcome in terms of morbidity and  
mortality (Sibbald et al., 1988; Kashdan, 2011).  In any evaluation of disease progression it 
PD\WKHUHIRUHEHQHFHVVDU\WRLQFOXGHZLWKLQDQDVVHVVPHQWLQGH[DPHDVXUHRIµZHOOQHVV¶RU
their mental attitude towards their illness  (Sibbald et al., 1988; Kashdan, 2011; Niemiec et al., 
2010).   
 
This study also attempted to explore the deeper picture of the overall health status in these 
SDWLHQWVZLWKWKHKHOSRIDQHZO\GHYHORSHG³6XQGHUODQG5HVSLUDWRU\:HOOQHVV4XHVWLRQQDLUH´
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suggesting the need for its use in patients with COPD to get a deeper picture of the overall 
health that ultimately has an impact in the form of improved outcomes and better management 
and prognosis in these patients. In addition, the psychological/wellness status enhances the 
assessment of overall health status incorporating general, physical and mental health status, 
which together improves overall health outcomes in these patients. 
 
The key factors that the patients felt impacted upon their wellness was questions related to 
physical and personal wellness.   
 
Therefore, the management of COPD should be carried out on an individual basis considering 
personal and social factors that interfere with the progression of this disease.  Additionally, 
how the healthcare workers approach these individuals is also an important factor that needs 
FRQVLGHUDWLRQ  )RU H[DPSOH JHQHUDOO\ ³VWRS VPRNLQJ´ LV WKH NH\ WDUJHW E\ FOLQLFLDQV WR
improve COPD related health outcomes.  However, attention should also be given on the 
contributing factors that prevent them from stopping smoking for example health related stress 
factors, social factors or attitude.   
 
 
7.5. Combining Qualitative & Quantitative Measures. 
 
Many studies into the development of indices of COPD progression have solely focussed on 
physical measures (Godtfredsen et al., 2008; Puhan et al., 2009).  Few have attempted to assess 
mental status and its association with COPD progression (Funk et al., 2009; Putman-Casdorph 
and McCrone., 2009); and health status (Gudmundsson et al., 2006).  However to date, no 
study brings together an assessment of a patients physical symptoms and a measure of their 
mental attitude (and the factors that impact upon it) in order that both aspects can be managed 
in terms of the long term management of the illness.  The present study explores this 
phenomenon for the first time.   
 
In all evaluations of disease progression, there is a need to evaluate both physical factors 
WRJHWKHUZLWK³ZHOOQHVV´DQGDWWLWXGH0DQDJHPHQWRIKHDOWKDQGWKHRXWFRPHRIGLVHDVHDUe a 
mixture of both and a multidisciplinary index should assess both measures. This means a 
blending of quantitative and qualitative methods.  However, in practice, this does not generally 
occur as studies are either carried out by physicians/clinicians or social scientists. 
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This study benefited from support from both types of expertise and it has illustrated the need to 
merge both types of research in terms of the development of future indices for the management 
of COPD. 
 
 
7.6.  Future Evaluation of COPD. 
 
Following the development and validation of the current indices, the next step for COPD 
researchers is to perform impact studies (Moons et al., 2009).  These studies should establish a 
firm conclusion in terms of their applicability as well as the impact on health and healthcare 
and their implementation in primary and secondary care settings.  A  study is also required that 
quantifies the effect of using a prognostic index on predefined outcomes including decision 
making, patient outcome, and cost effectiveness, compared with usual care without 
implementing the index (Moons et al., 2009). 
 
Another issue is whether or not a prognostic index should integrate predictors, preferably those 
that can be modified (Schunemann, 2009), and treatments that further improve the index 
scores, slow the progression and delay worse outcomes such as disability and death (Cote and 
Celli, 2005; Nasis et al., 2009).  Ultimately, indices should be integrated in such a way that 
self-management strategies can be defined for each individual.    
 
Further work is also needed to explore the variation in BOD scores between 2000-2008 and the 
ability to predict mortality after 2008.  It is a useful idea to identify group of patients who have 
improved their BOD scores over time and also to explore factors that the lead to the 
improvements in their respective BOD scores/categories that may possibly include dietary 
modifications, lifestyle changes, regular exercise, attending pulmonary rehabilitation 
programmes or any other interventions that are beneficial to individuals with improved BOD 
scores. 
 
Finally, applying a prognostic index in a population other than the one in which it was 
originally developed may require recalibration or modification.  In this regard, Puhan and 
colleagues (2009) carried out for BODE based on populations.  Therefore calibration or 
stratification of an index allows adjustments that can resolve the dilemma of this strong but 
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troublesome predictor (Graham et al., 2007).  Apart from age, calibration should be carried out 
for patients with a range of severity and also in patients with frequent exacerbations and 
patients on oxygen.   
 
The study plays a significant role in the field of COPD management as it provides new 
multidimensional indices BOD and BODAS for health professionals to assess the clinical 
impact of COPD in any setting where these patients are being treated.  It also helps patients to 
understand their prognosis and encourage them to modify their lifestyle and improve health 
status.  Furthermore, this study provides a new assessment tool to evaluate the modifiable 
mental status of these patients that in turn can be used to improve disease outcomes. 
However larger cohort studies over a longer time frame will be needed to confirm the findings 
of the present study.  In addition, validation of the newly developed wellness questionnaire and 
its role in improving outcomes will also be needed in different cohort.  
  
    ________________________ 
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Chapter 8 
 
 
CONCLUSION 
 
 
 
The following conclusions can be drawn from the work presented in this thesis: 
 
 
x The cohort of patients with COPD evaluated in this study was recruited in primary care. 
They differ from cohort studies reported in the literature which have been mainly 
identified in secondary care and thus represent a more severely affected group of 
patients with COPD.  The cohort was identified from 1999-2002 and mortality was 
censored in 2010.  The indices developed and evaluated with this cohort were found to 
be suitable for predicting disease progression and would be suitable for use with 
patients in the early stages of COPD. 
 
x The index evaluated in this study, BOD, was found to be a suitable predictor of disease 
progression and outcome. Using KM survival analysis BOD showed better prognostic 
potential than FEV1 as recommended in the GOLD/NICE guidance classification of 
severity, in that there was a higher mortality associated with the highest category 
calculated using BOD.  This superiority was confirmed using ROC analysis. BOD is 
likely to be a better index for use in a primary care/home setting as it does not include 
the exercise component found in other indices including BODE, which requires space. 
The exercise component is also not popular with patients suffering from COPD. 
 
x A number of other physical measures of COPD progression were evaluated and three 
were chosen for incorporation into the BOD index. Of the three the index incorporating 
smoking and age, BODAS, had a higher sensitivity on ROC analysis than BOD for 
predicting ten year mortality. 
 
x Health status as measured using the St Georges Respiratory Questionnaire (SGRQ) 
correlated with BOD and BODAS but not BODE (all measurements from 2007/2008). 
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However, SGRQ scores did not show a significant association with three year mortality 
on KM survival analysis. 
x Health status is based on an assessment of symptomatology so the value of examining 
³:HOOQHVV´ZDV H[SORUHGZLWK DQHZO\GHVLJQHGTXHVWLRQQDLUH )RFXV JURXS UHVHDUFK 
was used to validate and develop the questionnaire to be used with the cohort. A 
QXPEHURIDUHDVRILPSRUWDQFHLQWHUPVRIWKHHYDOXDWLRQRIµZHOOQHVV¶ZHUH identified 
these included: spirituality and a range of stress factors. 
 
x Although limited results were obtained free comments in the wellness questionnaire 
identified a range of factors that affect wellness in patients with COPD. These include a 
range of stress factors which includes environmental stress and the importance of a 
smoke free atmosphere, the importance of patients being able to manage their illness 
including the role of nutrition in terms of disease management and the problems of 
being reliant on other for support. 
 
x COPD is a complex illness with many physical and mental factors affecting the 
outcome for patients diagnosed with this disease. This study has combined both 
quantitative and qualitative research in the development of new methods for the 
evaluation of patients and management of their care. Whilst further research is needed 
to validate the new index BODAS, together with the newly developed questionnaire for 
µZHOOQHVV¶WKHUHVXOWVSURYLGHDVWDUWLQJSRLQWZKLFKZLOOHQDEOHKHDOWKFDUHSUDFWLWLRQHUV
to evaluate individual patients and devise care packages  that not only manage their 
ph\VLFDOV\PSWRPVEXWDOVRVXSSRUWWKHLUµZHOOQHVV¶ 
 
 
Problems Encountered during the Study 
 
 
A number of limitations were encountered during the present study.   The most important 
weakness of this study was the high dropout rate (n=179) that eventually reduced the repeat 
study cohort.  However, some of the dropouts were inevitable because of those who 
unfortunately died.   Another reason for drop out was non response either because of an in 
correct address on the hospital computers or because they did not wish to participate.  (Ethical 
issues do not allow a researcher to persuade study subjects to participate). Since the data base 
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was originally established from patients attending COPD and Asthma clinics in primary care 
and the subjects linked their symptoms with asthma more than COPD it may be possible that 
some dropped out because patients thought they had asthma and not COPD.  . 
 
 
Another limitation was that the study only examined the ability of the multidimensional index 
BOD in predicting 10 year mortality in COPD patients and did not examine the recommended 
index BODE over the full 10 year period. However, the comparison was not possible and/or 
not applicable to this study because the initial data base was established between 1999-2002 
whereas the BODE index was published in 2004.  However, the study did perform three years 
mortality and one year variation between BOD and BODE and their correlation with other 
COPD outcomes.   
 
 
Furthermore, the number of respondents for assessing wellness was also very low.  The reasons 
for large number of non-respondents were two fold. Firstly, wrong addresses were used as 
more than 50 questionnaires were returned back to the researcher. Secondly, there was  no 
verbal contact with the participants prior to sending the wellness questionnaire as this could 
potentially act as an influencing factor.  It was clearly mentioned on the Patient information 
VKHHW3,6WKDWDKRPHYLVLWFDQEHDUUDQJHGRQWKHSDWLHQW¶VUHTXHVWDQGFRQWDFWQXPEHUVRI
all research team members were supplied within the PIS.  Nevertheless the response rate was 
low.  Another major contributor was the bureaucratic governance and ethical process 
recommended by both NHS and the University.  It has been stated that UK health research 
activities are being seriously undermined by an overly complex regulatory and governance 
environment (The Academy of Medical Science, A new pathway for the regulation and 
JRYHUQDQFHRIKHDOWK UHVHDUFK-DQXDU\7KLV LV HYLGHQFHGE\D IDOO LQ WKH8.¶VJOREDO
share of patients in clinical trials and other health care researches, and by the increased time 
DQGFRVWVRIQDYLJDWLQJWKH8.¶VFRPSOH[UHVHDUFKDSSURYDOSURFHVVHV 
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Recommendations for further work 
 
 
9 Further valuation of BOD and BODAS as prognostic indicators needs to be carried out 
in primary care.   
 
9 Evaluate further the variation in BOD scores and their impact on mortality overtime 
particularly after 2008 in those with improvement in BOD scores. 
 
9 Comparison of BOD and BODE in a larger cohort would be useful. 
 
9 Study BOD in hospital based cohort and relate it to the exacerbations rate and DOSE 
and ADO index. 
 
9 Validate the Wellness questionnaire, its reproducibility and its correlation with other 
tools for assessing health status.   
 
9 Explore wellness as a concept in other ethnic groups. 
 
 
 
    _____________________________ 
 
 
